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Abstract 
 
Perioperative hypercoagulability may manifest as thromboembolic 
complications, such as myocardial infarction, deep vein thrombosis and 
pulmonary thromboembolism, which are critical pathological events that 
increase postoperative morbidity.  Reducing the incidence of both venous and 
arterial thromboses are key goals of improving perioperative outcomes. 
 
A large observational cohort study comprehensively characterised the 
alterations in coagulation status following major intra-abdominal surgery.  
Results confirmed that postoperative hypercoagulability is seen up to at least 
postoperative day 5.  This prothrombotic phenotype was diagnosed by pre-
defined thromboelastography criteria and not by conventional coagulation 
tests.  Goal directed fluid therapy in the immediate perioperative phase was 
associated with excessive fluid administration but no adverse effect in terms 
of haemodilution-induced TEG-defined hypercoagulability.  However, patients 
receiving goal directed therapy showed evidence of a higher degree of 
glycocalyx damage.   
 
Inflammation-induced hypercoagulability and scope for potential modification 
by putative anti-thrombotic agents were further explored using an ex vivo 
experimental model in healthy subjects and preoperative surgical patients.  
Statin and steroid therapy attenuated, while anti-oxidant N-acetylcysteine 
exacerbated, the prothrombotic state in the presence of inflammation.  The 
concept of cholinergic autonomic modulation of coagulation was supported by 
suppression of the hypercoagulable response by nicotine in the same model. 
 
In summary, perioperative hypercoagulability is common in the elective major 
surgical population and is associated with adverse outcome.  Data from this 
thesis confirm a patient phenotype at increased risk of thromboembolic 
complications.  Thrombotic risk may be modified by existing perioperative 
therapies which require further mechanistic evaluation.   
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1.1 Introduction 
 
Thromboembolic complications are the leading cause of preventable 
postoperative morbidity and mortality.  Of the 312 million surgical procedures 
performed worldwide each year (Weiser et al., 2016), an estimated 4% are 
complicated by arterial thrombosis and a further 4% by venous thrombosis 
(Donze et al., 2014). Postoperative myocardial infarction (MI), ischaemic 
stroke, deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE) 
constitute a substantial healthcare burden, despite routine 
thromboprophylaxis and improvements in perioperative care.  Reducing the 
incidence of both arterial and venous thrombotic events are key goals in 
improving perioperative outcomes and reducing healthcare expenditure. 
 
Understanding normal haemostasis, the pathogenesis of both arterial and 
venous thrombosis, the bidirectional relationship between inflammation and 
coagulation and the precise role of surgical trauma in producing 
hypercoagulability is key to fully characterise the postoperative pro-thrombotic 
phenotype and thus explore therapeutic targets to reduce thromboembolic 
complication rates. 
 
1.2  The normal haemostatic system 
 
Normal haemostasis comprises of primary and secondary haemostasis, two 
equally important processes that occur concurrently at the site of vascular 
injury. 
 
Primary haemostasis consists of platelet adhesion, activation and 
aggregation, which in turn lead to the formation of a platelet plug.  Following 
platelet adhesion to the site of vascular injury, platelet activation is promoted 
by certain agonists, including thromboxane A2, thrombin and collagen, 
stimulating the release of alpha and dense granule contents which promote 
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further platelet recruitment and then activation and aggregation.  
Subsequently platelets are linked by fibrinogen through surface glycoprotein 
IIa/IIIb receptors to form a platelet plug.   
 
Secondary haemostasis consists of a series of consequential reactions, 
ultimately resulting in the production of thrombin and covalently cross-linked 
fibrin.  This coagulation cascade is triggered in response to vascular injury by 
the exposure of tissue factor at the site of injury.  Tissue factor is expressed 
on subendothelial fibroblasts, injured vascular endothelium and activated 
monocytes.   
 
In the initiation phase, tissue factor complexes with circulating activated factor 
VII (VIIa) to form the extrinsic tenase complex (TF:VIIa), which is responsible 
for the cleavage and subsequent activation of factors IX and X.  Activated 
factor X (Xa) activates only a small amount of prothrombin to form thrombin 
because its cofactor, factor Va, is not yet available.  This small amount of 
thrombin, rather than generating fibrin, activates cofactors V and VIII to 
stimulate further platelet activation.  The extrinsic tenase complex is rapidly 
inactivated by the formation of a complex with factor Xa and tissue factor 
pathway inhibitor (TFPI).  This rapid inactivation means that continued 
coagulation is dependent on ongoing generation of factor Xa via factors VIIIa 
and IXa (Figure 1.1). 
 
An amplification phase follows whereby the formation of two enzyme 
complexes is responsible for the massive amplification in thrombin generation 
and results in rapid and extensive clot formation.  Factors IXa and VIIIa, which 
have formed during the initiation phase, bind via calcium ions to exposed 
platelet phospholipid on the surface of the haemostatic plug.  This binding 
creates the intrinsic tenase complex which then prompts the rapid generation 
of factor Xa.  The rapid localised increase in factor Xa concentration leads to 
the formation of the prothrombinase complex, consisting of factor Xa, calcium 
ions, platelet phospholipid and factor Va generated from initiation.  The 
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prothrombinase complex cleaves prothrombin to form thrombin.  Meanwhile 
factors Va and VIIIa act as accelerators, promoting the production of both 
factors Xa and thrombin. 
 
Thrombin then stimulates cleavage of fibrinogen to fibrin.  Moreover, thrombin 
directly activates factors V, VIII and IX.  Therefore, thrombin generation allows 
production of more accelerating cofactors, Va and VIIIa, resulting in a further 
large scale increase in thrombin production.  Fibrin monomers spontaneously 
form hydrophobic and electrostatic bonds with other fibrin monomers allowing 
formation of linear fibrin polymers to produce unstable fibrin clot.   The 
stabilisation of the fibrin clot occurs following formation of crosslinks between 
adjacent linear fibrin molecules, conducted by the transglutaminase, factor 
XIIIa, produced by the action of thrombin on factor XIII.  (Figure 1.2) 
 
Physiological inhibitors of blood coagulation exist to limit coagulation to the 
site of injury.  Tissue factor pathway inhibitor (TFPI) is synthesized by 
endothelial cells and binds to factor Xa and the TF:VIIa complex thereby 
limiting their activity.  Antithrombin III is a glycoprotein, synthesized by the 
liver and endothelium, that forms a complex with thrombin and other serine 
proteases causing inactivation.  Complex formation is substantially promoted 
by the action of heparin.  Protein C is a vitamin K dependent protein that both 
inhibits coagulation and stimulates fibrinolysis.  Protein C is activated by 
thrombin in the presence of the cofactor thrombomodulin.  Activated protein C 
inhibits coagulation by inactivating factors VIIIa and Va, thereby reducing the 
rate of thrombin generation.  Protein S is another vitamin K dependent 
protein, synthesized in the liver and endothelium, which complexes with 
activated protein C and calcium ions on platelets and on the endothelial 
surface, to further amplify the inhibitory activity of activated protein C.  
Thrombomodulin is present in the vascular endothelium and forms complexes 
with thrombin.  This complexed thrombin activates protein C much faster than 
free thrombin but does not cleave fibrinogen, activate factors V and VIII or 
aggregate platelets.  Protein C activation by the thrombomodulin-thrombin 
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complex occurs more efficiently when protein C is bound to endothelial cell 
protein C receptor (EPCR). 
 
The fibrinolytic system is responsible for the degradation and dissolution of 
formed fibrin clot within the circulation.  This is mainly achieved by the rapid 
and localized formation of the proteolytic enzyme, plasmin, formed from the 
activation of plasminogen at the site of clot formation.   Plasminogen 
activators can be subclassified as tissue-type (t-PA), synthesized and stored 
in vascular endothelium, or urokinase-type (u-PA), synthesized in the kidney.  
Both convert plasminogen to plasmin, with the presence of fibrin accelerating 
the process for t-PA but not u-PA.  
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Figure 1 
 
 
 
Figure 1.1 Normal haemostasis: Initiation of coagulation 
 
Coagulation is initiated when tissue factor (TF) is exposed to blood.  
Circulating factor VII binds to tissue factor exposed at site of injury.  Tissue 
factor is expressed on subendothelial fibroblasts, injured vascular 
endothelium and activated monocytes.  The tissue factor bound factor VIIa 
converts either factor IX or X to their respective enzyme forms.  The resulting 
factor Xa activates a small amount of prothrombin to form thrombin in 
insufficient amounts to generate significant amounts of fibrin.  However initial 
thrombin production is sufficient to cause localized platelet aggregation and 
activation of critical cofactors factors V and VIII.  Tissue factor bound factor 
VIIa (extrinsic tenase complex) is rapidly inactivated by the formation of 
complex with factor Xa and tissue factor pathway inhibitor (TFPI).  
  
Prothrombin Thrombin
XaX
IX IXa
Activation of 
factors V, VIII, XI 
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TF:TFPI:VII:X 
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Inactivation
TFPI
Xa
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Figure 2 
 
 
 
Figure 1.2 Normal haemostasis:  Amplification of coagulation 
 
The small amount of thrombin generated during the initiation phase activates 
platelets and converts factors V to Va, VIII to VIIIa, and XI to XIa. Factor IXa, 
produced in the initiation phase, forms the intrinsic tenase complex with 
activated cofactor factor VIIIa on the activated platelet surface, in the 
presence of calcium. The intrinsic tenase complex (VIIIa:IXa:PL:Ca2+) 
amplifies the activation of factor X. Factor Xa, with its activated cofactor, 
factor Va, forms the prothrombinase complex on the platelet surface. The 
intrinsic tenase complex (VIIIa:IXa) and the prothrombinase complex (Va:Xa), 
co-localised on the platelet membrane in the presence of calcium, create a 
positive feedback loop, the result of which is the rapid generation of thrombin.   
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Fibrinogen Fibrin Stable fibrin 
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Figure 3 
 
 
 
 
Figure 1.3 Normal haemostasis:  Fibrinolytic system 
 
The blood fibrinolytic system comprises an inactive proenzyme, plasminogen, 
that can be converted to the active enzyme, plasmin. Plasmin degrades fibrin 
into soluble fibrin degradation products (FDPs) by plasminogen activators 
(PA) including tissue-type PA (t-PA) and urokinase-type PA (u-PA). t-PA 
mediated plasminogen activation is mainly involved in the dissolution of fibrin 
in the circulation. u-PA binds to a specific cellular receptor (u-PAR) resulting 
in enhanced activation of cell bound plasminogen. Inhibition of the fibrinolytic 
system may occur either at the level of the PA by plasminogen activator 
inhibitor (PAI)-1 or at the level of plasmin by a2-macroglobulin.   
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1.3 Bidirectional cross-talk between inflammation and 
coagulation  
 
To elucidate the pathogenesis of postoperative hypercoagulability it is crucial 
to understand the bidirectional relationship between the inflammatory and 
coagulation processes, in the context of surgical trauma.   
 
The postoperative phase constitutes a pro-inflammatory shift in the 
haemostatic balance in favour of activation of coagulation.  Inflammatory 
mediators elevate platelet count and reactivity, downregulate natural 
anticoagulant mechanisms, initiate the coagulation cascade, facilitate 
propagation of the coagulation response and impair fibrinolysis.   
 
In experimental models of inflammation, levels of coagulation activation, as 
measured with thrombin-antithrombin complex (TAT), corresponded with 
interleukin (IL)-8 levels, with the effect attenuated by tissue factor pathway 
inhibitor (Johnson et al. 1996).  Inflammation leads to the induction of TF 
expression on leucocytes, especially monocytes, as demonstrated 
experimentally by endotoxin and tumour necrosis factor [TNFa] (Parry and 
Mackman, 1998).  Fibrinogen is an acute phase reactant, elevated during 
inflammatory processes, with elevated levels associated with increased 
incidence of thrombotic events (Hantgan et al. 2001).  C-reactive protein 
(CRP), similarly raised in inflammation, has been shown to facilitate monocyte 
endothelial cell interactions, promoting both plasminogen activator inhibitor-1 
(PAI-1) and TF production (Devaraj et al. 2003), with elevated CRP levels 
correlating with an increased risk of myocardial infarction (Ballantyne et al., 
2004).  Platelet production is increased by pro-inflammatory mediators such 
as chemokine interleukin (IL)-6, with newly formed platelets activated at lower 
concentrations of thrombin, thus being more thrombogenic (Burstein, 1997). 
Platelet responsiveness is indirectly increased by the inflammatory mediators 
IL-6, IL-8, histamine and TNFa, via release of ultra-large von Willebrand 
factor (vWF) multimers from the endothelium (Bernardo et al., 2004).   
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In terms of natural anticoagulant pathways, antithrombin inhibitory activity is 
markedly reduced in acute inflammation (Opal, 2000).  Similarly 
concentrations of vascular heparin-like molecules are reduced by 
inflammatory cytokines and neutrophil activation products (Klein et al., 1992).  
The protein C pathway is very sensitive to downregulation by inflammation.  
Endotoxin, IL-1b and TNFa all reduce thrombomodulin and EPCR levels, and 
thus ability to generate activated protein C, in experimental models 
(Fukudome and Esmon, 1994).  Thrombomodulin, EPCR and activated 
protein C levels are similarly reduced in patients with sepsis (Faust et al., 
2001).  Furthermore, thrombomodulin and EPCR expression is reduced on 
endothelium overlying atherosclerotic plaque, likely secondary to inflammatory 
cytokines generated within the lesion (Laszik et al., 2001).  
 
Meanwhile the coagulation system can amplify the inflammatory response via 
numerous mechanisms.  Activated platelets release high concentrations of the 
pro-inflammatory CD40 ligand, which induces TF synthesis and is associated 
with increased pro-inflammatory mediators, such as chemokine IL-8 (Henn et 
al. 1998).  The extrinsic tenase complex (TF:VIIa) can activate protease 
activated receptors (PARs) on endothelium, especially in the presence of 
factor X, resulting in the expression of adhesion molecules that facilitate 
leucocyte-mediated injury (Isermann et al., 2001).  
 
Conversely, antithrombin decreases both TF and IL-6 expression in 
monocytes and endothelium (Souter et al., 2001).  Thrombomodulin has direct 
anti-inflammatory activity via its lectin like N-terminal, which is not involved in 
protein C activation.  In mutant gene mice lacking this lectin domain, 
leucocyte recruitment is significantly greater following endotoxin challenge 
(Pixley et al., 1993). Activated protein C inhibits NF-kB signalling in 
monocytes conferring anti-inflammatory activity (Yuksel et al., 2002).  
 
The fibrinolytic system has multiple effects on inflammatory processes.  
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Fibrinogen and fibrin increase production of pro-inflammatory cytokines, 
including TNFa, IL1b, and chemokines.  In fibrinogen deficient mice, models 
of inflammation produce reduced macrophage adhesion and less cytokine 
production (Szaba and Smiley, 2002).  Fibrinolysis inhibitors play a role in 
modulating cytokine production, with plasminogen activation inhibitor-1 (PAI-
1) inhibiting endotoxin-induced TNFa production by mononuclear cells 
(Robson et al. 1990). 
 
1.3.1 The integral role of the autonomic nervous system  
 
Given the bidirectional relationship between inflammation and coagulation, the 
impact of the sympathetic nervous system on this interaction is increasingly 
recognised.  Following physiological stress such as surgical trauma, but also 
with pain, anaesthesia and prolonged fasting, catecholamines (epinephrine 
and norepinephrine) levels are increased.  It is now well established that 
catecholamines regulate immune and inflammatory responses such that 
macrophages and neutrophils, when stimulated, can generate and release 
catecholamines de novo, which regulate mediator release from these 
phagocytes via interaction with adrenergic receptors (Flierl et al. 2007).  
Furthermore, literature suggests a dose-dependent stimulation of factor VIII 
activity, vWF antigen, tissue type plasminogen activator and platelets 
following infusion of epinephrine (Von Ka È Nel and Dimsdale 2009). 
 
 
 
 
 
 
 
Figure 4 
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1.4  Shared biological mechanisms in arterial and venous 
thrombosis 
 
Traditionally arterial and venous thromboses have been considered as 
separate entities with distinct pathogeneses.  However, with more 
epidemiological data there is increasing evidence of shared mechanistic 
properties, largely through inflammatory pathways.  Reports on the incidence 
of venous thromboembolic events with subsequent arterial thrombosis show a 
consistent association (Prandoni et al., 2003; Sørensen et al., 2007), with the 
relative risk for MI following a DVT or PE being 1.60 and 2.60 respectively, 
with the risk highest in the first year diagnosis of venous thromboembolism 
(Sørensen et al., 2007).   Moreover, of the agents specifically targeted to 
prevention of arterial thrombotic disease, statins show promise in reducing the 
occurrence of venous thrombotic risk (Ageno et al., 2008). 
 
This association has previously been attributed to common risk factors.  
Increasing age, concomitant cancer, immobility, obesity, smoking, diabetes 
and metabolic syndrome all increase the likelihood of developing both venous 
and arterial thrombotic events (Agnelli, 2004).  Within these risk factors, 
inflammation, elevated levels of coagulation factors and inherited 
thrombophilia are characteristics of both disorders.   
 
Arterial thrombosis mainly occurs at the site of a ruptured, lipid-rich 
atherosclerotic plaque, as the usual precipitating event in the transition from 
stable or subclinical atherosclerotic disease to myocardial infarction (MI), 
stroke or peripheral arterial occlusion. Pathologic studies of coronary arteries 
in acute MI suggest that the acute thrombosis likely involves activation of both 
platelets and the coagulation system.  Following atherosclerotic plaque 
rupture, platelets initially adhere to exposed subendothelial vWF and collagen. 
Platelet adhesion to the vascular subendothelium induces a series of 
intracellular signalling events that result in platelet activation. The binding of 
fibrinogen and vWF to the conformationally active form of the glycoprotein 
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IIb/IIIa receptor results in platelet aggregation, and further propagation of the 
platelet thrombus. Plaque rupture also results in exposure of subendothelial 
TF, which initiates the coagulation cascade and leads to the thrombin 
generation and fibrin clot formation. While arterial thrombi are traditionally 
considered to be composed predominantly of platelets, accumulating 
evidence suggests that certain arterial thrombotic disorders are associated 
with greater activation of the coagulation system, which results in occlusive 
thrombi that are relatively rich in fibrin (Chan et al. 2008).  
Venous thrombosis is more closely associated with stasis and 
hypercoagulability than changes in vessel wall integrity.  Precisely how 
thrombosis commences is poorly understood but impaired venous blood flow, 
with valvular sinus stasis and an associated hypoxic hypercoagulable 
microenvironment, is likely. Venous thrombi have a characteristic laminar 
structure, rich in fibrin and red blood cells and pervaded by large numbers of 
leukocytes (Wakefield et al., 1995).  Subsequent upregulation of procoagulant 
activity including TF on endothelium initiates the coagulation response.  In a 
mouse model of DVT, the rapid accumulation of neutrophils and monocytes 
were demonstrated as indispensable for DVT development with subsequent 
leucocyte-derived, TF-mediated activation of coagulation (von Brühl et al., 
2012).   
Although the initial phases of thrombosis are distinct, the pro-inflammatory 
milieu that propagates each response is shared. A persistent pro-
inflammatory response has long been recognised as a major determinant for 
MI and stroke as well as DVT and PTE.  In a large observational cohort of 
over 2.3 million surgical procedures, preoperative sepsis was an important 
independent risk factor for both arterial and venous thrombosis, with about 3 
times the risk of each complication compared to patients without evidence of 
preoperative sepsis (Donze et al., 2014).  This supports the hypothesis that 
inflammation contributes significantly to both processes through endothelial 
injury, platelet aggregation and a procoagulant, anti-fibrinolytic state.  
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1.5 Pathogenesis of surgery-associated hypercoagulability 
 
In considering perioperative hypercoagulability, it is necessary to examine to 
effect of both surgical and patient factors. 
1.5.1  Surgical trauma 
 
Surgical trauma is associated with tissue injury itself but also additive effects 
of anaesthesia, pain, hypothermia, bleeding and fasting which are all 
associated with physiological stress.  These factors combine to initiate 
inflammatory, hypercoagulable, stress and hypoxic states. 
The inflammatory state involves increases in TNF-a, IL-1b, IL-6 and CRP 
which, as previously discussed, may have a direct role in plaque fissuring 
prior to arterial thrombosis as well as venous thromboembolism.  The 
hypercoagulable state involves increased platelet number and reactivity, 
elevated prothrombotic markers such factor VIII and vWF, accompanied by 
decreases in coagulation inhibitors, AT and protein C (Bezeaud et al., 2007). 
Enhanced thrombin generation with increased thrombin-antithrombin (TAT) 
concentrations is seen following tissue injury (Schreiber et al. 2005) with 
raised D-dimer concentrations also indicative of recent thrombin burst in 
surgical patients (Yoo et al., 2009).  Hyperfibrinogenaemia is consistently 
demonstrated following surgery conferring increased risk of thrombosis even 
with normal markers of thrombin generation. Lison et al. examined a 
heterogeneous group undergoing major surgery and identified longitudinal 
changes in procoagulant factors.  Factor VIII, vWF and fibrinogen were 
consistently elevated compared to baseline from postoperative days 2 to 6.  
The majority of other clotting factors including factors II, VII, X, XI and XII 
showed a significant decrease from baseline at postoperative day 1 with all 
except factor VII remaining reduced until postoperative day 3 (Lison et al., 
2011).  
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1.5.2 Surgical subtype 
 
The severity of the surgical trauma and indeed the site of surgery produces a 
variable degree of hypercoagulability and pro-inflammatory response.  In a 
study comparing open and laparoscopic surgery, both produced elevations in 
prothrombin fragment F1+2, TAT and fibrinogen, with concordant decreases in 
AT, protein C and plasminogen but the changes were significantly more 
marked in the open surgery group.  The pro-inflammatory cytokine response, 
with increased IL-6 and IL-1b, was similarly more exaggerated following open 
surgery up to postoperative day 6 (Schietroma et al. 2004).   
Different surgical cohorts have demonstrated similar patterns of postoperative 
hypercoagulability, such as major abdominal surgery including liver resection 
and pancreatic surgery (Cerutti et al., 2004; De Pietri et al., 2010), joint 
replacement and major orthopaedic surgery including trauma (Selby et al., 
2009), neurosurgery (Goobie et al. 2001), aortic surgery (Gibbs et al., 1992), 
pelvic cancer surgery (Benyo et al., 2012) and surgery requiring 
cardiopulmonary bypass (Lison et al., 2011).  Without thromboembolic 
prophylaxis, the incidence of DVT has been shown to be 14% following 
gynaecological surgery, 22% following neurosurgery, 26% following 
abdominal surgery and between 44 and 60% following orthopaedic surgery 
(Bombeli et al. 2004).  Although this is likely influenced by the degree of 
immobilisation it may also reflect differential activation of coagulation related 
to the operative location.  The susceptibility of neurosurgical patients to 
postoperative thrombosis, for example, may be partly due to parenchymal 
manipulation of highly TF enriched brain tissue (Abrahams et al., 2002). 
Although each cohort is invariably exposed to a determined surgical insult, 
there are numerous additional perioperative factors which differ in each 
subgroup including mode of anaesthesia, volume of fluid administration, 
exposure to tumour in cancer surgery, introduction of biomaterials, relative 
circulatory stasis following immobilisation and the use of cardiopulmonary 
bypass (Rafiq et al., 2012).  
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1.5.3 Mode of anaesthesia 
 
Neuroaxial anaesthesia has been shown to have favourable outcome in terms 
of thromboembolic events compared to general anaesthesia.  Epidural 
analgesia is associated with lower PAI-1 levels and enhanced release of 
plasminogen activators, thus diminishing the procoagulant response.  This 
may be mediated by off-target anti-inflammatory properties of local 
anaesthetics, such as lidocaine, as shown in animal models (Beloeil et al., 
2005). 
1.5.4 Haemodiluton 
 
Intravenous fluid administration is required to a variable degree 
perioperatively, depending on surgical subtype and the extent of blood loss, 
fluid shifts and impaired vasomotor tone.  With larger intravascular volume 
resuscitation comes haemodilution, which has differential effects on 
coagulation depending on the type of fluid administered.  Numerous in vitro 
and in vivo studies have demonstrated induced hypercoagulability due to 
haemodilution up to 30%, with crystalloid solutions such as isotonic saline and 
Ringers lactate (Roche et al. 2006; Ruttmann et al. 1996).  The reverse effect 
has been shown at higher crystalloid dilutions of more than 40%, which are 
arguably less clinically relevant (Coats et al. 2006).  The underlying 
mechanism is poorly understood but may represent a disproportionate dilution 
of natural anticoagulants, such as AT, or alternatively an increase in thrombin 
generation, as suggested by unchanged TAT concentrations despite 
haemodilution seen in vivo (Ng et al., 2002).   
The effect of colloid administration is more equivocal and remains 
controversial.  All colloids induce a specific decrease in vWF and factor VIII:c. 
(De Jonge and Levi 2001). The consensus from multiple in vivo studies is that 
gelatin-induced haemodilution confers a net anticoagulant effect (Evans et al., 
1998).  The interaction between the negatively charged colloid and the 
platelet membrane, resulting in impaired platelet adhesion and aggregation is 
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a plausible mechanism. Similarly, in vitro haemodilution with hydroxyethyl 
starch solutions produces a hypocoagulable effect, particularly solutions 
comprised of higher molecular weight starches (Petroianu et al., 2000). 
1.5.5 Cancer 
 
The association between cancer and hypercoagulability is well established 
and first reported in 1865 by Trousseau.  Cancer is a major risk factor for the 
development of thromboembolic disease, increasing risk by 6 to 10-fold 
(Piccioli et al., 1996), with 20% new diagnoses of thrombosis associated with 
cancer (Thorson et al., 2014). 
The pathogenesis is multifactorial and can be subdivided into tumour-specific 
and iatrogenic factors.  Many tumour cells constitutively express TF, with 
exposure of TF-rich tumour cell surface or TF-microparticles (MPs) initiating 
coagulation activation by forming a complex with factor VII.  Numerous 
studies have demonstrated high levels of circulating tumour-derived TF-MPs 
in patients with active cancer (Geddings and Mackman, 2013).  TF expression 
increases with histologic grade in different cancer types, including pancreatic 
cancer, and a correlation between the level of TF and venous thromboembolic 
events has been demonstrated in pancreatic and brain tumours.  Cysteine 
proteases secreted by carcinoma cells can directly activate factor X to 
produce thrombin.  Tumour-derived inflammatory cytokines also serve to 
activate endothelial and platelet adhesion cells. In examining coagulation 
changes in thoracoabdominal malignancy, van Haren et al. demonstrated 
elevated markers of thrombin generation (prothrombin fragment F1+2), 
endothelial activation (factor VIII) and fibrinolysis (D-dimer) postoperatively, 
supported by hypercoagulable changes in rotational thromboelastometry (Van 
Haren et al., 2014).  Subjects became hypercoagulable immediately following 
surgery and did not return to normocoagulable parameters until 9 months 
after cancer resection, with around 30% deemed hypercoagulable even prior 
to surgery. 
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1.5.6 Age 
 
Increasing age is associated with an exponential increase in risk of both 
arterial and venous thrombotic events (Lowe, 2008).  There is a relative pro-
inflammatory, hypercoagulable state which may be exacerbated by increased 
likelihood of prolonged immobilisation and concurrent infections.  A persistent 
pro-thrombotic state is demonstrated by elevated D-dimer and prothrombin 
fragment F1+2  (Lowe et al., 1997), with increased IL-6 and CRP levels, in 
elderly cohorts, conferring a higher risk of arterial and venous thrombosis 
(Rosendaal et al. 2007). 
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1.6  Identification of the hypercoagulable state  
 
The detection of hypercoagulability is difficult because the coagulation 
mechanism is complex and thus far coagulation tests have not been well 
characterised for their capacity to detect hypercoagulability.   
Standard laboratory tests for coagulation include prothrombin time (PT), 
activated partial thromboplastin time (APTT), thrombin time (TT) and 
fibrinogen assay. Each provides assessment of different components of the 
traditionally described in vitro coagulation cascade.  PT measures the function 
of coagulation factors in the extrinsic pathway, APTT measures the intrinsic 
pathway, TT measures the conversion of fibrinogen to fibrin by thrombin and 
the fibrinogen assay quantifies the plasma concentration of fibrinogen.  These 
haematological parameters provide a well-established screening tool for in 
vivo, with alterations requiring specific factor assays to identify underlying 
abnormalities. Despite being widely used to diagnose bleeding diatheses, 
these routine investigations are unable to reliably detect hypercoagulability. 
Fibrinogen is an acute phase reactant and although associated with a pro-
thrombotic state is commonly raised in inflammatory states so is non-specific 
in determining hypercoagulability.  D-dimer is commonly used as an adjunct to 
imaging studies to exclude the presence of DVT or PTE (Aguilar et al., 2002).  
When a thrombus is degraded by thrombin, D-dimers and other fibrin split 
products are formed from cross-linked chains of fibrin clot.  However, D-dimer 
is similarly non-specific, with elevated D-dimer levels commonly seen in 
cancer, sepsis and excessive bleeding.  
The identification of more specific biomarkers of hypercoagulability is crucial 
to better assess thromboembolic risk such that these biomarkers have 
incremental predictive value for demonstration of the high risk or 
‘prethrombotic’ phenotype.  Such biomarkers reflect different functional 
haemostasis activity groups.   
Vascular injury, inflammation and endothelial activation are commonly 
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assessed by measurement of coagulation factor VIII, vWF, soluble TF, 
microparticles, thrombomodulin, tissue-type plasminogen activator (t-PA) and 
soluble P-selectin.  vWF is an adhesive protein produced by endothelial cells 
and plays a crucial role in platelet adhesion to the subendothelial matrix of 
vessels and in plasma factor VIII stability.  Increases in factor VIII:C and vWF 
have been shown to be independent risk factors for arterial thrombosis 
(Folsom et al., 1997).  Microparticles are formed by outward blebbing of 
plasma membranes of endothelial cells and leucocytes, subsequent release 
as small phospholipid vesicles and selective packaging of surface proteins 
including tissue factor and adhesion molecules.  TF-MPs are procoagulant not 
only due to the presence of TF but also the exposure of negatively charged 
phospholipids, such as phosphatidylserine, facilitates assembly of positively 
charged coagulation protein complexes (Figure 1.4).  Functional TF-MP 
assays have been shown to correlate with venous thromboembolism in 
cancer patients (Geddings and Mackman, 2013).  Thrombomodulin and 
EPCRs are abundant on the arterial endothelial wall and thus are elevated 
following vascular injury associated with initiation of coagulation.   
Thrombin generation can be assessed by biomarkers such as prothrombin F 
1+2 and thrombin-antithrombin (TAT) complexes, both commonly employed in 
assessing postoperative changes in coagulation (Bezeaud et al., 2007; Van 
Haren et al., 2014).  Individual clotting factors can be easily measured with 
activity assessed using clot-based reactions employing modifications of the 
APTT and PT. Natural anticoagulants such as protein C, protein S and 
antithrombin (AT) also have readily available commercial assays.  Widely 
used biomarkers for fibrinolysis include D-dimer and plasminogen activation 
inhibitor (PAI)-1, both routinely used in studies examining coagulation 
changes perioperatively. 
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Figure 1.4  Leucocyte-mediated tissue factor release 
 
When monocytes are stimulated by cytokines or endotoxin, it triggers tissue 
factor synthesis, shape change and release of microparticles, containing 
adhesion molecule, P-selectin glycoprotein-1 (PSGL-1).  Tissue factor rich 
microparticles bind to activated platelets through the counter receptor P-
selectin thereby concentrating tissue factor on the site of injury.  
Microparticles also have negatively charged surface phosphatidylserine (PS) 
allowing tissue factor to concentrate at the injury site and express potent 
coagulant activity.   
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Tests of global haemostasis have attracted attention in examining not only 
hypercoagulability but in the management of major haemorrhage.  
Viscoelastic modalities are dynamic tests of whole blood which evaluate the 
kinetics of clot formation, mechanical properties of clot and time to dissolution 
of clot (Lancé 2015).  Tensile strength of clot provides information about the 
capacity of clot to achieve haemostasis and kinetics determine the adequacy 
of quantitative factors available for clot to form.  Therefore, whole blood 
viscoelastic testing provides a composite picture reflecting the interaction of 
plasma, blood cells and platelets, rather than isolated components, thus more 
closely reflecting the situation in vivo.  There are three commercially available 
point-of-care (POC) viscoelastic devices:  thromboelastography (TEGâ), 
rotational thromboelastometry (ROTEMâ) and Sonoclot.  All devices measure 
rate of fibrin formation, clot strength and clot lysis. 
Viscoelastic testing has been extensively used in surgical cohorts associated 
with major blood loss, such as liver transplantation and cardiac surgery, to 
continuously monitor haemostasis and has beenshown to effectively limit 
unnecessary transfusion of blood components (Whiting et al., 2015; Wikkelsø 
et al., 2016).  However, it is now well established in the clinical setting as a 
rapid means to detect and quantify hypercoagulability and predict thrombotic 
risk.  Postoperative hypercoagulability by viscoelastic criteria has been 
demonstrated for TEG (Mahla et al., 2001; De Pietri et al., 2010), ROTEM 
(Van Haren et al., 2014) and Sonoclot (Pivalizza et al. 1997) Viscoelastic 
defined hypercoagulability has been shown to consistently correlate with 
corresponding changes in individual prothrombotic biomarkers (Bezeaud et 
al., 2007; Lison et al., 2011).  Moreover, in patients deemed hypercoagulable 
by viscoelastic criteria, there is a clear association with likelihood of both 
arterial and venous thrombotic events, in multiple clinical settings (Kashuk et 
al., 2009; McCrath et al., 2005; Rafiq et al., 2012) 
Thrombin generation tests (TGTs) are an alternative global haemostatic 
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assessment hitherto largely confined to the research setting.  TGTs quantify 
the continuous and dynamic properties of thrombin generation in the presence 
of fibrin(ogen) following a given tissue factor stimulus. The classic thrombin 
generation curve has a waveform from which a series of specified parameters 
can be calculated (lag time, thrombin generation velocity, peak thrombin 
concentration, time-to-peak thrombin and endogenous thrombin potential). In 
comparison to viscoelastic tests, which assess the fibrin clot formation in 
general, the TGT could give more information on the haemostatic capacity in 
total because the generation of thrombin does not stop at the moment when 
the fibrin clot has been generated. TGT can be performed in platelet poor 
plasma (PPP), platelet rich plasma (PRP) or whole blood. The major 
drawback of TGTs is the time taken to perform which has precluded more 
widespread use clinically.  However, there are numerous studies to validate 
the use of TGTs in the context of postoperative hypercoagulability (Lison et 
al., 2011; Potze et al., 2015).  
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1.7 The perioperative conundrum in managing 
postoperative hypercoagulability 
 
Surgical intervention is associated with higher thromboembolic risk such that 
the indication for thromboprophylaxis should be evaluated in all surgical 
patients.  However thrombotic risk needs to be balanced against bleeding risk 
on an individualised basis taking into account the likelihood of clinically 
significant intraoperative or immediate postoperative bleeding versus specific 
patient and surgical risk factors for thromboembolic complications.  This net 
risk is dynamic with the absolute magnitude and duration not equal for all 
patients or for a given individual over time.   
Pharmacological thromboprophylaxis is the mainstay of treatment, typically 
with low molecular weight heparin (LMWH), together with early ambulation 
and mechanical thromboprophylaxis, such as compression stockings and 
intermittent pneumatic calf compression.  Numerous guidelines have been 
published to provide risk stratification in different cohorts and encourage 
appropriate thromboprophylaxis proportional to the net risk (Farge et al. 2012; 
Geerts et al. 2008).  Since the widespread introduction of pharmacological 
thromboprophylactic regimes worldwide, the rates of thromboembolic 
complications have been reduced by up to 80% in high-risk surgical 
populations (Agnelli, 2004).  However, concern remains over bleeding 
complications, in the context of both perioperative anticoagulant and 
antiplalelet administration.  
Perioperative administration of aspirin has been shown to prevent 
thromboembolic complications by inhibiting thrombus formation.  Although 
there is strong evidence that aspirin prevents venous thromboembolism after 
non-cardiac surgery (PEP Trial Collaborative Group 2000), anticoagulant 
therapy is more commonly used for the prevention of venous 
thromboembolism.  Nevertheless, approximately one third of patients 
undergoing non-cardiac surgery receive perioperative aspirin (Devereaux et 
al., 2005).  In the POISE-2 study, administration of aspirin preoperatively and 
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immediately postoperatively had no significant effect on the rate of a 
composite of death or nonfatal myocardial infarction but did increase the risk 
of major bleeding (Devereaux et al., 2014a). 
Therefore, in detecting and managing postoperative hypercoagulability, 
challenges remain in mitigating thrombotic risk without exaggerating 
perceived bleeding risk.  By examining the pathogenesis of the perioperative 
pro-thrombotic phenotype, there are opportunities to identify potential 
thrombomodulatory targets outside the traditional anticoagulant or antiplatelet 
regimes.  Numerous commonly used perioperative agents have putative anti-
inflammatory or anti-thrombotic off-target actions, including sympatholytics 
(Giebelen et al., 2008) and statins (Steiner et al., 2005), and thus require 
further evaluation on the potential to ameliorate hypercoagulability without 
necessarily modifying bleeding risk.  
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1.8 Conclusion 
 
Thromboembolic complications are a major determinant of postoperative 
morbidity and mortality.  Hypercoagulability promoted by the pro-inflammatory 
surgical stimulus is implicated in both arterial and venous thrombosis.  
Accurate identification and quantification of perioperative hypercoagulability is 
vital to determine high risk groups with a ‘pre-thrombotic’ phenotype.  
Viscoelastic testing such as thromboelastography allows more dynamic global 
assessment of changes in coagulation status seen perioperatively compared 
to standard haematological investigations.  Thromboelastography has been 
demonstrated to reliably detect postoperative hypercoagulability and predict 
risk of thromboembolic complications in specific surgical cohorts.  
Perioperative pharmacological thromboprophylaxis and aspirin significantly 
reduces risk of postoperative thromboembolic complications but benefits are 
offset by concern of bleeding in high risk surgery.   
Therefore, further work is essential to better characterise the perioperative 
hypercoagulable state by employing multimodal assessment of both 
coagulation and inflammation processes and examining the effect of surgical 
factors, such as surgical subtype and haemodilution, on coagulation status. 
To understand the aetiology more comprehensively, it is necessary to further 
explore the precise effect of inflammatory stimuli on coagulation parameters, 
and robustly determine the thrombomodulatory potential of different 
perioperative therapies with previously reported anti-inflammatory or anti-
thrombotic properties.  
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1.9 Hypothesis 
 
The presence of an inflammatory stimulus, both clinically in high risk surgical 
patients, and in vitro with an inflammatory model produces a reproducible 
hypercoagulable state, as defined by thromboelastographic criteria and 
corroborated by selected haematological biomarkers 
 
 
1.10 Aims 
 
1. Comprehensively characterise longitudinal alterations in coagulation 
parameters following high risk major surgery using standard 
haematological investigations, thromboelastography and selected 
coagulation and inflammatory biomarkers 
2. Examine the effect of different surgical factors such as surgical subtype 
and the role of different perioperative fluid regimens on the same 
perioperative coagulation parameters 
3. Determine the effect of a standardised inflammatory stimulus on the 
coagulation status of both healthy volunteers and preoperative surgical 
patients, using thromboelastography and a validated in vitro model of 
inflammation. 
4. Evaluate the putative thrombomodulatory potential of selected 
perioperative therapies on the inflammation-induced hypercoagulability 
produced in the same in vitro model of inflammation. 
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2.1  Clinical Study 
 
The clinical study cohort investigated in this thesis was a subset of surgical 
patients recruited to the POM-O (Post Operative Morbidity Oxygen) trial. Trial 
patients in this sub-study were recruited exclusively at the Royal Free 
Hospital, between May 2011 and October 2012 and prospectively studied 
(n=50).   
 
2.1.1 POM-O trial  
 
The parent POM-O trial (ISCRTN 76894700; UK NIHR Portfolio CSP: 22346) 
was a multicentre, double-blind, randomised controlled trial undertaken in four 
London university hospitals.  All subjects presented for major elective intra-
abdominal surgery, predominantly hepatobiliary at the Royal Free site, 
associated with a high incidence of postoperative morbidity.  The primary 
objective of the trial was to determine if enhancing oxygen delivery by goal-
directed therapy (GDT) to a pre-determined target, immediately 
postoperatively, reduced morbidity and length of hospital stay in high-risk 
surgical patients.  The secondary objective was to demonstrate whether there 
was an acquired loss of parasympathetic autonomic function as an 
unintentional result of goal directed haemodynamic therapy.  However, the 
POM-O thromboelastography (TEG) sub-study detailed here specifically 
examined alterations in the perioperative coagulation profile in a smaller 
group of subjects, in addition to the outcome measures for the parent trial.  
 
Adult patients undergoing major elective surgery expected to last for at least 
120 minutes were eligible for recruitment, provided the following high-risk 
criteria were satisfied: American Society of Anesthesiologists classification of 
3 or more; surgical procedures with an estimated or documented risk of 
postoperative morbidity (as defined by the Postoperative Morbidity Survey) 
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exceeding 50%; modified Revised Cardiac Risk Score of 3 or more, as 
defined by age 70 years or more, a history of cardiovascular disease 
(myocardial infarction, coronary artery disease, cerebrovascular accident, 
electrocardiographic evidence for established cardiac pathology), cardiac 
failure, poor exercise capacity (anaerobic threshold <11 mL/kg per min 
assessed by cardiopulmonary exercise testing or Duke Activity Status Index), 
renal impairment (serum creatinine ≥130μmol/L), or diabetes mellitus.  
Exclusion criteria included refusal of consent, pregnancy, lithium therapy or 
allergy, recent myocardial ischaemia (within the previous 30 days), acute 
arrhythmia, acute bleeding, and patients receiving palliative treatment only.  
Across the four trial sites, 599 subjects were assessed for eligibility but 395 
were excluded due to either patient refusal, type of surgery planned or 
undertaken not fulfilling inclusion criteria, participation in other research trials, 
anaesthetist refusal or lack of research staff.  Therefore, 204 subjects were 
enrolled and subsequently randomised to either treatment arm, between May 
2010 and February 2014. 
The POM-O trial was approved by the South London Research Ethics 
Committee Office (09/H0805/58).  Written informed consent was obtained 
prior to enrolment to POM-O. Potential participants were screened by local 
investigators having been identified from surgical and pre-admission clinic 
lists, and by communication with the relevant nursing, surgical and medical 
staff. There were no financial payments offered to patients.  Non-English 
speakers were provided with full access to NHS translation services to ensure 
appropriate understanding of the trial and consent process. Patients who 
lacked capacity to give or withhold informed consent were not recruited. 
 
Anaesthesia was undertaken using a protocolised regimen for all enrolled 
patients.  Before any anaesthetic intervention, an arterial line was inserted 
into a radial artery under local anaesthetic in the anaesthetic room. 
Preoperative oxygen delivery was calculated using the LiDCO cardiac output 
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monitor, after the lithium-based calibration, by determining preoperative 
cardiac output. At least three calibration curves were constructed routinely to 
ensure accuracy of haemodynamic data. Once these calibration data were 
obtained, anaesthetic preparation (insertion of thoracic epidural catheter, 
endotracheal intubation) commenced and surgery followed, during which time 
haemodynamic data were captured throughout, but not revealed to any 
operating room staff including attending anaesthetists. Alternative 
haemodynamic monitors were permitted during surgery.  
 
2.1.1.1  Randomisation and masking  
 
Randomisation occurred immediately following completion of surgery.  The 
randomisation list was generated by Stata and then concealed by envelope. 
Participants were centrally allocated to treatment groups. All principal 
investigators were masked to study group allocation. To further minimise the 
possibility of bias, the medical research and nursing staff delivering the 
haemodynamic protocol did not reveal the study group allocation to critical 
care staff, attending surgical or physician teams. Every patient enrolled had a 
central venous catheter inserted after induction of anaesthesia. A syringe with 
saline or dobutamine was connected via extension tubing to the central 
venous catheter, with the identity of the syringe contents covered. Patients 
were followed up by an investigator unaware of the patients’ achievement or 
not of the baseline oxygen delivery target. All participants were admitted as 
elective postoperative cases to a critical care facility.  
 
2.1.1.2 Postoperative haemodynamic therapy intervention 
 
The intervention period commenced once the patient reached the critical care 
unit after surgery and continued for 6 hours (Figure 2.1). Both randomisation 
groups (goal-directed therapy and control patients) were managed by 
research staff during the postoperative study period. Before the intervention, 
General Methods 
 
 
 
43 
the LiDCO lithium-based sensor was recalibrated to determine cardiac output. 
Research staff were entirely responsible for haemodynamic management 
within this period, and intensive care unit staff played no part in this aspect of 
care. All patients received standard measures to maintain oxygenation (SpO2 
≥94%), haemoglobin (>80 g/L), core temperature (≥36°C), and heart rate 
(<100 beats per min). Supplemental oxygen, packed red cells, and forced 
warm-air heating were administered when any of these thresholds were 
breached. Compound sodium lactate (Hartmanns solution) was administered 
at 1 ml/kg per hour as maintenance fluid, with additional fluid administered 
only by the study research staff guided by pulse rate, arterial pressure, urine 
output, and central venous saturation. Mean arterial pressure was maintained 
between 60 mm Hg and 90 mm Hg using an α1- adrenoceptor agonist as 
needed. Postoperative analgesia was provided by thoracic epidural infusion 
(low dose mixture of bupivacaine and fentanyl), intravenous infusion, or 
patient-controlled analgesia (morphine or fentanyl).  
The goal-directed therapy group patients received intravenous fluid and 
inotropic therapy guided by the haemodynamic therapy algorithm targeting the 
preoperative oxygen delivery value for each individual patient. The first hour 
of the intervention period was dedicated to achieving maximum stroke volume 
with the use of the synthetic gelatin-based colloid, Gelofusineâ. If the 
preoperative oxygen delivery target was not met after the first hour of stroke 
volume optimisation, patients in the goal-directed therapy group also received 
an intravenous infusion of dobutamine (1–20 µg/kg/min) through a central 
venous catheter. Administration and dose of dobutamine were strictly 
controlled by ensuring that heart rate remained at less than 100 beats per 
min, or not more than 25% from baseline heart rate at the start of the 
intervention period. If heart rate exceeded one or more of these thresholds, 
the dobutamine infusion was discontinued. At the end of the 6 hour 
intervention period, dobutamine if needed was titrated to stop over the course 
of the next hour. Cardiac output monitoring was not done in the control group 
unless specifically requested by clinical staff because of patient deterioration. 
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Haemodynamic parameters were recorded in the control group, but 
calculation of oxygen delivery values was delayed until the end of the 
intervention. All other management decisions were taken by senior clinicians 
who retained the discretion to alter any aspect of patient care, having 
informed the site principal or chief investigator if this affected haemodynamic 
management during the study intervention period.  
Achievement of the preoperative oxygen delivery target was determined by 
analysing mean oxygen delivery throughout the postoperative intervention 
period, and relating this value to the number of predefined hourly time points 
during the intervention where postoperative oxygen delivery met, or 
exceeded, the preoperative value. 
 
2.1.1.3 Data collection 
 
Data entry was performed using a secure university site. Automated validation 
checks included plausibility ranges and cross-checks between data fields. 
Further manual data checks were done both centrally and through source 
data verification.  
Preoperative clinical and demographic data were recorded prospectively, 
including age, sex and comorbidities including hypertension, ischaemic heart 
disease (IHD), cerebrovascular disease and chronic kidney disease (CKD).  
Intraoperative clinical variables were recorded, such as duration of surgery, 
estimated blood loss, volume of fluid administered, patient blood management 
details, and vasopressor support.  Similarly, postoperative haemodynamic 
variables were collected including volume of fluid administered, presence of 
dobutamine infusion and patient blood management details.   
 
Postoperative visits were performed on postoperative day (POD) 2, 3, 7 and 
14, where appropriate, in addition to the day of hospital discharge, with data 
and samples collected as indicated (Figure 2.2).  Postoperative morbidity was 
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assessed using both the Postoperative Morbidity Survey (POMS) and the 
Clavien-Dindo scale, with grade II or more defining a deviation from normal 
postoperative recovery (Clavien et al., 2009).  
  
Further postoperative outcomes were collected including time to become 
morbidity free and length of hospital stay.  Parasympathetic autonomic 
function was assessed by specific heart rate variability parameters, measured 
by Holter ECG recording at pre-determined perioperative time points. 
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Figure 5 
 
Figure 2.1 POM-O trial postoperative haemodynamic therapy 
intervention protocol 
 
Treatment algorithm for each trial patient on day of surgery.  Patients 
randomised to postoperative haemodynamic therapy intervention, CONTROL 
or GDT.  DO2I = oxygen delivery index.  UO = urine output.  MAP = mean 
arterial pressure.  ScvO2 = central venous oxygen saturation 
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Figure 6 
 
 
 
Figure 2.2 POM-O trial data and sample collection summary 
 
Flowchart to demonstrate perioperative time points used for data and sample 
collection.  Blood analysis denotes samples taken for parent POM-O trial and 
routine blood tests as per standard care.  POM-O TEG study blood samples 
were taken to coincide with the time points shown plus 2 additional time points 
pre- and post-intervention. 
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2.1.2  POM-O TEG sub-study 
 
This sub-study evaluated alterations in the coagulation profile in POM-O trial 
subjects at the Royal Free Hospital site only, between May 2011 and October 
2012 (n=50).   
 
Blood samples were collected for analysis by thromboelastography at 5 
perioperative time points: immediately postoperatively (prior to POM-O study 
intervention), 6 hours postoperatively (following POM-O study intervention) 
and both 2 and 5 days postoperatively (early morning samples).  
 
Samples were obtained preoperatively from 20-gauge arterial cannulae in 
conscious surgical patients but postoperatively by venepuncture, from the 
antecubital fossa, using a 19G butterfly needle.  Arterial samples were drawn 
from transducer sets primed with 0.9% NaCl, with the first 5ml discarded. 
Similarly, the first 5ml of venepuncture samples were discarded to minimise 
the effects of the tourniquet.  Samples were collected into Vacutainer tubes 
(Becton Dickinson, Plymouth, UK) containing sodium citrate 3.8% (for 
thromboelastography and laboratory coagulation screen) or EDTA (for full 
blood count) and gently inverted to ensure mixing of sample. 
 
Thromboelastography with citrated native TEGs was performed, following 
recalcification of citrated blood, 20 mins after collection at each time point. 
 
Routine haematological parameters were measured, including full blood 
count, coagulation screen (including prothrombin time and activated partial 
thromboplastin time) and fibrinogen level at each perioperative time point, as 
part of routine perioperative care, within the Haematology clinical laboratory at 
the Royal Free Hospital.  Haemoglobin, haematocrit and platelet count were 
measured using a Sysmex FBC analyser.  Prothrombin time (PT), activated 
partial thrombin time test (APTT), thrombin time (TT), fibrinogen and D-
dimers were all measured using an ACL TOP coagulometer 
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[using Recombiplastin-2G, SynthaSIL, thrombin reagent, QFA reagent and D-
dimer reagents respectively (all from Instrumentation Laboratory, USA)]. 
 
In a further subset of patients, a more detailed haematological assessment 
was undertaken to evaluate corroborative haematological data to any 
alterations in thromboelastographic variables (n=15).  Further blood samples 
were taken at the same perioperative time points with the exception of the 
post-intervention sample as this usually occurred outside normal laboratory 
working hours.  Therefore, an early morning sample on the first postoperative 
day was taken as a surrogate for the post-intervention sample.   
 
Additional blood samples were collected into Vacutainer tubes (Becton 
Dickinson, Plymouth, UK) containing either sodium citrate 3.8% or SST (silica 
and gel) and a single S-Monovette tube (Sarstedt, Leicester, UK) containing 
0.106mmol/l trisodium citrate, with pre-added corn trypsin inhibitor (CTI).  CTI 
is used to abolish contact activation and prevents imprecision in thrombin 
generation assays, and was added to S-Monovette tubes within 72 hrs prior to 
sample collection.  These samples were analysed in a specialist Haemophilia 
clinical laboratory at the Royal Free Hospital and processed by a dedicated 
senior biomedical scientist. 
 
Detailed haematological assessment involved measurement of: individual 
clotting factor levels; D-dimer and von Willebrand factor antigen (vWF:Ag); 
natural anticoagulants, such as antithrombin, protein C and protein S; and 
biomarkers of endothelial injury, such as syndecan-1, thrombomodulin and 
soluble P-selection.  Moreover, thrombin generation assays were performed 
at each time point.  Thus a global assessment of coagulation was undertaken 
encompassing endothelial activation, activation of coagulation with thrombin 
generation and fibrinolysis.   
 
Factor VIII (FVIII:C) levels were measured by one stage APTT based clotting 
assay and factors VII (FVII), factor V (FV), factor VII (FVII) and factor X (FX) 
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were measured by one stage prothrombin based assays as 
previously described. vWF antigen was measured by ELISA, as previously 
described (Agarwal et al., 2012). 
 
Plasma levels of tissue factor activity, tissue factor pathway inhibitor (TFPI), 
thrombomodulin (all Sekisu, American Diagnostica GmbH, Germany) and 
syndecan-1 [CD138] (Abcam Ltd, Cambridge, UK) were measured according 
to the manufacturers’ instructions. 
 
Thrombin generation (TG) was assessed at all time-points on PPP by using 
the Calibrated Automated Thrombography (CAT) method as described 
(Hemker et al. 2003) TG assays were triggered with 5pM tissue factor (TF) 
reagent containing 4µM Phospholid (Thrombinoscope B.V., Maastricht, 
Netherlands). Parameters measured were endogenous thrombin potential 
(ETP) or total thrombin generated, peak height (PH) and lag time (LT) or time 
to initial thrombin formation, time to peak, ST and Slope. All TG values were 
normalised using the same normal pooled plasma (NPP) that had been 
included in each TG run of samples, by dividing the TG parameter with the 
respective NPP parameter value and multiplying by 100 to obtain a 
normalised % parameter result. 
 
. 
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2.2  Ex vivo incubation experimental study 
 
2.2.1  LPS TEG experimental model 
 
This experimental model was developed on the basis of published work which 
both validated the use of lipopolysaccharide (LPS) in vitro as a surrogate for 
the systemic inflammatory response syndrome (SIRS) seen following surgery 
and the use of thromboelastography in the assessment of coagulation 
activation seen perioperatively (Koch et al. 2009; Spiel et al. 2006; 
Zacharowski et al. 2006). 
 
Lipopolysaccharide (LPS), or endotoxin, is a key component of the cell 
membrane of gram negative bacteria. Endotoxin is one of the most potent 
known activators of innate immunity and the inflammatory response in 
humans.  Endotoxin is hypothesized to enter the systemic circulation by 
translocation of gut commensal microbes or by LPS fragments moving across 
the intestinal mucosal barrier during period of relative hypotension and 
hypoperfusion.  LPS is released into sterile compartments of the organism 
and in turn is detected by pattern recognition receptors (PRRs), like toll-like 
receptor (TLR)4, resulting in initiation of inflammation and coagulation 
(Nakamura et al. 2007).  TLR4 is the key receptor involved in LPS recognition 
and signal initiation, with TLR4 mutations in humans associated with 
hyporesponsiveness to LPS (Arbour et al., 2000).  Serum LPS binding protein 
(LBP) is responsible for extracting LPS from bacterial membranes or vesicles 
released by bacteria. LBP then transfers LPS to CD14, which can be found 
either in soluble form or linked to the cell surface by a 
glycosylphosphatidylinositol anchor. CD14 splits LPS aggregates into 
monomeric molecules and presents them to the TLR4MD-2 complex. 
Aggregation of the TLR4MD-2 complex after binding LPS leads to activation 
of multiple signaling components, including NF-B, and the subsequent 
production of pro-inflammatory cytokines.  The intracellular signalling 
mechanism for LPS is complex but LPS stimulation of coagulation has been 
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shown to be reduced by both specific inhibition of the NF-κB pathway and p38 
MAPK inhibition in an ex vivo incubation model using thromboelastography 
(Koch et al., 2012). 
Experimental models characterising the effect of LPS stimulation on both 
inflammation and coagulation have been described.  LPS-stimulated human 
whole blood is associated with elevated levels of pro-inflammatory cytokines, 
such as TNFa, IL-6 and IL-8, and increased cytokine gene expression in both 
in vivo and in vitro models (De Forge and Remick, 1991).  Different 
experimental paradigms have consistently demonstrated the ability of LPS to 
initiate coagulation activation via tissue factor (TF) expression on endothelial 
cells and blood monocytes (Moore et al., 1987), mainly regulated at 
transcriptional level (Franco et al., 2000).  LPS administration to human 
subjects is associated with elevated TF positive monocytes and biomarkers of 
coagulation activation, such as prothrombin fragment F1+2, in vivo 
(Pernerstorfer et al., 1999).  Endotoxin activity levels have been shown to 
directly correlate with viscoelastic parameters of coagulation activation in 
patients with early systemic inflammation, independent of the cause being 
non-infectious or infectious (Koch et al. 2013)  
Viscoelastic testing has been extensively used for the determination of LPS 
stimulated coagulation activation in whole blood samples.  Following addition 
to whole blood, LPS reduces clotting time (CT) as measured with rotational 
thromboelastometry, with an 50% effective concentration (EC50) of 18μg/mL 
(Zacharowski et al., 2006).  Endotoxaemia in vivo produces a 
hypercoagulable state with shortened CT correlating well with peak plasma 
levels of prothrombin fragments F1+2 (Spiel et al., 2006).  In whole blood 
stimulated with increasing concentrations of LPS ex vivo, alterations in all 
ROTEM parameters consistent with increased activation of coagulation, were 
demonstrated with LPS concentration of 100ng/ml (Koch et al., 2009b). 
Therefore, on the basis of the validated use of thromboelastography for the 
assessment of inflammation-induced activation of coagulation, an ex vivo 
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incubation model was chosen for this LPS-TEG sub-study, using LPS at a 
final concentration of 100ng/ml.  The effect of LPS, compared to endotoxin-
free saline, on activation of coagulation in whole blood of both surgical 
patients and healthy volunteers was quantified, using thromboelastography.  
Furthermore, the hypothesis that various perioperative drugs, associated with 
potential to reduce thrombotic risk,  could attenuate the procoagulant effect of 
LPS was tested using thromboelastography. 
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2.2.2 Study population 
 
Subjects included both healthy drug-naïve volunteers, from the Anaesthetics 
Department at the Royal Free Hospital, and patients recruited to the POM-O 
TEG clinical sub-study, as described earlier.  Enrollment of both healthy 
volunteers and additional blood sampling from the patients recruited to the 
POM-O study was undertaken following local Research Ethics Committee 
approval (UCL Ethics Project Approval ID 4353/001 & 4353/002) and written 
consent.  
 
Exclusion criteria for healthy volunteers included subjects less than 18 years 
old, pregnancy, any known history of coagulopathy and concomitant use of all 
prescription or over the counter medications.  POM-O trial surgical patients 
taking preoperative anticoagulation therapy were excluded and any 
antiplatelet medications were discontinued 7 days preoperatively. Written 
informed consent was obtained prior to enrolment.  There were no financial 
payments offered to volunteers.   
 
 
2.2.3 Study protocol 
 
The study was designed as a prospective case-control study.  Following 
enrolment, blood samples were taken at a single time point (immediately 
preoperatively in the surgical cohort).   
 
Blood samples were obtained either from 20-gauge arterial cannula in 
conscious surgical patients or by venepuncture in healthy volunteers, from the 
antecubital fossa, using a 19G butterfly needle.  Arterial samples were drawn 
from transducer sets primed with 0.9% NaCl, with the first 5ml discarded. 
Similarly, the first 5ml of venepuncture samples were discarded to minimise 
the effects of the tourniquet.  Samples were collected into 2-3 Vacutainer 
tubes (Becton Dickinson, Plymouth, UK) containing sodium citrate 3.8% and 
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gently inverted to ensure mixing of sample.  Arterial blood sampleing was 
limited to preoperative collection whereas all other samples were venous 
blood.  Previous studies have highlighted potential differences in TEG 
parameters between arterial and venous blood, in cardiac surgical patients, 
with a tendency to shorter R-time and larger MA in native arterial samples 
(Manspeizer et al., 2001).  Therefore, it was important to ensure a 
standardised sampling technique was used in each subject group.   
 
Aliquots of 1 ml citrated blood were subsequently transferred to Eppendorf 
(1.5ml) tubes prior to incubation at 37oC for 4 hours.  In each subject, 1ml 
citrated blood was incubated with either 10μl LPS (Salmonella typhus) or 
endotoxin-free sterile 0.9% NaCl (normal saline), added immediately prior to 
incubation.  The final concentration of LPS was 100ng/ml, although a further 
subset of experiments was conducted with lower concentrations, following 
dilution of stock LPS solution. 
 
For drug treated samples, only venous whole blood from healthy volunteers 
was used.  Each citrated blood aliquot was pre-treated with a selected drug 
20 mins prior to the addition of LPS or sterile saline.  Samples were gently 
inverted following both drug pre-treatment and addition of LPS or sterile 
saline, to ensure mixing of the sample (Figure 2.3).  Drug solutions had sterile 
normal saline, unless otherwise stated, as vehicle control. 
 
Following incubation, thromboelastography was performed, after 
recalcification of citrated blood, immediately before 4 hours following the time 
of blood collection.  TEG measurements have been demonstrated to produce 
accurate and reproducible results up to 4 hours in citrated blood (Camenzind. 
et al, 2000). 
 
In drug treated samples, whole blood was incubated with doses at the upper 
range of plasma concentrations reported in previous publications.  Drug 
selection was based on existing use in the perioperative scenario, together 
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with previously reported putative anti-inflammatory or anti-thrombotic effect. 
 
Perioperative drugs tested were categorised broadly into the following 
categories, with clinically relevant concentrations shown in Table 2.1. 
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Figure 7 
 
 
 
Figure 2.3 LPS TEG study experimental protocol 
 
Blood samples were collected 20 mins prior to pre-treatment with nominated 
drug or sterile saline (control) in 1ml aliquots of citrated whole blood.  
Following 20 minutes, pre-treated samples were then treated or ‘spiked’ with 
LPS or sterile saline (control) to form 4 corresponding samples.  After 
adequate mixing, samples were transferred for incubation before TEG 
analysis was performed at 4 hours.  A typical TEG trace with 4 superimposed 
traces for each corresponding sample with own control is shown. 
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Table 2.1 Selected perioperative drug classes and doses 
administered in ex vivo LPS incubation model 
 
Table 1 
Drug class Experimental drug & 
dose 
Reference 
Statins (HMG coA 
reductase inhibitors) 
Simvastatin (10-
25ng/ml) 
(Backman et al., 2000)  
(Ziviani et al. 2001)  
β1-adrenergic receptor 
antagonists 
Metoprolol (100ng/ml) 
Atenolol (500ng/ml) 
 
Carvedilol (100ng/ml) 
(Aqil et al., 2007) 
(Spanakis and Niopas 
2013) 
(Neugebauer et al., 1990) 
α2-adrenergic receptor 
agonists 
Clonidine (5ng/ml) (Anavekar et al., 1982)  
Steroids Dexamethasone 
(40ng/ml or 100nM) 
(Dandona et al., 1999) 
Local anaesthetics Lidocaine (5ng/ml) (Herroeder et al., 2007)  
Antioxidants N-acetylcysteine 
(500ng/ml) 
(Prescott et al., 1989)  
Electrolytes Magnesium sulphate 
(2mM) 
(Maier et al., 2004) 
 
 
 
Experimental in vitro drug doses based on previous publications of upper  
range of plasma concentrations (References included) 
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2.3 Thromboelastography (TEG) 
 
2.3.1 Principles of thromboelastography 
 
Thromboelastography was first described in 1948 (Hartert 1948), as a method 
to assess the viscoelastic properties of coagulation in whole blood.   
Viscoelastic point-of-care haemostatic assays, such as TEG and rotational 
thromboelastometry (ROTEM), provide a graphical representation of the 
different stages of the haemostatic process from the initiation of clot formation 
to subsequent clot lysis.  The term ‘thromboelastography’ or TEGâ was used 
generically until 1996 when both became registered trademarks of 
Hemoscope Corp (Niles, IL) and so hitherto describes assays performed by 
Hemoscope, or latterly, Haemonetics instruments only.  Rotational 
thromboelastometry (ROTEMâ) is an alternative instrument using modified 
technology developed by Pentapharm GmbH (Munich, Germany).  Both 
technologies provide a visual assessment of clot formation and subsequent 
lysis under low shear conditions, similar to the microenvironment of the vena 
cava and below that seen in venules, large veins, and the arterial system. 
Viscoelastic tests are dynamic modalities that provide a composite picture 
reflecting the interaction of plasma, blood cells and platelets, thereby more 
closely reflecting the situation in vivo than conventional coagulation tests, 
which are performed solely in plasma and measure only isolated end points.  
They provide real-time information about the quality of the clot and the 
kinetics of its formation, thus characterising the interaction between the 
vascular endothelial wall, platelets, von Willebrand factor (vWF), pro- and 
anticoagulant factors and blood flow. This global assessment of haemostasis 
more realistically represents the cell-based model of coagulation (Hoffmann & 
Munroe 2001), as opposed to the traditional description of intrinsic and 
extrinsic pathways, by encompassing the entire process of thrombin 
generation and the role of platelets. For effective haemostasis, there must be 
sufficient thrombin generation (coagulation factors and platelets), adequate 
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substrate (fibrinogen) and clot stability. Thus, viscoelastic tests are 
advantageous in measuring changes in clot tensile strength in real-time, 
assessing the dynamics of clot formation (coagulation factors and 
anticoagulant activity), clot strength (platelets and fibrinogen) and clot stability 
(fibrinolysis and factor XIII). 
In thromboelastography blood is incubated in at 37oC in a special stationary 
cylindrical cup with a pin suspended freely from a torsion wire within the cup.  
The cup and pin are oscillated relative to each other through an angle of 
4o45’, with the movement initiated by the cup (compared to the pin in 
ROTEM), as shown in Figure 2.4.  As fibrin forms between the cup and the 
pin, the transmitted rotation from the cup to pin is detected at the pin and a 
trace generated.  The strength of fibrin-platelet bonding affects the magnitude 
of pin motion, such that strong clots move the pin directly in phase with cup 
motion.  Therefore, the magnitude of the output is directly related to the 
strength of the clot.  During clot lysis, these bonds are broken and the transfer 
of cup motion is diminished. This rotational movement of the pin is transduced 
to an electrical signal that is monitored by computer software.  A characteristic 
TEG trace, as depicted in Figure 2.5, provides a comprehensive haemostasis 
profile measuring the time taken for the first fibrin strand to be formed, the 
kinetics of clot formation, the clot strength and the subsequent dissolution of 
the clot. 
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Figure 8 
 
 
 
Figure 2.4 Schematic diagram of TEG cup and pin components of the 
TEG 5000 analyser   
 
A depiction of the TEG device used in which a pin suspended from a torsion 
wire is immersed in a cup of whole blood. The cup is held in a heating block 
and continually oscillates through 4 45o every 5 sec. Changes in viscoelastic 
clot strength are directly transmitted to the torsion wire and detected by an 
electromechanical transducer.  
TEGâ Haemostasis Analyser images and Tracings are used by permission of 
Haemonetics Corporation 
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Figure 9 
 
 
 
Figure 2.5 Schematic diagram of typical TEG trace demonstrating 
nomenclature of TEG parameters 
 
A depiction of a TEG output demonstrating clot initiation, propagation, 
stabilisation and lysis. TEG parameters are defined in the main text (R, R-
time; K, K-time; a, angle; MA, maximum amplitude; Ly30, lysis time; EPL, 
estimated percent lysis 
TEGâ Haemostasis Analyser images and Tracings are used by permission of 
Haemonetics Corporation 
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2.3.2 TEG parameters 
 
The standard parameters used for viscoelastic testing are depicted in Table 
2.2, illustrating the difference in nomenclature between TEG and ROTEM.  
 
TEG parameters relate to either clot formation or clot lysis and are specifically 
defined as follows:   
 
Clot formation: 
• R-time is the time from placing the blood is placed in the cuvette until 
the tracing amplitude reaches 2mm, denoting initial fibrin formation and 
representing the enzymatic portion of coagulation.   
• K-time is measured from R to the point where the amplitude if the 
tracing reaches 20mm, representing clot kinetics.   
• The alpha (a) angle is the angle formed by the slope of the TEG 
tracing from the R to K value, thus measuring the rapidity of fibrin build-
up and cross-linking (clot strengthening).   
• The maximum amplitude (MA) is the greatest amplitude of the TEG 
tracing and is a reflection of the absolute strength of the fibrin clot and 
platelet function/aggregation. 
 
Clot lysis: 
• Lysis 30 and Lysis 60 (LY30 and LY60) are the percent reductions in 
the area under the TEG curve, assuming MA remains constant, that 
occur 30 and 60 min after MA is reached. 
• Estimated Percent Lysis (EPL) is the estimated percent lysis at 30 
minutes after MA. This parameter gives an idea of the percent lysis 
prior to 30 minutes after MA. EPL is computed by finding the slope 
connecting MA to any point between MA and 30 minutes after and then 
extrapolating to the amplitude at 30 mins. 
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Further derived parameters are available in TEG analysis to represent more 
composite or standardised values and are presented in numerous 
publications: 
 
• CI (Clotting Index):  global assessment of clot formation using a linear 
combination of the variables: R, K, MA, and Angle (a).  
• G (Shear Modulus Strength): Maximum amplitude (MA) is transformed 
into an actual measure of clot strength. G measured in Kdynes/cm2  
• E (Elasticity Constant):  normalised value of G such that a normal 
maximum amplitude (MA) of 50 mm will yield an E value of 100 
Various activators and reagents are used with both TEG and ROTEM to either 
improve speed of analysis, with the addition of tissue factor or kaolin, or 
provide extra diagnostic capabilities, with heparinase used to reverse heparin 
and functional fibrinogen (TEG) or FIBTEM (ROTEM) used to present 
information on fibrinogen levels (Table 2.3).  
 
2.3.3 TEG experimental procedure 
 
Given that the experimental hypothesis centered on the initiation of clot 
formation, by the release of tissue factor and subsequent activation of 
coagulation cascades, the TEG parameters chosen to measure in both the 
clinical and ex vivo incubation studies were absolute, non-derived variables of 
clot formation.  Further parameters of clot lysis, such as LY30, were not 
considered relevant to this experimental paradigm and so are not presented 
(Table 2.3). 
 
Manufacturer instructions stipulate that native TEGs must be performed within 
6 minutes of blood sampling.  Therefore, citrated blood samples were required 
to allow both adequate time for transfer of collected blood samples for the 
clinical study or for the 4 hour incubation period in the LPS TEG study. In all 
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experiments, citrated native TEGs were performed using citrated blood in 
plain TEG cups, under standardised conditions, following recalcification with 
CaCl2.  Citrated storage is a routine and validated means to facilitate TEG 
analysis beyond the timeframe of immediate collection.  Although earlier 
studies comparing native and citrated samples showed a tendency to 
hypercoagulability, in terms of R-time reduction, in citrated samples with 
prolonged storage, larger more recent studies demonstrate reproducible 
citrated TEG parameters both within reference ranges and comparable to 
non-citrated native samples, up to 4 hours from collection (Dias et al., 2017; 
Wasowicz et al., 2008),(Whiting and Dinardo, 2014). 
 
The influence of both exogenous and endogenous heparins was accounted 
for in an experimental subset of the clinical study.  Exogenous heparins form 
the mainstay of pharmacological thromboprophylaxis and are administered in 
the perioperative period to minimise risk of thromboembolic complications.  
Endogenous heparinoid activity is increasingly recognized in liver surgery, 
with both heparinase-modified TEGs and anti-Xa activity demonstrating 
heparin-like activity in cirrhotic patients and following orthotopic liver 
transplantation (Kettner et al., 1998; Senzolo et al., 2009).  Naturally occurring 
heparin-like activity, in the form of endogenous heparin and heparan sulphate 
proteoglycans, have also been shown in normal human plasma.  However, 
the role of endogenous heparinoids in major surgery, particularly liver 
resection, has hitherto not been investigated, despite the potential impact that 
heparin-like activity would produce on the postoperative coagulation status.  
Therefore, in a subset of patients in the clinical study, additional citrated 
native TEGs with heparinase were undertaken (340μL blood added to a 
heparinase TEG cup, recalcified with 20μL of CaCl2 0.2M).. 
 
Thromboelastography was performed using a computerized TEG coagulation 
analyser (Model 5000; Haemonetics, Braintree, MA, USA), using software 
TEG 5000 Hemostasis System Version 4.2 (Figure 2.6).  The TEG analyser 
was calibrated and maintained according to strict manufacturer guidelines and 
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institutional laboratory standards.  The TEG analysers were located in the 
Point-of-Care laboratory, within the operating theatre suite at the Royal Free 
Hospital, which has a dedicated biomedical scientist charged with 
maintenance of all laboratory equipment.  Polypropylene and polyethylene 
pipettes were used to process blood and reagents. 
 
Quality control (QC) procedures included electronic ‘eTest’ determination, to 
ensure electronic function of the analyser was maintained, which was 
undertaken daily and applied to each individual channel.  TEGs would not be 
undertaken unless all 8 channels in the laboratory had successfully passed 
eTests on any given day.  Use of biological controls served as a further 
operational check and calibration verification.  Level I and II QCs were 
performed weekly.  These controls contain animal citrated whole blood, 
including platelets and plasma, stabilizers, and buffer.  Level I has been 
formulated to simulate a normal blood sample, while Level II simulates an 
abnormal sample of a bleeding patient.  Data regarding instrument 
performance was collected and included failed eTests, 
nonsense/questionable results and analyser eTest errors. 
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Tabl 
Table 2.2 Comparison of TEG and ROTEM nomenclature 
e 2 
Haemostatic 
phase 
TEG ROTEM Description 
Clot initiation R (reaction)-
time 
CT (clotting 
time)  
Time to initial clot 
formation 
Clot kinetics K-time CFT (clot 
formation time) 
Speed to reach defined 
level of clot strength 
Angle (a)  a Rate of clot formation 
(fibrin build up and cross 
linking) 
Clot strength MA 
(maximum 
amplitude) 
MCF 
(maximum clot 
firmness) 
Strength of clot (fibrin 
and platelet binding) 
Clot stability Lysis (Ly) 30  CLI (clot lysis 
index) 
Fibrinolysis (rate of 
amplitude reduction of 
clot strength at 30 mins) 
 
 
 
Viscoelastic tests use different nomenclature for parameters representing the 
same haemostatic process.  However, the corresponding nomenclature is not 
interchangeable due to the different operating characteristics of the individual 
viscoelastic technology and modality specific reference ranges.   
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Table 2.3  Commercially available thromboelastography assays 
ble 3 
Assay  Activator/Inhibitor  Role  
Native  None  Non-activated assay  
Kaolin  Kaolin  Assessment of clot formation, 
fibrin polymerisation and 
fibrinolysis via the intrinsic 
pathway.  
Heparinase  Kaolin + heparinise  Assessment of clot formation in 
heparinised patients (both 
unfractionated and low molecular 
weight)  
Platelet 
mapping  
ADP Arachidonic acid  Assessment of platelet function 
and monitoring of antiplatelet 
therapy (such as aspirin or 
clopidogrel)  
Rapid TEG  Kaolin + tissue factor  Provides more rapid results than 
standard kaolin assay (mean 20 
minutes versus 30 minutes for 
standard TEG with initial results in 
less than one minute)  
Functional 
fibrinogen 
assay  
Lyophilized tissue 
factor + platelet 
inhibitor  
Partitions clot strength (MA) into 
contributions from platelets and 
fibrin  
 
 
 
TEG assays can be modified by addition of reagents to the in vitro blood 
sample.  Reagents are broadly classified as activators, such kaolin or tissue 
factor, or neutralisers such as heparinase, used to eliminate any heparin 
effect. 
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Figure 10 
 
Figure 2.6  TEGâ 5000 analyser (Haemonetics) 
   
TEGâ Haemostasis Analyser images and Tracings are used by permission of 
Haemonetics Corporation 
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2.4 Reagents 
 
Reagent Supplier Address 
Lipopolysaccharide (from 
Salmonella Typhosa) 
Stock solution in PBS sterile 
filtered, stored at 4ºC 
Sigma Aldrich 
 
Dorset, UK 
Simvastatin Sigma Aldrich 
 
Dorset, UK 
Metoprolol Astra Zeneca UK Ltd Bedfordshire, 
UK 
Atenolol Sigma Aldrich 
 
Dorset, UK 
Clonidine Boehringer Ingelheim Berkshire, UK 
Dexamethasone Hameln 
Pharmaceuticals  
Gloucester, UK 
Lidocaine Hameln 
Pharmaceuticals Ltd. 
Gloucester, UK 
N-acetylcysteine Phoenix Laboratories Co. Meath, 
Ireland 
Magnesium sulphate Martindale 
Pharmaceuticals Ltd. 
Essex, UK 
Nicotine Sigma Aldrich 
 
Dorset, UK 
SB265610 Sigma Aldrich 
 
Dorset, UK 
LY294002 Sigma Aldrich 
 
Dorset, UK 
ZSTK474 Sigma Aldrich 
 
Dorset, UK 
Dobutamine Hameln 
Pharmaceuticals Ltd. 
Gloucester, UK 
Hartmanns solution Baxter Healthcare Berkshire, UK 
Gelofusineâ solution B. Braun Medical Sheffield, UK 
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2.5 Equipment and disposables 
 
Equipment Supplier Address 
TEG 5000 analyser Haemonetics 
Corporation 
Braintree, MA, USA 
TEG cups 
Plain & heparinise 
Haemonetics 
Corporation 
Braintree, MA, USA 
Gilson Pipetmanâ 
P1000 & P100 pipettes 
Gilson Inc Middleton, WI, USA 
Diamondâ Tipack 
DF1000 & DF100 
pipette tips 
Gilson Inc Middleton, WI, USA 
Eppendorf tubes 1.5ml Eppendorf UK Ltd Stevenage, UK 
Vacutainer tubes 
(sodium citrate, EDTA, 
SST) 
BD (Becton, Dickinson 
& Company) 
Plymouth, UK 
S-Monovette tube 
(trisodium citrate) 
Sarstedt AG & Co. Leicester, UK 
Butterfly needle BD Valusetä 
(Becton, Dickinson & 
Company) 
Plymouth, UK 
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2.3  Statistics 
 
2.3.1 General points 
 
Categorical data are presented as absolute values (with percentage) and 
were compared using Pearson’s Chi2 or Fisher’s exact test depending on 
group size.  
 
Continuous data are presented as median with interquartile range (IQR), or 
mean with standard deviation (SD) for normally distributed data. Normality 
was assessed using the D’Agostino & Pearson normality test.  
 
In the clinical study, differences were determined either between values 
measured at different perioperative time point with respect to the baseline 
preoperative value or between different groups (such as treatment groups or 
surgical subgroups) at corresponding time points.  Data from postoperative 
time points were compared with preoperative values using one-way ANOVA 
(with Bonferroni’s multiple comparisons test) or Friedman test (with Dunn’s 
multiple comparisons test).  In longitudinal series with missing data at 
postoperative time points, Kruskal-Wallis test (with Dunn’s multiple 
comparisons test) was used as an alternative to Friedman’s test.  Differences 
in values at each perioperative time point between groups were compared 
using unpaired t-tests or Mann Whitney test for parametric and non-
parametric data respectively.   
 
In the laboratory study, differences between treatment groups were compared 
using a 2-tailed paired t-test or one-way ANOVA (with Bonferroni’s multiple 
comparisons test) for parametric datasets of 2 or more groups, as 
appropriate. Wilcoxon signed rank test or Kruskall Wallis test (with Dunn’s 
multiple comparison test) were used for non-parametric datasets of 2 or more 
groups, as appropriate.   
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Statistical significance was set at p < 0.05.  GraphPad Prism 8 (San Diego, 
CA, USA) was used for statistical analysis. 
 
 
2.3.2 Sample size calculations 
Sample size for laboratory work was based on the following: 
• Previous studies describe ~60% reduction in clotting time CT (R-time 
equivalent) following LPS incubation (Koch et al. 2009). 
• Reversal of LPS-induced decrease in R-time by 50% would be 
biologically important 
 
Therefore, to address the hypothesis that selected drugs attenuate pre-
defined LPS-induced hypercoagulability, at least 6 subjects per experimental 
comparison would be required to detect this R-time difference at the alpha = 
0.05 level (80% power).   
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Chapter 3 
 
Postoperative goal directed 
haemodynamic therapy and the 
perioperative coagulation profile 
following major intra-abdominal 
surgery
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3.1  Introduction 
 
Thromboembolic complications, such as deep vein thrombosis (DVT), 
pulmonary embolism (PE), ischaemic stroke and myocardial infarction (MI), 
are associated with increased postoperative morbidity and higher healthcare 
costs (Anderson and Spencer 2003; Kakkar et al. 1993).  Major abdominal 
surgery is more commonly associated with a postoperative hypercoagulable 
state that, in itself, is increasingly recognised as a contributory factor in the 
occurrence of these thromboembolic complications (Mahla et al., 2001).  
Mechanisms of hypercoagulability following surgery relate to increased 
activation of coagulation, reduction of natural anticoagulants or impaired 
fibrinolysis, in addition to more generic risk factors such as immobilisation and 
the presence of cancer.  The perioperative coagulation status is influenced by 
specific surgical factors with tissue trauma and haemodilution producing a 
more hypercoagulable state compared to major haemorrhage and vascular 
clamping more associated with hypocoagulability.   
 
Goal directed therapy (GDT) constitutes individualised haemodynamic 
management of high risk surgical patients, using cardiac output monitoring to 
guide intravenous fluid administration with or without inotropic support, as part 
of a treatment algorithm. Numerous trials have shown that goal directed 
therapy is associated with improved patient outcomes in high risk surgical 
patients. Postoperative complications and death occur more commonly in high 
risk patient groups, with advancing age and concomitant medical co-
morbidities, undergoing major non-cardiac surgery (Khuri et al., 2005; Pearse 
et al., 2012). Consequently, haemodynamic therapy algorithms using cardiac 
output monitoring devices are recommended by the National Institute for 
Health and Care Excellence in this high risk cohort undergoing major surgery.  
However, a Cochrane review in 2014 suggested the benefit may be more 
marginal than previously thought and more recent studies investigating goal 
directed therapy regimens in both sepsis (Peake et al., 2014; Yealy et al., 
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2014) and following major gastrointestinal surgery (Pearse et al., 2014) 
showed no significant benefit over routine care. 
 
The impact of goal directed therapy on either the perioperative coagulation 
profile or the relative risk of thromboembolic complications has not been 
specifically studied. In contrast, the components of haemodynamic therapy 
algorithms, intravenous fluids and inotropic support, have each been 
demonstrated to affect the perioperative coagulation profile either in vitro or in 
vivo.  Increasing concern exists whether potential harm is associated with 
goal directed therapy regimens, potentially attributable to fluid excess (Wei et 
al., 2008), autonomic dysfunction (Ackland et al., 2015a), myocardial injury or 
invasive monitoring devices.  Potentially deleterious off-target effects of 
implementing goal directed therapy may be a generic phenomenon or specific 
to individual regimens given that published goal directed therapy protocols are 
considerably heterogeneous.  There is wide variation between published 
studies in terms of patient selection, haemodynamic optimisation thresholds 
and targets, cardiac output monitoring devices and choice of intravenous fluid 
and/or inotropic therapy administered.  
 
Excessive fluid administration with goal directed therapy leads to 
haemodilution (Pearse et al., 2014).  The degree of haemodilution is highly 
variable and is related to the fluid regimen within each haemodynamic 
protocol, with different strategies used to optimise cardiac output, including 
stroke volume or oxygen delivery optimisation.  Protocols invariably use 
crystalloid solutions as maintenance intravenous fluid as a pre-determined 
rate with administration of additional fluid boluses determined by specific 
haemodynamic variables.  There is significant variation in the choice of both 
crystalloid and colloid intravenous fluids used within the myriad of studies 
published.  The in vitro and in vivo effects of crystalloids, such as isotonic 
saline or Ringers lactate have consistently demonstrated haemodilution 
associated hypercoagulability, as determined by biomarkers of coagulation 
activation and viscoelastic testing (Ruttmann et al. 2002).   
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In addition to the effect of goal directed therapy and perioperative fluid 
management, the investigation of perioperative alterations in coagulation must 
also take into account the influence both exogenous and endogenous 
heparins.  Exogenous heparins form the mainstay of pharmacological 
thromboprophylaxis and are administered in the perioperative period to 
minimise risk of thromboembolic complications.  Endogenous heparinoid 
activity is increasingly recognized in liver surgery, with both heparinase-
modified TEGs and anti-Xa activity demonstrating heparin-like activity in 
cirrhotic patients and following orthotopic liver transplantation (Kettner et al., 
1998; Senzolo et al., 2009).  Naturally occurring heparin-like activity, in the 
form of endogenous heparin and heparan sulfate proteoglycans, have also 
been shown in normal human plasma.  However, the role of endogenous 
heparinoids in major surgery, particularly liver resection, has hitherto not been 
investigated, despite the potential impact that heparin-like activity would 
produce on the postoperative coagulation status.   
 
The central issue highlighted by studies evaluating perioperative coagulation 
is how best to measure the global coagulation status of the surgical patient 
and thus determine the risk of thromboembolic complications.  The interaction 
of coagulation components and time course of coagulation changes are 
poorly described.  This acquired postoperative prothrombotic condition cannot 
be diagnosed by routine laboratory tests such as prothrombin time (PT) and 
activated partial thromboplastin time (APTT).  However, thromboelastography 
(TEG) provides a comprehensive evaluation of the viscoelastic properties of 
blood and thus assesses platelet activation, fibrin formation and clot retraction 
(Mallett and Cox, 1992).  TEG has been shown to be one of the most 
sensitive methods for detecting and monitoring postoperative 
hypercoagulability (Kashuk et al., 2009; Lison et al., 2011; Mahla et al., 2001).  
However, there is no universal method for defining hypercoagulability using 
TEG criteria, with previous publications requiring TEG parameters relevant to 
both enzymatic and cellular components of the coagulation cascade to be 
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deranged to be deemed hypercoagulable. 
 
3.1.1. Hypothesis 
 
Thromboelastography (TEG) parameters demonstrate postoperative 
hypercoagulability following major elective intra-abdominal surgery in a high-
risk surgical cohort.  Goal directed therapy is associated with excessive 
intravenous fluid administration and is associated with alterations in the 
perioperative coagulation profile, as assessed by thromboelastography (TEG). 
 
3.1.2 Aims 
 
The hypothesis was addressed by characterising the perioperative changes in 
coagulation indices in a defined surgical cohort randomised to 2 treatment 
arms of postoperative haemodynamic therapy. 
 
Primary outcome 
TEG (citrated native TEG) parameters at each pre-defined perioperative time 
point  
 
Secondary outcome 
• Routine haematological data (Haemoglobin, Haematocrit, Platelets, PT, 
APTT, Fibrinogen) at each pre-defined perioperative time point 
• Citrated heparinase TEG parameters at each pre-defined perioperative 
time point in a subgroup analysis, to assess the potential role of 
endogenous heparin activity and exclude any influence of exogenous 
heparin. 
• Further haematological parameters (Individual clotting factor levels, 
selected biomarkers of endothelial injury and fibrinolysis and natural 
anticoagulants) in a subset of patients, at each pre-defined perioperative 
time point. 
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3.2 Methods 
 
3.2.1 Post Operative Morbidity Oxygen (POM-O) trial 
 
Surgical patients recruited to the POM-O (Post Operative Morbidity Oxygen) 
study, at the Royal Free Hospital, between May 2011 and October 2012, were 
prospectively studied.  This cohort presented for major elective intra-
abdominal surgery under general anaesthesia, predominantly hepatic and 
pancreatic surgery, associated with a high incidence of postoperative 
morbidity.  Subject recruitment, detailed study protocol, data collection and 
statistical methods are discussed in the General Methods section.  
Demographic data and details of indications for surgery and precise surgical 
procedure undertaken were collected. 
 
Participants were centrally randomised to either postoperative intervention 
group, GDT (goal directed therapy) or control, as outlined in detail in Chapter 
2.   All principal investigators were masked to study group allocation.   The 
intervention period commenced once the patient reached the critical care unit 
after surgery and continued for 6 hours. Both randomised groups (GDT and 
control) were managed by research staff during the postoperative study 
period.  The goal-directed therapy group patients received intravenous fluid 
and inotropic therapy guided by the haemodynamic therapy algorithm 
targeting the preoperative oxygen delivery value for each individual patient.  
Haemodynamic parameters were recorded in the control group, but 
calculation of oxygen delivery values was delayed until the end of the 
intervention.   
Patients receiving anticoagulation preoperatively were excluded while aspirin 
and other antiplatelet medications were discontinued 7 days preoperatively.  
Low molecular weight heparin (LMWH) was prescribed postoperatively, with a 
standardized 6pm administration time, and variable administration was 
recorded. 
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3.2.2 POM-O thromboelastography sub-study 
	
3.2.2.1 Study protocol 
	
This sub-study evaluated alterations in the coagulation profile in POM-O trial 
subjects at the Royal Free Hospital site only.  Demographic data and details 
of indications for surgery and precise surgical procedure undertaken were 
collected. 
 
Blood samples were collected immediately pre-operatively, immediately 
postoperatively (prior to POM-O study intervention), 6 hours postoperatively 
(following POM-O study intervention) and both 2 and 5 days postoperatively 
(early morning samples), as described in the General Methods section.   
 
Routine haematological parameters were measured, including full blood 
count, coagulation screen (including prothrombin time and activated partial 
thromboplastin time) and fibrinogen level at each time point. 
 
Thromboelastography with citrated native TEGs was performed using citrated 
blood, collected at each perioperative time point.  The procedure for blood 
sampling, performing thromboelastography, the TEG parameters used and 
the reference ranges have been discussed in the Methods section.  
 
Hypercoagulability was defined, in our surgical cohort, as the presence of at 
least one of the following TEG parameters: 
• Shortened R +/- K time 
• Increased angle 
• Increased maximum amplitude (MA) 
 
The hypercoagulable state was further defined according to the underlying 
mechanism.  Hypercoagulable states may be characterized by rapid fibrin 
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formation, with subsequent clot formation (enzymatic hypercoagulability) or 
hyperactive platelet function, characterized by rapid clot development and 
abnormally high clot strength (platelet hypercoagulability).  Enzymatic 
hypercoagulability is detected by shortened R +/- K time, platelet 
hypercoagulability with increased angle and MA, or combined enzymatic and 
platelet hypercoagulability with all of these alterations at the same time. 
 
In a further subset of patients, a more detailed haematological assessment 
was undertaken to include thrombin generation assays; measurement of 
individual clotting factor levels; D-dimer and von Willebrand factor antigen 
(vWF:Ag); natural anticoagulants, such as antithrombin, protein C and protein 
S; and biomarkers of endothelial injury, such as syndecan-1, thrombomodulin 
and soluble P-selection.  
 
According to local departmental policy, low molecular weight heparin (LMWH) 
was administered at 1800h (>12hrs prior to POD2 & POD5 blood sample 
collection), and was not administered when routine laboratory data showed 
INR >1.5. 
 
Details of the POM-O study intervention period (volume of fluid administered 
+/- inotropy) were collected (as per POM-O study protocol). 
 
 
3.2.2.2 Outcome  
 
The primary endpoint was difference in each thromboelastographic parameter 
at each perioperative time point comparing: 
• postoperative time points to the preoperative baseline (each patient 
acting as own control) within each treatment group  
• perioperative time points between treatment groups to detect whether 
goal directed therapy produced any significant changes in 
thromboelastographic parameters with respect to the control arm. 
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Secondary outcomes were differences between perioperative time points and 
between treatment arms in both routine laboratory haematological 
investigations and the additional comprehensive research laboratory 
haematological assessment. 
 
 
3.2.3 Statistical analysis 
 
Values are expressed as numbers (with percentages), means (with SD) or 
medians (with interquartile ranges) as appropriate.  For continuous data, 
normality was assessed using the D’Agostino & Pearson normality test.  To 
calculate differences between values measured at each perioperative time 
point within each treatment arm with respect to the baseline preoperative 
value, the repeated measures ANOVA or Friedman test were used as 
appropriate.  In longitudinal data sets with missing values, ordinary one-way 
ANOVA (with Dunnett’s multiple comparisons test) or Kruskal-Wallis test (with 
Dunn’s multiple comparisons test) were used as alternatives, in parametric 
and non-parametric data sets respectively.  Differences in values at each 
perioperative time point between treatment groups were compared using 
unpaired t-tests or Mann Whitney test for parametric and non-parametric data 
respectively.  Statistical significance was set at p < 0.05.  GraphPad Prism 8 
(San Diego, CA, USA) was used for statistical analysis. 
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3.3 Results 
 
3.3.1 Baseline patient characteristics 
 
50 consecutive patients were enrolled into this POM-O TEG sub-study from 
79 patients recruited into the POM-O parent trial at the Royal Free site. The 
coagulation sub-study commenced shortly after the parent trial had started, 
with a dedicated research fellow appointed to oversee the sub-study, and 
terminated when recruitment ceased at this site.  
 
Baseline patient characteristics are summarised in Table 3.1.  Demographic 
data are similar between treatment groups, control (n=26) and goal directed 
therapy (n=24).  All patients underwent major intra-abdominal surgery 
however it should be noted that the control group had a higher proportion of 
pancreatic resections (54%), compared to the goal directed therapy, where 
hepatic resections were the predominant procedure (79%).  This was further 
reflected by the histological diagnosis with the goal directed therapy group 
comprised of mostly metastatic liver disease, compared to underlying 
pancreatic malignancy in the control group.  The majority of patients (88%) 
had confirmed presence of malignancy, either primary or metastatic, at 
surgical resection. 
 
All subjects fulfilled the high-risk criteria for trial recruitment, as outlined in the 
General Methods section, with American Society of Anesthesiologists 
classification of 3 or more.   The commonest medical co-morbidities were 
cardiovascular disease (hypertension, coronary artery disease and valvular 
heart disease) and diabetes mellitus.  Coexisting medical comorbidities were 
broadly similar between the treatment arms. 
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Table 3.1 Baseline patient characteristics 
 Control (n=26) GDT (n=24) 
Age (years) 69 (54-86) 72 (47-84) 
Gender 
Male 
Female 
 
16 (62%) 
10 (38%) 
 
14 (58%) 
10 (42%) 
Weight (kg) 77.6 (16.1) 76 (18.0) 
Haemoglobin (g/l) 12.8 (1.6) 12.7 (1.9) 
Albumin (g/l) 42.3 (5.0) 43.5 (4.0) 
Creatinine (µmol/l) 81.4 (21.5) 84.7 (18.6) 
Medical co-morbidities 
GFR < 60 ml/min 
Diabetes mellitus 
Cardiovascular disease 
Cerebrovascular disease 
 
4 (15%) 
6 (25%) 
20 (77%) 
0 (0%)  
 
4 (17%) 
5 (21%) 
18 (75%) 
2 (8%) 
Surgical procedure 
Hepatic resection 
Hemihepatectomy 
Wedge resection 
GB fossa resection 
Pancreatic resection 
Whipples procedure 
Distal pancreatectomy & splenectomy 
Total pancreatectomy 
Other 
Extrahepatic bile duct reconstruction 
Hepaticojejunostomy 
Gastrojejunostomy 
Excision of retroperitoneal sarcoma 
Excision of GIST 
 
7 (27%) 
2 
4 
1 
14 (54%) 
12 
1 
1 
5 (19%) 
1 
1 
1 
1 
1 
 
19 (79%) 
8 
11 
0 
3 (13%) 
2 
1 
0 
2 (8%) 
0 
0 
1 
1 
0 
Histology 
Metastatic liver disease 
Colorectal 
Breast 
GIST 
Hepatocellular carcinoma 
Intrahepatic cholangiocarcinoma 
Extrahepatic cholangiocarcinoma 
Pancreatic adenocarcinoma 
Pancreatic NET 
Pancreatic cystadenoma 
IPMN 
Gallbladder papillary carcinoma 
Bile duct tubulopapillary adenoma 
Indeterminate 
No histological specimen 
 
 
5 
0 
0 
1 
0 
1 
9 
1 
0 
2 
1 
1 
1 
3 
 
 
13 
1 
1 
2 
1 
0 
3 
1 
1 
0 
0 
0 
0 
1 
 
Data are median (range), mean (SD) or n (%).  GIST = gastrointestinal stromal tumour. IPMN 
= intrapapillary mucinous neoplasm.  NET = neuroendocrine tumour. 
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3.3.2 Intraoperative management 
 
Intraoperative clinical management is summarized in Table 3.2.   In both 
treatment arms similar volumes of intravenous fluid were administered 
intraoperatively, with comparable volumes of both crystalloid and colloid 
solutions.  Blood products were transfused in a comparably low proportion of 
patients in both treatment groups. Postoperative haemoglobin and arterial 
lactate (at the end of surgery), duration of surgery and mode of anaesthesia 
were similar for both control and goal directed therapy groups. 
 
 
 
Table 3.2 Intraoperative clinical management 
 
Data are mean (SD) or n (%).  GDT = goal directed therapy. GA = general 
anaesthesia.  CSL = crystalloid solution. PRBC = packed red blood cell. 
 
  
 Control 
n=26 
GDT 
n=24 
Duration of surgery (mins) 300 (134) 319 (84) 
Mode of anaesthesia 
GA 
GA + epidural 
 
14 (54%) 
12 (46%) 
 
10 (42%) 
14 (58%) 
Intravenous fluids  
CSL (ml/kg) 
Colloid (ml/kg) 
 
54.7 (10.3) 
16.4 (11.6) 
 
54.2 (20.3) 
12.3 (9.5) 
Blood products  
PRBC transfusion 
PRBC (ml/kg) 
 
2 (7.7%) 
0.4 (1.3) 
 
3 (12.5%) 
0.7 (2.1) 
Haemoglobin (end of surgery, g/l) 10.3 (1.4) 10.5 (1.6) 
Lactate (end of surgery, mmol/l) 2.05 (1.2) 2.47 (1.3) 
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3.3.3 Postoperative haemodynamic therapy intervention 
 
Differences between treatment arms in the postoperative intervention period 
are summarized in Table 3.3.  The goal directed therapy group received 
significantly more colloid during the 6hr intervention (p = 0.001).  The volume 
of crystalloid was similar, as defined by the maintenance fluid regime in the 
interventional protocol (Figure 4.1).  The proportion of patients receiving blood 
transfusion and the volume of packed red blood cells in the goal directed 
therapy group was not significantly different from the control group.  In the 
goal directed therapy group, 41.7% required dobutamine to achieve baseline 
oxygen delivery target, as per the haemodynamic therapy algorithm. 
 
 
 
Table 3.3 Haemodynamic management during postoperative intervention 
period 
 
 Control 
n=26 
GDT 
n=24 
Intravenous fluids  
CSL (ml/kg) 
Colloid (ml/kg) 
 
6.2 (0.7) 
11.9 (8.2) 
 
6.6 (1.1) 
22.4 (9.6)† 
Blood products  
PRBC transfusion 
PRBC (ml/kg) 
 
3 (11.5%) 
0.6 (1.6) 
 
5 (20.8%) 
0.87 (1.8) 
Dobutamine infusion 0 (0%) 10 (41.7%) 
 
 
Data are mean (SD) or n (%).  GDT = goal directed therapy. CSL = crystalloid 
solution. PRBC = packed red blood cell. † p < 0.05 between GDT and control groups 
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3.3.4 Longitudinal changes in perioperative thromboelastographic 
parameters and the effect of goal directed therapy 
 
The pattern of alteration in TEG parameters in both treatment arms over each 
perioperative time point is depicted in Figure 3.1.  R-time was reduced 
immediately postoperatively (POST) and post-intervention (POST6), 
compared to baseline preoperative TEG (PRE), in both groups.  R-time 
remained significantly lower than baseline on postoperative day 5 (POD5) in 
the GDT group only.  There were no significant inter-group differences at any 
perioperative time point. K-time was reduced immediately postoperatively 
(POST) and on POD2 in the control group but on POD5 only in the GDT 
group.  K-time at POD 5 was significantly lower in the GDT group compared 
to the control group.  The angle was increased immediately postoperatively in 
the control group and at POD5 in the GDT group, both compared to baseline 
and the control group. Maximum amplitude (MA) was outside normal range on 
POD2 and POD5 in both groups, but did not differ significantly compared to 
baseline preoperative normocoagulable values for either treatment arm.  MA 
was reduced immediately post-intervention compared to preoperative 
baseline in the control group only. 
 
The relative changes in TEG parameters at each postoperative time point 
were compared and expressed as a relative percentage of preoperative 
baseline values, as shown in Figure 3.2.  Inter-group differences between 
control and GDT were demonstrated at POD5 only, with more pronounced 
reductions in K-time and increased angle in the GDT group. 
 
The coagulation status was defined at each time point for each treatment 
group, based on normal reference ranges for each TEG parameter, as 
illustrated in Table 3.3.  Both control and GDT groups met criteria for 
hypercoagulability at each postoperative time point with preoperative values 
showing baseline normocoagulability.  In the early postoperative period, both 
groups demonstrated enzymatic hypercoagulability whereas at POD2 and 
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POD5 both enzymatic and platelet hypercoagulability was seen in each group. 
 
Surgical subgroups 
Results were compared, within each treatment arm, depending on the type of 
surgery undertaken with subgroups for hepatic, pancreatic and other surgery.  
As illustrated in Table 3.1, the hepatic surgical subgroup was predominant in 
the GDT group whereas the pancreatic subgroup comprised the majority of 
the control treatment arm. The perioperative trend for each subgroup is shown 
in Figure 3.3. Inter-group differences were compared between each surgical 
subtype for each TEG parameter at all perioperative time points in each 
treatment arm.  Differences were detected between the hepatic and 
pancreatic subgroups preoperatively with R-time in the GDT group and 
immediately post intervention with K-time and angle in the control group.  The 
R-time at POD5 was reduced in the other surgical subgroup compared to 
pancreatic subgroup, in the control arm alone.  
 
Comparison between native and heparinase TEG parameters 
Coagulation changes in a subset of the cohort (n=31) were further 
characterised by measuring heparinase TEG parameters at the same 
perioperative time points, within each treatment arm.  This further subset was 
limited due to resources, mainly availability of heparinise TEG cups.  The 
treatment arm subset characteristics differed with the control group having a 
more varied surgical subgroup [hepatic (n=6); pancreatic (n=6), other (n=5)], 
whereas the GDT group was predominantly hepatic surgical patients [hepatic 
(n=11; pancreatic (n=1), other (n=1)].   Differences were demonstrated 
between native parameters, as indicated in Table 3.5.  However, for the 
heparinase TEG to demonstrate any effect of exogenous or endogenous 
heparins, the heparinise value is lower than the corresponding native variable.  
Therefore, the only heparinase TEG parameter to show a ‘heparin effect’ with 
respect to native parameters was TEG angle immediately post intervention 
and on POD2 in the GDT group only.   
 
 
GDT & perioperative coagulation following major surgery 
 
 89 
 
 
 
Figure 3.1 Longitudinal changes in TEG parameters following major intra-
abdominal surgery in different haemodynamic intervention arms 
 
Samples from both treatment arms, Control (n=26) and GDT (n=24), were collected at 5  
Perioperative time points: PRE (immediately preoperatively); POST (immediately  
postoperatively); POST6 (following 6hr randomised postoperative haemodynamic treatment  
intervention); POD2 (postoperative day 2); POD5 (postoperative day 5).  
Citrated native thromboelastography (TEG) parameters are shown: A. R-time. B. K-time C.  
Angle. D.Maximum amplitude (MA).   
Dashed line demonstrates upper/lower limits of reference range for each TEG parameter  
(shown in text).  Data are median (IQR). 
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal Wallis test  
with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis test with  
Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point (Mann  
Whitney test) 
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Table 3.4 TEG defined net effect on coagulation profile at each perioperative time point in control and goal directed 
therapy groups 
 
 Control GDT 
 R K Angle MA  R K Angle MA  
PRE 9.5 
(8.0-14.3) 
2.6 
(2.3-3.1) 
57.0 
(54.0-60.2) 
62.4 
(60.1-71.3) 
Normo 9.3 
(7.6-11.4) 
2.6 
(1.8-3.8) 
57.4 
(44.9-63.9) 
63.1 
(53.9-65.4) 
Normo 
POST 4.8 
(3.8-5.7) 
1.9 
(1.7-2.6) 
64.7 
(57.9-67.7) 
61 
(55.1-65.8) 
HyperE 5.3 
(4.1-6.1) 
2.3 
(1.7-3.0) 
59.8 
(55.7-65.9) 
56.1 
(52.1-63.1) 
HyperE 
POST6 5.7 
(4.8-8.0) 
2.8 
(1.8-3.7) 
54.1 
(45.3-64.0) 
56.75 
(52.7-65.5) 
HyperE 4.4 
(3.6-7.6) 
2.2 
(1.8-3.1) 
61.3 
(54.3-64.9) 
57.6 
(51.0-60.5) 
HyperE 
POD2 7.2 
(6.1-8.0) 
1.8 
(1.6-2.5) 
64.4 
(56.2-71.4) 
65.2 
(57.5-72.1) 
HyperEP 6.3 
(5.4-9.9) 
2.2 
(1.2-3.7) 
62.7 
(57.3-70.6) 
65.6 
(62.0-70.5) 
HyperEP 
POD5 7.3 
(6.1-10.0) 
2.0 
(1.3-2.7) 
64.3 
(60.4-65.9) 
67.3 
(60.7-72.8) 
HyperEP 6.5 
(5.4-7.7) 
1.4 
(1.1-2.0) 
70.1 
(63.3-73.4) 
69.9 
(64.2-72.3) 
HyperEP 
 
 
Data are median (IQR).  5 perioperative time points: PRE (immediately preoperatively); POST (immediately postoperatively); POST6 
(following 6hr randomised postoperative haemodynamic treatment intervention); POD2 (postoperative day 2); POD5 (postoperative day 
5). Citrated native TEG parameters with normal ranges: R-time, 9-27 mins; K-time, 2-9 mins; Angle, 22-58 degrees; MA, 44-64 mm.  
Normo/HyperE/HyperP/HyperEP denotes net effect on coagulation profile: either normocoagulable or hypercoagulable based on TEG  
criteria for enzymatic (E), platelet (P) or combined enzymatic/platelet (EP) hypercoagulability
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Figure 11 
 
Figure 3.2 Relative percentage change in TEG parameters at each 
postoperative time point compared with baseline preoperative 
values  
 
The relative percentage change at each postoperative time point in each treatment  
arm was compared to immediately preoperatively (PRE) for TEG parameters in each  
patient.  POST (immediately postoperatively); POST6 (following 6hr randomised  
postoperative haemodynamic treatment intervention); POD2 (postoperative day 2);  
POD5 (postoperative day 5). Treatment arms were: Control (n=26, blue) or GDT  
(n=24, red). Citrated native thromboelastography (TEG) parameters are shown: R- 
time; K-time; Angle; Maximum amplitude (MA). Data are median (IQR and range  
shown).   
*p <0.05 (with p-values reported, by Mann-Whitney test, between Control and GDT 
treatment groups).  
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Figure 3.3 Longitudinal changes in TEG parameters following major intra-
abdominal surgery in different surgical subgroups in different 
haemodynamic intervention arms 
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6;  
POD2; POD5. Citrated native thromboelastography (TEG) parameters are shown: A1. R- 
time (Control). A2. R-time (GDT). B1. K-time (Control). B2. K-time (GDT). C1. Angle  
(Control). C2. Angle (GDT). D1. MA (Control).  D2. MA (GDT) 
Data are median (IQR, not presented for other surgical subgroup in GDT group).  
Treatment arms:  Control [n=26, solid lines with subgroups; hepatic (n=7); pancreatic  
(n=14); other (n=5)]; GDT [n=24, dotted lines with subgroups: hepatic (n=19); pancreatic  
(n=3); other (n=2)].  
* p <0.05 between hepatic and pancreatic surgical subgroup at given perioperative 
time point (Kruskal Wallis test with Dunn’s multiple comparisons test) 
# p <0.05 between pancreatic and other surgical subgroup at given perioperative 
time point (Kruskal Wallis test with Dunn’s multiple comparisons test).
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Table 3.5 Longitudinal changes in native and heparinase TEG parameters 
following major intra-abdominal surgery in different 
haemodynamic intervention arms 
 
  Control (n=17) GDT (n=14) 
  Native  Heparinase p<0.05 Native  Heparinase p<0.05 
R 
PRE 9.7 (6.2-16.8) 9.8 (6.20.5) 0.008 9.1 (5.9-28.2) 10.6 (4.8-26.6)  
POST 4.9 (2.5-10.3) 5.5 (3.1-9.1) 0.01 4.8 (3.3-7.3) 6.3 (3.6-8.2) 0.001 
POST6 7.1 (2.5-21.8) 6.1 (2.5-16.6)  4.3 (2.3-7.8) 5.0 (2.6-8.6) 0.02 
POD2 7.2 (4.5-20.9) 7.4 (4.9-13.1)  5.8 (3.1-10.1) 6.7 (3.6-11.7) 0.02 
POD5 6.2 (4.4-8.6) 7.4 (4.9-8.6) 0.02 5.6 (4.6-8.6) 6.0 (5.1-9.4) 0.02 
K 
PRE 2.6 (1.9-5.4) 2.7 (1.9-5.0)  3.1 (1.1-7.2) 3.8 (1.3-9.6)  
POST 1.8 (1.1-5.6) 2.0 (1.1-5.8)  2.3 (1.0-4.0) 1.8 (0.9-3.4)  
POST6 3.4 (1.1-6.2) 2.2 (1.2-5.8)  2.1(0.8-9.3) 2.2 (0.8-10.2) 0.05 
POD2 1.7 (1.2-7.7) 1.8 (1.1-3.3)  2.0 (1.0-2.7) 2.2 (1.4-7.2) 0.02 
POD5 1.9 (1.5-10.0) 1.8 (1.6-7.5)  1.3 (1.0-2.4 1.4 (0.9-2.8)  
Angle 
PRE 57.6 (31.9-64.1) 56.4 (35.5-64.2)  53.0 (27.5-75.6) 47.4 (23.5-71.1)  
POST 64.4 (37.4-74.7) 61.9 (37.2-77.0)  59.8 (45.2-77.1) 65.2 (49.6-76.0)  
POST6 49.7 (34.3-75.0) 61.9 (39.6-71.2) 0.02 62.2 (32.1-79.0) 61.0 (30.9-77.4) 0.03* 
POD2 66.6 (23.2-75.5) 63.9 (47.8-76.0)  62.2 (32.1-79.0) 61.0 (29.8-70.1) 0.02* 
POD5 64.6 (47.5-68.6) 63.9 (20.3-68.1)  70.8 (59.5-75.5) 70.0 (55.1-76.0)  
MA 
PRE 62.2 (51.0-81.4) 61.3 (48.8-82.8)  61.2 (49.6-82.4) 58.3 (45.1-78.5)  
POST 68.5 (48.3-74.2) 58.3 (38.5-71.2) 0.04* 60.5 (45.1-79.6) 56.3 (47.7-79.8)  
POST6 55.8 (43.1-76.1) 56.1 (38.2-73.1)  64.5 (49.4-77.0) 63.6 (50.3-73.6)  
POD2 62.8 (46.7-80.5) 64.4 (50.3-80.3)  64.5 (49.4-77.0) 63.6 (50.3-73.6)  
POD5 65.4 (30.5-74.1) 65.8 (34.8-76.1)  69.1 (59.8-74.7) 68.7 (57.1-72.4)  
 
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2; 
POD5. Treatment arms were: Control (n=17) or GDT (n=14).  
Data are median (range).  
* p <0.05 between native and heparinase TEG parameters at each perioperative time 
point within each treatment arm (Wilcoxon matched pairs signed rank test): figures in  
bold* represent clinically relevant difference. 
Figure 12 
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3.3.5  Longitudinal changes in conventional haematological variables 
and the effect of goal directed therapy 
 
Haemoglobin concentration and haematocrit declined postoperatively and  
Remained significantly less than baseline up to and including POD5 (Figure  
3.4), in both treatment groups.  There were no differences between the control  
and GDT groups at any perioperative time point to suggest more  
haemodilution in the GDT group. 
 
Platelet count was reduced in both treatment arms post-intervention and on  
POD2 in the GDT group but had returned to baseline by POD5 for the GDT  
group and by POD2 for the control group.  Prothrombin time was elevated in  
both groups at every postoperative time point, except POD5 for the GDT  
group.  There were no significant alterations in APTT except for a reduction  
seen immediately postoperatively in the control group only.  Fibrinogen  
concentration was significantly reduced, in both treatment arms, until POD2.  
There was a difference between the control and GDT groups at both  
preoperative and postoperative time points until POD2.  
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Figure 13 
Figure 3.4 Longitudinal changes in routine haematological parameters 
following major intra-abdominal surgery in different haemodynamic 
intervention arms 
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. Haemoglobin (Hb).  B. Haematocrit (HCT). C. Platelet count (Plt). D.  
Prothrombin time (PT).  E. Activated thromboplastin time (APTT).  E. Fibrinogen.  Data  
are median (IQR).  
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal Wallis  
test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis test  
with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point  
(Mann Whitney test) 
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4.3.6 Longitudinal changes in specific coagulation biomarkers and 
individual clotting factors and the effect of goal directed therapy 
 
Additional blood samples from 15 patients within the POM-O trial cohort had  
More detailed haematological assessment in a dedicated haemophilia  
research laboratory.  Sample size was limited by funding for the additional  
laboratory expenses involved.  This subset comprised patients randomised to  
postoperative interventions of both control (n=7) and GDT (n=8) treatment  
arms.  However, it should be noted that within this subset, the control group  
consisted of 6 patients undergoing pancreatic resection (86%), whereas the  
GDT group had 7 patients having liver resection (87.5%), so the groups were  
not well matched in terms of surgical procedure. 
 
D-dimer levels were increased from POD1 to POD5 in both treatment groups,  
With no inter-group difference detected (Figure 3.5).  vWF antigen (vWF:Ag)  
was unchanged throughout the perioperative period in both groups. 
 
Reductions in coagulation factors II, VII, X, XI, and XII, in comparison to  
baseline values, were demonstrated on POD1 in both groups, before  
returning to baseline (Figure 3.6).  In the GDT group, reduced levels of factors  
II and X were shown immediately postoperatively to POD2 and immediately  
postoperatively for factor XII.  In both groups, factor XIII:A was significantly  
reduced from POD1 to POD 5 in relation to preoperative levels.  No significant  
difference between control and GDT groups was demonstrated for any  
coagulation factor at any time point. 
 
Thrombin generation testing did not show any variation, in either LT (lag time  
i.e time needed for thrombin concentration to reach 1/6th of the peak  
concentration), endogenous thrombin potential (ETP) or slope (velocity index  
between end of lag time and peak thrombin generation), at any postoperative  
time point when compared to baseline preoperative values (Figure 3.7).  
Furthermore, there was no difference in any parameter between the  
 
GDT & perioperative coagulation following major surgery 
 
 97 
postoperative intervention groups. 
 
The perioperative profile of the natural anticoagulants is shown in Figure 3.8.  
Antithrombin levels declined immediately postoperatively in both groups and 
remained reduced in the GDT group until POD5.  Protein C reduced until 
POD2 and POD5 in the control and GDT groups respectively.  There were 
similar reductions in Protein S with lower concentrations postoperatively until 
POD2 in both groups.  There were no significant differences detected 
between treatment arms at each time point for any anticoagulant biomarker.   
 
Selected biomarkers for endothelial injury were measured and presented in 
Figure 3.9.  Syndecan-1 was significantly increased following the 
postoperative intervention in the GDT group with respect to both the control 
group and the baseline value within the GDT group.  No differences were 
detected either between perioperative time points or between groups for 
soluble P-selectin, TFPI or thrombomodulin concentrations.  Soluble tissue 
factor was reduced in the GDT groups on POD1 and POD2 but there was no 
demonstrable difference between the treatment arms at any time point 
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Figure 14 
 
Figure 3.5 Longitudinal changes in D-dimer and von Willebrand factor 
antigen following major intra-abdominal surgery in different 
haemodynamic intervention arms 
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. D-dimer.  B. von Willebrand factor antigen (vWF:Ag).  Data are median  
(IQR).  
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal  
Wallis test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis  
test with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point  
(Mann Whitney test) 
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Figure 15 
Figure 3.6 Longitudinal changes in individual clotting factors following 
major intra-abdominal surgery in different haemodynamic 
intervention arms  
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. Factor II (FII). B.FV. C. FVII. D. FVIII:C. E. FIX. F. FX. G. FXI. H. FXII. G.  
FXIII:A. Data are median (IQR).  
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal Wallis 
test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis test  
with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point  
(Mann Whitney test) 
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Figure 16 
Figure 3.7 Longitudinal changes in thrombin generation assay variables 
following major intra-abdominal surgery in different 
haemodynamic intervention arms  
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. Lag time (LT). B. Endogenous thrombin potential (ETP). C. Slope.  Data  
are median (IQR). 
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal  
Wallis test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis  
test with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point  
(Mann Whitney test). 
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Figure 17 
Figure 3.8 Longitudinal changes in natural anticoagulants following major 
intra-abdominal surgery in different haemodynamic intervention 
arms  
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. Antithrombin. B. Protein C. C. Protein S Free.  Data are median (IQR).  
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal  
Wallis test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis  
test with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point  
(Mann Whitney test) 
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Figure 18 
 
Figure 3.9 Longitudinal changes in selected biomarkers of endothelial 
injury following major intra-abdominal surgery in different 
haemodynamic intervention arms  
 
Samples were collected at 5 perioperative time points: PRE; POST; POST6; POD2;  
POD5. A. Antithrombin. B. Protein C. C. Protein S Free.  Data are median (IQR).  
# p < 0.05 postoperative time point vs. baseline (PRE) in Control group (Kruskal Wallis  
test with Dunn’s multiple comparisons test).   
† p < 0.05 postoperative time point vs. baseline (PRE) in GDT group (Kruskal Wallis test 
with Dunn’s multiple comparisons test).    
* p < 0.05 between Control and GDT treatment groups each perioperative time point 
(Mann Whitney test) 
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3.4 Discussion 
 
3.4.1  Key findings 
 
1. Postoperative goal directed therapy was associated with 
administration of larger volumes of intravenous fluid in the 
immediate postoperative period. 
In the GDT treatment arm, the haemodynamic treatment algorithm used 
gelatin based colloid solution to optimise pre-defined haemodynamic 
variables.  The excessive fluid administration shown was solely due to 
colloid administration, with no inter-group differences in the volume of 
crystalloid solution, blood or blood products.  However, no difference 
between the control and GDT groups was demonstrated for haemoglobin 
or haematocrit to suggest significantly more haemodilution as a 
consequence of increased fluid administration. 
 
2. Thromboelastographic profiles seen postoperatively following major 
intra-abdominal surgery were similar for both control and goal 
directed therapy groups.   
Postoperative hypercoagulability was consistently demonstrated as per 
TEG criteria, with significant differences compared to baseline in the early 
postoperative period.  GDT did not significantly affect either the absolute 
values of each TEG parameter or the relative change compared to control.   
 
3. In the hepatic surgical subgroup there was a trend towards return to 
baseline coagulation status immediately post treatment intervention 
in the control treatment arm. 
In determining the effect of surgical subtype on the alteration of coagulation 
status, the effect of GDT compared to control treatment was different in 
hepatic surgery subgroup as demonstrated by a transient relative return to 
baseline immediately post treatment intervention in K-time and angle in the 
control group, whereas in the GDT group, the corresponding values 
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remained in the hypercoagulable range throughout the postoperative 
period. 
  
4. No consistent heparinoid effect is demonstrable at any perioperative 
time point.   
There was no clinically relevant difference between the native and 
heparinase thromboelastography variables in either treatment arm.  
Alteration of TEG angle postoperatively in the GDT group alone without 
corresponding changes in MA to signify modulation of hypercoagulability is 
difficult to consider as significant.  There was a marked difference in the 
subset characteristics between the treatment groups in this subset so any 
effect potentially attributable to hepatic surgery, in terms of endogenous 
heparin and heparan sulfate proteoglycans, was not demonstrated in other 
TEG parameters.   This subset comparison was not designed to assess the 
adequacy of thromboprophylaxis or indeed if low molecular weight heparin 
had been administered.  
 
5. Conventional coagulation tests (PT and APTT) failed to demonstrate 
postoperative hypercoagulability.  
Prothrombin time was actually prolonged postoperatively, in both treatment 
groups, until POD5, thereby masking the underlying hypercoagulable state.  
However, D-dimer was significantly elevated in both treatment groups from 
POD1 to POD5. 
 
6. Alterations in individual coagulation factors were consistent with 
similar previous studies. 
Factors II, VII, X, XI and XII levels were reduced, as reported in other 
surgical cohorts, in the immediate postoperative period only.  Reductions in 
factor XIII:A were more prolonged, until POD5 in both treatment groups.  
The effect of goal directed therapy, not specifically examined in previous 
studies, was subtle with the GDT treatment arm associated with slightly 
prolonged reductions in factors II, VII and X, together with reductions in 
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factor V, immediately postoperatively.  However, no significant differences 
between treatment groups were demonstrated at the postoperative time 
points. 
 
7. Thrombin generation testing did not demonstrate postoperative 
hypercoagulability  
Thrombin generation variables were not significantly altered, in either 
treatment group, throughout the perioperative period.  Thrombin generation 
testing was, however, performed in the absence of soluble thrombomodulin 
(TM) and not thrombomodulin-modified as in more recent studies. 
 
8. Goal directed therapy was associated with a higher degree of 
endothelial injury in the immediate post-intervention period 
Syndecan-1 levels were significantly higher in the GDT group following the 
postoperative intervention period, compared to the control group, indicating 
a relative increase of glycocalyx damage. 
 
 
3.4.2 Importance of findings 
 
This is the first study to fully characterise the effect of a goal directed therapy 
regimen on the coagulation profile in patients undergoing major surgery.  The 
principal differences between the haemodynamic treatment algorithms were 
the volume of fluid, specifically colloid, administered and the use of  
dobutamine as vasopressor therapy in around 40% of the GDT group.  The  
recent OPTIMISE trial (Pearse et al., 2014) similarly demonstrated extra  
colloid administration during a postoperative goal directed therapy intervention  
but other studies have produced conflicting results.  This highlights the  
heterogeneity of goal directed therapy studies in terms of the haemodynamic  
treatment protocol used and the choice of fluid administered.  POM-O used an  
individualised oxygen delivery target during the intervention period whereas  
other published studies have relied on population based values to determine  
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fluid responsiveness. 
 
Both treatment groups were associated with a hypercoagulable profile in the 
postoperative period, as defined by thromboelastographic parameters outside  
the reference range, until at least postoperative day 5.  The hypercoagulable  
values observed were reflective of both enzymatic and platelet  
hypercoagulability but the predominant mechanism was enzymatic.  There  
were no consistent differences between the control and GDT groups in  
absolute TEG parameters to suggest that postoperative GDT significantly  
altered the pro-thrombotic postoperative profile.  However, GDT was  
associated with an exacerbated hypercoagulable phenotype, with respect to  
relative changes compared to baseline, at postoperative day 5, in  
terms of TEG K-time and angle.  This result should be interpreted with caution  
in the absence of further inter-group differences in TEG parameters. 
 
A substantial finding from our results is that the goal directed therapy protocol  
used in this study was associated with promotion of endothelial damage.  
Syndecan-1, a transmembrane endothelial proteoglycan and constituent of  
the endothelial glycocalyx, was significantly elevated following the  
haemodynamic treatment intervention compared to the control group,  
indicating glycocalyx shedding as a consequence of this therapy.   
 
The glycocalyx forms the endothelial surface layer, consisting of a variety of  
endothelial membrane-bound molecules, including glycoproteins and  
proteoglycans, that form a negatively charged barrier to circulating cells and  
macromolecules. It plays a key role in microvascular and endothelial  
physiology, by regulating microvascular tone and endothelial permeability,  
maintaining an oncotic gradient across the endothelial barrier, regulating  
adhesion/migration of leukocytes, and inhibiting intravascular thrombosis  
(Becker et al., 2010).   
 
Destruction of the glycocalyx can lead to capillary leak, oedema, accelerated  
 
GDT & perioperative coagulation following major surgery 
 
 107 
inflammation, platelet aggregation, hypercoagulability and loss of vascular  
responsiveness. Triggers of glycocalyx shedding include inflammation, trauma  
or hypervolaemia. Degradation occurs experimentally with pro-inflammatory  
mediators, such as TNFa (Chappell et al., 2009) and lipopolysaccharide  
(Marechal et al., 2008).  High circulating syndecan-1 levels have been  
demonstrated in trauma patients, in correlation with elevated pro-inflammatory  
cytokines and biomarkers of coagulation activation, with associated increased  
mortality (Johansson et al., 2011).  Hypervolaemia promotes glycocalyx  
shedding via the release of atrial natriuretic peptide (ANP) secondary to atrial  
stretch. Animal studies have demonstrated both elevated syndecan levels and  
increased extravasation of colloid following administration of ANP.  
 
Our results demonstrate elevated syndecan-1 levels, with respect to both  
preoperative baseline and the control treatment group, immediately 
following goal directed therapy.  The underlying mechanism cannot be  
confirmed but may be attributable to either relative excess fluid administration  
or a more pro-inflammatory phenotype in this treatment group. 
 
In terms of defining the perioperative coagulation profile, postoperative  
hypercoagulability was not identified in either group by conventional  
coagulation testing or thrombin generation testing.  Despite clearly defined  
hypercoagulability by TEG criteria in the postoperative phase, the changes  
seen in the laboratory parameters were confusing and often falsely interpreted  
by clinicians as being indicative of normo- or hypocoagulability.  For example,  
using PT-INR values, in isolation, in the immediate postoperative period to  
determine whether pharmacological thromboprophylaxis can be administered  
risks failure to identify a hypercoagulable state.  Thus if low molecular weight  
heparin is withheld on the basis of routine coagulation tests, a crucial window  
of opportunity for prevention of thromboembolic complications is being  
missed.  Previous studies have highlighted the failure of routine laboratory  
parameters to detect the hypercoagulable state following major surgery (Lison  
et al. 2011), with our results confirming this finding. Particularly in the context  
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of major hepatobiliary surgery, prothrombin time and activated partial  
thromboplastin time are shown to evaluate narrow aspects of haemostasis,  
rather than the overall haemostatic status.   
 
Thrombin generation assays have been previously used to demonstrate 
normal or enhanced thrombin generation in the presence of prolonged PT and  
APTT, as seen in liver disease (Lisman et al., 2010).  The total amount of  
thrombin generated during in vitro coagulation is measured in a global test,  
taking plasma concentrations of pro- and anticoagulants into account.   
However recent work has shown that the thrombomodulin modification of  
thrombin generation assays is required to identify the resultant  
hypercoagulability following liver surgery (Potze et al., 2015).  Standard  
thrombin generation assays, as performed in our study, in the absence of  
thrombomodulin, do not detect hypercoagulability demonstrated by a  
combination of TEG parameters and alterations in individual pro- and  
anticoagulants. 
 
The importance of identifying postoperative hypercoagulability has been 
highlighted by previous surgical cohort studies demonstrating an association 
between TEG-defined hypercoagulability in the perioperative phase and 
higher risk postoperative thromboembolic complications, including DVT/PTE, 
MI and ischaemic stroke (Kashuk et al., 2009; McCrath et al., 2005). Similarly, 
in a cardiac surgical cohort, hypercoagulability detected by similar criteria in 
patients undergoing coronary artery bypass grafting, has been shown to be 
associated with an adverse 30 day combined event rate of MI, stroke and 
mortality (Rafiq et al., 2012).  The presence of hypercoagulability identified by 
TEG in these diverse surgical cohorts has therefore been shown to be 
predictive of postoperative thromboembolic events. 
 
A multitude of similar studies have demonstrated the presence of 
hypercoagulability in the postoperative cohort, without demonstrating this 
association with adverse outcome, although largely in highly specific surgical 
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subgroups (Bell et al., 1996; Bezeaud et al., 2007; Cerutti et al., 2004; Gibbs 
et al., 1992; Goobie et al.; Lindberg et al., 2000; Wilson et al., 2001). 
 
Our study cohort reflects a high-risk surgical population having major intra-
abdominal surgery.  Similar studies have investigated hepatic surgery cohorts 
in isolation whereas we examined the coagulation changes in patients 
undergoing hepatic, pancreatic and other intra-abdominal oncological surgery 
together.  
 
In comparing our study with cohorts linking postoperative hypercoagulability 
with adverse outcome, there are differences in how hypercoagulability has 
been defined.  McGrath et al. used MA values alone and defined a 
dichotomous cut-off point between control and hypercoagulable groups as MA 
> 68mm.  Kashuk et al. defined hypercoagulability as clot strength (G) >12.4 
dynes/cm2.  The rationale for using the derived parameter G was suggested 
as a better reflection from a single parameter of the enzymatic and platelet 
components of haemostasis.  Our study examined the differences seen in 
each standard measured TEG parameter to allow determination of the type of 
hypercoaguability, whether enzymatic, platelet or combined, to more 
accurately understand the pathogenesis of the resultant prothrombotic 
phenotype. 
 
3.4.3 Strengths and limitations 
 
This study is the first to specifically examine to effect of goal directed therapy  
on the coagulation profile rather than composite postoperative outcome  
measurements.  Concurrent measurement of routine haematological  
parameters, thromboelastography, individual coagulation factors, natural  
anticoagulants and specific biomarkers of endothelial injury facilitated the  
most comprehensive evaluation of perioperative coagulation to date.  In  
addition to confirming postoperative hypercoagulability, as per multiple  
previous studies, in both treatment groups, we have demonstrated that goal  
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directed therapy does not significantly modify the hypercoagulable state but  
may have potentiate endothelial injury, with increased glycocalyx damage.  
 
If resources had not been limited, more detailed assessment of the  
Inflammatory changes seen, with measurement of pro- and anti-inflammatory  
cytokines would have been useful.  Furthermore, we were unable to measure  
microparticles in this sub-study, which would potentially have provided more  
mechanistic information. 
 
The surgical cohort was largely comprised of hepatobiliary surgical patients  
with pre-existing cancer.  Therefore, the confounding effect of underlying  
malignancy on the perioperative coagulation profile needs to be considered.   
Despite robust randomisation procedures in the main trial, our TEG study  
treatment groups were skewed with regard to the surgery undertaken, such  
that the goal directed therapy group was compromised of mostly liver  
resections whereas the control group have a higher proportion of pancreatic  
surgery.  This difference was more pronounced in the subset undergoing  
more detailed haematological assessment.  The effect of surgical subtype has  
been addressed in the previous chapter, but should be accounted for when  
interpreting these results. 
 
Our study compared favourably in terms of cohort size to previously published 
studies on hypercoagulability in postoperative patients.  The heterogeneity of 
the surgical cohort was also more noticeable than other similar studies, which 
largely concentrated on liver resection (Bezeaud et al. 2007, Cerutti et al. 
2004).  However, although the study used a comparatively large cohort, the 
sample size was determined pragmatically, by the number of patients 
recruited into the parent POM-O trial, with further sub-studies limited in 
number by restricted funding. 
 
Our results are presented both as a total surgical population as well as within 
different surgical subgroups to examine potential differences between 
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changes seen in hepatic and non-hepatic surgical patients.  Haemostatic 
balance after both liver resection and pancreatic surgery is unpredictable and 
so it is reasonable to consider these subgroups separately.  During liver 
resection, in particular, conflicting influences exists between the removal of 
hepatic mass, impaired hepatic synthesis of clotting factors, vascular 
clamping and massive haemorrhage promoting hypocoagulability, whereas 
hypercoagulability can result from impaired hepatic synthesis of 
anticoagulants, extensive tissue trauma and haemodilution.  Differential 
alteration in TEG parameters in liver surgery, compared to other major intra-
abdominal surgery, was only demonstrated transiently in the control arm 
immediately after the haemodynamic intervention period.  However, caution is 
needed in interpreting the surgical subgroup results given the strong 
preponderance of hepatic surgery patients in the GDT groups, making 
meaningful comparison within this treatment arm difficult. 
 
TEG parameters were measured preoperatively, thus providing a baseline to 
quantify any changes seen postoperatively and also detect any presence of 
preoperative hypercoagulability. McGrath et al. did not measure preoperative 
values in their outcome study so it was not possible to guarantee that the 
postoperative hypercoagulable state was due to surgery itself or a pre-existing 
prothrombotic condition. 
 
The length of postoperative TEG monitoring is one feasible limitation of our 
study.  In detecting hypercoagulability up to postoperative day 5, we were 
unable to identify the time point at which there was a return to 
normocoagulability (or baseline value) in all surgical subgroups.  Previous 
studies have detected postoperative hypercoagulability up to 7 days 
postoperatively following major intra-abdominal surgery (Mahla et al., 2001) 
and up to 6 weeks postoperatively following surgery for proximal femoral 
fracture (Wilson et al., 2001).  Our study was not designed to follow up 
subjects beyond hospital discharge so TEG monitoring was therefore limited 
to within the short-term postoperative period. 
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Similarly, the objective of our study was not to investigate postoperative 
outcome, in terms of any association between postoperative 
hypercoagulability and thromboembolic complications in the short- and long-
term postoperative phase.  We limited our follow up to the time of hospital 
discharge and so data on any subsequent thromboembolic event was not 
collected. 
 
3.4.4 Conclusion 
 
Thromboelastography allowed the detection of the hypercoagulable state 
postoperatively, in the absence of any consistent changes in routine 
haematological parameters. 
 
Postoperative hypercoagulability is not demonstrably modified by a goal 
directed haemodynamic therapy protocol although changes in individual 
components were seen.  Endothelial injury is promoted by goal directed 
therapy, in the context of excessive fluid administration, in the immediate 
post-intervention period.  Further work is required to assess the effect of 
different fluid regimens on both biomarkers of coagulation activation and 
endothelial injury, accounting for different underlying pathology and the type 
of surgery undertaken.  This will allow more individualised assessment of 
thrombotic potential in patients undergoing major surgery and 
mitigate risk of thromboembolic complications. 
 
Further work is required to delineate the association between TEG-defined 
postoperative hypercoagulability and incidence of postoperative 
thromboembolic complications such DVT/PTE, MI and ischaemic stroke.  The 
duration of postoperative hypercoagulability following major intra-abdominal 
surgery needs to be further defined to allow for improvement of 
thromboprophylaxis and reduction of postoperative morbidity and mortality. 
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Commonly used perioperative 
therapies and modulation of 
coagulation 
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4.1 Introduction 
 
Postoperative hypercoagulability may manifest as thromboembolic 
complications, such as myocardial infarction, deep vein thrombosis and 
pulmonary thromboembolism, which are critical pathological events that 
increase morbidity in the perioperative period (Mantilla et al., 2002).  
Reducing the incidence of both venous and arterial thromboses are key goals 
of improving perioperative outcomes.  However, preventing thrombosis, whilst 
mitigating the risk of bleeding, is a frequent perioperative conundrum (Acedillo 
et al., 2013; Korte et al., 2011).  Although widespread introduction of 
pharmacological thrombophylaxis regimens has significantly reduced the 
rates of thromboembolic complications in high-risk surgical populations 
(Agnelli, 2004), concern remains over bleeding complications in the context of 
both perioperative anticoagulant and anti-plalelet administration.  Low 
molecular weight heparins remain the commonest pharmacological 
thromboprophylaxis strategy used in surgical patients but may be associated 
with higher rates of postoperative bleeding complications in certain surgical 
specialties (Freedman et al., 2000).  Similarly, perioperative administration of 
aspirin has been demonstrated to increase risk of major bleeding but has no 
significant effect on the rate of a composite of death or non-fatal myocardial 
infarction (Devereaux et al., 2014a). Therefore, challenges remain in reducing 
thrombotic risk, without exaggerating perceived bleeding risk, with existing 
pharmacological strategies. 
Numerous perioperative therapies including statins, sympatholytics (β 
blockers and α2 agonists), steroids, antioxidants and local anaesthetics have 
attracted attention, with postulated roles in reducing risk of arterial and venous 
thrombosis postoperatively.  Inflammation-induced hypercoagulability may be 
modulated by these commonly administered drugs through off-target effects, 
although the precise mechanisms remain ill-defined. 
 
Statin therapy has been recommended in high-risk surgical patients before 
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surgery, as preoperative therapy is associated with improved postoperative 
outcome (Dunkelgrun et al., 2009; Durazzo et al., 2004; Schouten et al., 2009; 
Warltier et al., 2006).  More recently, attention has focused beyond the lipid-
lowering effects of statins, with more understood about anti-inflammatory and 
anti-thrombotic properties.  The 2009 JUPITER trial highlighted a potential 
anti-thrombotic effect, by demonstrating a significant reduction in deep vein 
thrombosis in normolipidaemic patients, with elevated CRP levels, treated 
with rosuvastatin (Glynn et al., 2009; Ridker et al., 2008).  Furthermore, there 
is increasing evidence of an anti-inflammatory action, with inhibition of 
cytokine formation and adhesion molecule expression (Albert et al., 2005; 
Rezaie-Majd et al., 2002).  Simvastatin has a powerful inhibitory effect on 
neutrophil recruitment, mediated by CXC chemokines (Zhang et al., 2011a).  
In experimental endotoxaemia, simvastatin has been shown to suppress the 
inflammatory response and attenuate both monocyte tissue factor expression 
and thrombin generation (Ferro et al., 2000; Steiner et al., 2005).  
 
Perioperative b-blocker regimens have demonstrated a reduction of 
myocardial events in the perioperative period, although serious harmful 
effects, such as increased ischaemic stroke and non-cardiac mortality, have 
prevented widespread perioperative use in major non-cardiac surgery (POISE 
Study Group et al., 2008).  The mechanism for preventing non-fatal 
myocardial infarctions is poorly understood.  In addition to cardioprotection, b-
blockers also restrain organ-specific inflammation during sepsis (Ackland et 
al., 2010).  One plausible mechanism for modulation of hypercoagulability 
centres on catecholamines that are endogenously synthesized by immune 
cells, independently of the autonomic nervous system. Phagocyte and 
lymphocyte-derived catecholamines act in an autocrine/paracrine fashion, 
modulating lymphocyte trafficking, cell proliferation, cytokine production and 
the functional activity of leukocytes, independently of endothelial interactions 
(Flierl et al. 2007).  Thus, activation of the adrenergic system during an 
inflammatory response greatly enhances the local inflammatory response and 
hence potentially contributes to a prothrombotic, hypercoagulable state. 
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Central sympatholytics such as clonidine, an α2 agonist used commonly 
perioperatively, have been demonstrated to suppress acute inflammation with 
reduction of proinflammatory cytokines seen in both experimental models 
(Hofer et al., 2009) and in clinical cohorts (Kim and Hahn, 2000). Although 
smaller initial trials suggested clonidine reduces perioperative MI (Wallace 
and Wallace, 2006), the larger more recent POISE-2 trial (Devereaux et al. 
2014) had conflicting results.  Although it has been postulated that clonidine 
may modify perioperative coagulation, attenuation of the hypercoagulable 
response to the surgical stimulus has hitherto not been demonstrated (Ganter 
et al., 2005). 
 
Beyond the well-established anti-inflammatory properties of steroid use, the 
relationship between steroids and perioperative coagulation remains 
controversial.  Inhibition of platelet aggregation by dexamethasone has been 
demonstrated in animal models (van Giezen et al., 1994), while in human 
studies, glucocorticosteroids were historically found to significantly decrease 
the activated partial thromboplastin time, fibrinogen, and plasminogen 
concentrations, even after 2 days of treatment (Jørgensen et al., 1982).  
Administration of high dose dexamethasone in healthy volunteers has been 
shown to increase the concentration of von Willebrand factor (vWF) and 
soluble P-selectin, thus promoting coagulation (Jilma et al., 2005). Prolonged 
preoperative steroid therapy is not associated with either an increased 
bleeding tendency or an altered risk of thromboembolic complications to 
suggest manifested changes in coagulation status (Turan et al., 2010).   
 
N-acetylcysteine (NAC) is a thiol-containing free radical scavenger, with 
antioxidant, anti-inflammatory and microcirculatory effects (Aitio, 2006).  NAC 
administration is commonplace in the treatment of paracetamol overdose, 
prevention of acute kidney injury following contrast exposure (Birck et al., 
2003) and major cardiovascular surgery (Macedo et al., 2006) and as a 
hepatoprotective agent, in improving graft function in orthotopic liver 
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transplantation (Hilmi et al., 2010; Thies et al., 1998), with equivocal results.  
Furthermore, it has been extensively investigated in sepsis, both clinically and 
in experimental models, with conflicting results (Emet et al. 2004; Parmentier 
et al. 2000).  Previous studies on the effect of NAC on haemostatic 
parameters in healthy subjects have demonstrated reduction of both vitamin K 
dependent coagulant and anticoagulant proteins in vivo (Pizon et al.  2011), 
and elevation of prothrombin time in vitro (Knudsen et al., 2005).  In surgical 
patients undergoing abdominal aortic aneurysm surgery, NAC administration 
was associated with a decreased PT value, prolonged coagulation time on 
thromboelastometry and attenuated platelet aggregation, with no significant 
effect on blood loss (Niemi et al., 2006).  However, the exact mechanism by 
which NAC interferes with haemostasis remains undefined. 
 
Local anaesthetics have similarly been reported to have anti-inflammatory and 
anti-thrombotic properties.  Lidocaine has been shown to reduce inflammation 
following experimental sepsis (Gallos et al., 2004; Schmidt et al., 1997). 
Furthermore, infusion of lidocaine perioperatively reduces systemic cytokine 
levels (Herroeder et al., 2007).  Bupivocaine has been demonstrated to 
reduce clot strength, as assessed by maximum amplitude on 
thromboelastography, at clinically relevant concentrations (Kohrs et al., 1999; 
Leonard et al., 2000). 
 
Magnesium sulphate (MgSO4) has been demonstrated to prevent arterial 
thrombus formation in a rat model (Mussoni et al., 2001), in addition to 
attenuating haemodilution-induced hypercoagulability in human healthy 
volunteers (Ruttmann et al. 2007).  Recently, intraoperative MgSO4 infusion to 
maintain Mg levels at the upper limit of normal range, has been shown to 
attenuate postoperative hypercoagulability in gynaecological patients 
undergoing pelviscopic surgery, as assessed by rotational 
thromboelastometry (Na et al., 2012). 
 
To investigate the effect of these commonly used perioperative drugs on 
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coagulation, an experimental model was used to allow any effect of pre-
treatment on human whole blood, in a relative hypercoagulable state, to be 
quantified ex vivo.  Lipopolysaccharide (LPS) is used commonly as a 
laboratory model for inflammation and sepsis in vivo and in vitro, reproducing 
the inflammatory stimulus of a septic, or in the case of this study, surgical 
insult.  LPS induced activation of coagulation has been robustly 
demonstrated, with thromboelastography shown to be a suitable monitoring 
tool (Koch et al., 2009b; Spiel et al., 2006; Zacharowski et al., 2006).  This 
experimental protocol has been described in detail in Chapter 2.  In summary, 
the effect of pre-treatment with selected therapies, with postulated 
thrombomodulatory potential, prior to stimulation or ‘spiking’ of whole blood 
with LPS ex vivo, was assessed by quantifying any modifying effect on TEG 
parameters following a pre-determined incubation period. 
 
 
4.1.1 Hypothesis 
 
Lipopolysaccharide administered to whole blood results in activation of 
coagulation producing hypercoagulability, as assessed by 
thromboelastography. 
 
Selected perioperative therapies with putative anti-thrombotic activity 
attenuate the promotion of hypercoagulability by LPS. 
 
 
4.1.2 Aims 
 
The hypothesis was addressed by characterising the coagulation changes in 
whole blood, taken from both healthy volunteers and preoperative surgical 
patients, following the addition of LPS (model for inflammatory stimulus) and 
selected perioperative therapies. 
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Primary outcome 
TEG (citrated native TEG) parameters following treatment with selected 
perioperative therapies, compared to control, in whole blood incubated with 
either LPS or endotoxin-free saline. 
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4.2 Methods 
 
4.2.1. Study population 
 
Following ethics committee approval and informed consent, venous blood 
samples were taken from healthy, drug-naive volunteers at the Royal Free 
Hospital.  Further blood samples were taken from surgical patients recruited 
to the POM-O (Post Operative Morbidity Oxygen) trial.  Both healthy 
volunteers and preoperative surgical patients were used in the initial stages to 
assess the whole blood TEG response to LPS (100ng/ml dose only), to 
maximise our sample size.  However, in determining the thrombomodulatory 
potential of selected drugs, only healthy volunteers were included in this 
experimental paradigm, as including both volunteers and surgical patients in 
the same experimental group was not considered appropriate.  Recruitment 
and exclusion criteria have been described in detail in the Methods section. 
 
4.2.2 Study protocol 
 
Blood samples were obtained in a standardised manner from both healthy 
volunteers and preoperative surgical patients, as previously outlined.  
Following collection into Vacutainer tubes containing sodium citrate 3.8% 
(Becton Dickinson, Plymouth, UK), samples were gently inverted to ensure 
mixing of sample and then transferred in 1ml aliquots to polypropylene tubes.  
In LPS treated samples, 1ml blood was incubated at 37oC with 100ng/ml LPS 
(Salmonella typhus) or endotoxin-free sterile 0.9% NaCl for 4 hours.  In drug 
treated samples, the following drugs were added to volunteer whole blood 20 
mins prior to incubation with LPS or saline: dexamethasone (40ng/ml), 
metoprolol (100ng/ml), atenolol (500ng/ml), carvedilol (100ng/ml), clonidine 
(75ng/ml), simvastatin (10ng/ml), N-acetylcysteine (500ng/ml), lidocaine 
(5ng/ml) or magnesium sulphate (2mM).  Different sample sizes were 
produced with different candidate drugs due mainly to drug availability and 
resources.  In determining the effect of pre-treatment with b-blockers, 
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metoprolol was used as a β1 adrenoceptor antagonist control within the other 
β-blocker studies, to account for inter-individual genetic variation in adrenergic 
receptor signalling, hence producing different sized treatment groups. 
 
4.2.3 Simvastatin sub-study 
 
To further elucidate the proposed mechanism of action by simvastatin, an 
additional drug was studied, namely the CXCR2 antagonist, SB265610 (1μM).  
This experimental drug was added in the same manner as the selected 
perioperative drugs prior to incubation with LPS or saline.  The aim of this 
sub-study was to investigate if any anti-thrombotic effect seen by simvastatin 
on TEG could be recapitulated by blocking the CXC chemokine pathway. 
 
Simvastatin reduces neutrophil infiltration most likely through reduced release 
of CXC chemokines, in animal models (Zhang et al. 2006, Zhang et al. 2010).  
Neutrophil depletion reverses in vivo experimental thrombosis (von Bruhl et al. 
2012). 
 
4.2.4  Thromboelastography 
 
Thromboelastographic assays were performed immediately after the 
incubation period and following recalcification of incubated citrated blood, as 
described in Chapter 2.  Citrated native TEG parameters were measured: R-
time (reaction time, reference range 2-27 min); K-time (reference range 2-9 
min); angle (a, reference range 22-58 degrees); maximum amplitude (MA, 
reference range 44-64 mm).  Each TEG parameter and the terminology of 
hypercoagulability have been previously defined in the Methods section. 
 
4.2.5  Statistical analysis 
 
Data are expressed as means (with SD) or medians (with interquartile ranges) 
as appropriate.  In data sets fewer than 5 subjects, individual raw data points 
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are presented.  The normality of continuous data was assessed using the 
D’Agostino & Pearson normality test.  Differences between paired treatment 
groups were compared using a 2-tailed paired t-test or Wilcoxon matched-
pairs signed rank test for paired groups for parametric and non-parametric 
data respectively.  Differences between unmatched multiple treatment groups 
were compared using ordinary one-way ANOVA (with Dunnett’s multiple 
comparison test) or Kruskall Wallis test (with Dunn’s multiple comparison test) 
for parametric and non-parametric data sets, as appropriate.  Statistical 
significance was set at p < 0.05.  GraphPad Prism 8 (San Diego, CA, USA) 
was used for statistical analysis. 
 
Sample size calculations 
We powered the primary outcome (TEG R-time) on the basis that potential 
anti-thrombotic therapies would reverse the LPS-induced decrease in R-time 
by 50%. Previous work described ~60% reduction in clotting time CT (R-time 
equivalent) following LPS incubation (Koch et al. 2009).  Thus, for selected 
drugs to attenuate pre-defined LPS-induced hypercoagulability, at least 6 
subjects per experimental comparison would be required to detect this R-time 
difference at the alpha=0.05 level (80% power).   
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4.3  Results 
 
4.3.1 Effect of lipopolysaccharide on whole blood coagulation 
 
Lipopolysaccharide at test concentration 100ng/ml produced hypercoagulable 
changes in all TEG parameters (Figure 4.1).  The relative change seen in 
each TEG parameter following LPS 100ng/ml was calculated with respect to 
control, with healthy volunteer (n=61) and surgical patient (n=16) samples 
producing similar responses, in terms of magnitude of LPS stimulated 
hypercoagulability (Figure 4.2).   
 
Similar effects were evoked with reduced concentrations of LPS of 10ng/ml, 
except for the maximum amplitude which was not significantly increased at 
the lower concentration (Figure 4.3).  
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Figure 19 
 
 
Figure 4.1 TEG parameters in whole blood from healthy volunteers and 
preoperative surgical patients incubated with LPS (100ng/ml) for 
4 hrs  
 
Samples from both healthy volunteers (HV; n=61) and preoperative surgical patients 
(PT; n=16) were incubated with either LPS (100ng/ml) or sterile saline (CTRL) to 
produce a 2 paired experimental groups.  Data are median (IQR and range shown). 
Citrated native thromboelastography (TEG) parameters are shown with reference 
ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. (22-58 
degrees) D. Maximum amplitude (MA, 44-64mm).  p-values reported, by Wilcoxon 
matched-pairs signed rank test, CTRL vs. LPS. 
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Figure 4.2 Comparison of LPS-induced TEG changes in healthy volunteers 
and preoperative surgical patients 
 
Relative (%) LPS-induced changes of TEG parameters with respect to control were 
calculated for both healthy volunteers (HV; n=61) and preoperative surgical patients 
(PT; n=16), following incubation with LPS 100ng/ml. Data are median (IQR and 
range shown).  * p <0.05 HV vs. PT (Mann-Whitney test). 
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Figure 21 
 
Figure 4.3 TEG parameters in whole blood incubated with different 
concentrations of LPS for 4 hrs  
 
Samples from healthy volunteers were incubated with LPS 10ng/ml (n=6), LPS 
100ng/ml (n=61) or sterile saline (CONTROL, n=77).  Data are median (IQR and 
range shown). Citrated native thromboelastography (TEG) parameters are shown 
with reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. 
Angle. (22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  * p <0.05 
CONTROL vs. LPS at given concentration (Mann-Whitney test). 
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4.3.2 Effect of simvastatin on LPS-induced hypercoagulability 
 
Pre-treatment with simvastatin (10ng/ml) attenuated the hypercoagulable 
effect following LPS incubation with relative increases in R-time and K-time, 
and relative reduction in angle, with respect to LPS alone (Figure 4.4).  This 
effect related to enzymatic hypercoagulability rather than platelet 
hypercoagulability, as there was no effect on MA relative to LPS alone.  There 
was no attenuation of LPS-induced hypercoagulability in any TEG parameter 
with simvastatin pre-treatment at higher concentration [25ng/ml] (Figure 4.5). 
 
The effect of post-treatment with simvastatin (10ng/ml), 20 minutes after 
addition of LPS, was also investigated, to compare with the effect of pre-
treatment.  However, post-treatment did not attenuate LPS-induced 
hypercoagulability and conversely produced reduction in K-time and increase 
in MA, with respect to LPS alone (Figure 4.5). 
 
In the simvastatin sub-study, pre-treatment with the CXCR2 antagonist 
SB265610 produced a similar effect to simvastatin on enzymatic 
hypercoagulability, with attenuation of the LPS-stimulated reduction in R-time 
while other TEG parameters were unaffected (Figure 4.6). 
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Figure 22 
Figure 4.4 TEG parameters in whole blood pre-treated with simvastatin 
(10ng/ml) prior to incubation with LPS  
 
Samples from healthy volunteers were pre-treated with simvastatin (10ng/ml) prior to 
incubation with LPS (100ng/ml) for 4hr (n=11).  Data are median (IQR and range 
shown). Citrated native thromboelastography (TEG) parameters are shown with 
reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. 
(22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  p-values reported, by 
Wilcoxon matched-pairs signed rank test, LPS vs. LPS + simvastatin (SIMVA).  
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Figure 23 
 
Figure 4.5 TEG parameters in whole blood either pre- or post-treated with 
simvastatin in relation the addition of LPS 
 
Samples from healthy volunteers were either pre-treated with sterile saline (CTRL, 
n=19), simvastatin 10ng/ml (n=11); pre-treated with simvastatin 25ng/ml (n=4); post-
treated with simvastatin 10ng/ml (n=4), in relation to addition of LPS followed by 
incubation for 4hr.  Data are presented as individual raw data points with median and 
IQR shown. Citrated native thromboelastography (TEG) parameters are shown with 
reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. 
(22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  * p <0.05 LPS vs. LPS + 
simvastatin (SIMVA) at given concentration (Mann-Whitney test). 
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Figure 24 
 
Figure 4.6 TEG parameters in whole blood pre-treated with CXCR2 
antagonist, SB265610, prior to incubation with LPS  
 
 
Samples from healthy volunteers were pre-treated with SB265610 (1μM) prior to 
incubation with LPS (100ng/ml) for 4hr (n=7).    Data are median (IQR and range 
shown). Citrated native thromboelastography (TEG) parameters are shown with 
reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. 
(22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  p-values reported, by 
Wilcoxon matched-pairs signed rank test, LPS vs. LPS + SB265610 (CXCR2-). 
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4.3.3 Effect of sympatholytics on LPS-induced hypercoagulability  
 
Pre-treatment with each selected b blocker did not attenuate the 
hypercoagulable effect of LPS with no significant difference seen for any TEG 
parameter (Figure 4.7). 
 
Pre-treatment with clonidine also did not significantly affect LPS-induced 
hypercoagulability, at both normal (5ng/ml) and supramaximal (75ng/ml) dose, 
with no differences seen for any TEG parameter (Figure 4.8). 
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Figure 25 
 
Figure 4.7 TEG parameters in whole blood pre-treated with selected b-
blockers prior to incubation with LPS   
 
Samples from healthy volunteers were pre-treated with the following b-blockers prior  
to incubation with LPS (100ng/ml) for 4 hrs: metoprolol, 100ng/ml (n=13); atenolol, 
500ng/ml (n=9); carvedilol, 100ng/ml (n=5).  Data are median (IQR and range 
shown). Citrated native thromboelastography (TEG) parameters are shown with 
reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. 
(22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  * p <0.05 LPS vs. LPS + 
given b-blocker (Mann-Whitney test). 
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Figure 26 
 
Figure 4.8 TEG parameters in whole blood pre-treated with clonidine prior 
to incubation with LPS  
 
Samples from healthy volunteers were either pre-treated with either sterile saline 
(CTRL, n=17); clonidine, 5ng/ml (CLON 5, n=8) or 75ng/ml (CLON 75, n=9) prior to 
incubation with LPS for 4hrs.  Data are median (IQR and range shown). Citrated 
native  
thromboelastography (TEG) parameters are shown with reference ranges in 
brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. (22-58 degrees) D. 
Maximum amplitude (MA, 44-64mm).  * p <0.05 LPS vs. LPS + clonidine (CLON) at 
given concentration (Mann-Whitney test). 
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4.3.4 Effect of dexamethasone on LPS-induced hypercoagulability  
 
Pre-treatment with dexamethasone attenuated the hypercoagulable effect 
following LPS incubation with a relative increase in R-time and reduction of 
MA, with respect to LPS alone (Figure 4.9).  Therefore, this effect reflects 
modulation of both enzymatic and platelet hypercoagulability. 
 
 
 
Figure 27 
Figure 4.9 TEG parameters in whole blood pre-treated with dexamethasone 
prior to incubation with LPS  
 
Samples from healthy volunteers were pre-treated with dexamethasone (40ng/ml) 
prior to incubation with LPS (100ng/ml) for 4hr (n=7).    Data are median (IQR and 
range shown). Citrated native thromboelastography (TEG) parameters are shown 
with reference ranges in brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. 
Angle. (22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  p-values reported, 
by Wilcoxon matched-pairs signed rank test, LPS vs. LPS + dexamethasone (DEXA) 
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4.3.5 Effect of lidocaine on LPS-induced hypercoagulability  
 
Pre-treatment with the selected local anaesthetic, lidocaine, did not attenuate 
the hypercoagulable effect of LPS with no significant difference seen for any 
TEG parameter (Figure 4.10). 
 
 
Figure 28 
Figure 4.10 TEG parameters in whole blood pre-treated with lidocaine prior to 
incubation with LPS  
 
Samples from healthy volunteers were pre-treated with lidocaine (5ng/ml) prior to 
incubation with LPS (100ng/ml) for 4hr (n=4).    Data are presented as individual raw 
data points with median and IQR shown. Citrated native thromboelastography (TEG) 
parameters are shown with reference ranges in brackets: A. R-time (9-27 mins). B.  
K-time (2-9 mins) C. Angle. (22-58 degrees) D. Maximum amplitude (MA, 44-64mm).  
* p <0.05 LPS vs. LPS + lidocaine (LIDO), Wilcoxon matched-pairs signed rank test. 
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4.3.6 Effect of N-acetylcysteine (NAC) on LPS-induced 
hypercoagulability  
 
Pre-treatment with the selected antioxidant, NAC, exacerbated the 
hypercoagulable effect of LPS, with further reduction in both R-time and K-
time and relative increase in both angle and MA, compared to LPS alone 
(Figure 4.11).  This represents a distinct promotion of both enzymatic and 
platelet TEG hypercoagulability.    
 
 
Figure 29 
Figure 4.11 TEG parameters in whole blood pre-treated with NAC prior to 
incubation with LPS  
 
Samples were pre-treated with N-acetylcysteine (500ng/ml) prior to incubation with 
LPS (100ng/ml) for 4hr (n=10).    Data are mean (SD). Citrated native 
thromboelastography (TEG) parameters are shown with reference ranges in 
brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. (22-58 degrees) D. 
Maximum amplitude (MA, 44-64mm).  p-values reported, by paired t-test, LPS vs. 
LPS + N-acetylcysteine (NAC). 
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4.3.7 Effect of MgSO4 on LPS-induced hypercoagulability  
 
Pre-treatment with MgSO4 did not attenuate the hypercoagulable effect of 
LPS, with no significant difference seen for any TEG parameter (Figure 4.12). 
 
 
Figure 30 
 
Figure 4.12 TEG parameters in whole blood pre-treated with MgSO4 prior to 
incubation with LPS  
 
Samples were pre-treated with MgSO4 (2mM) prior to incubation with LPS 
(100ng/ml) for 4hr (n=5).    Data are median (IQR and range shown). Citrated native 
thromboelastography (TEG) parameters are shown with reference ranges in 
brackets: A. R-time (9-27 mins). B.  K-time (2-9 mins) C. Angle. (22-58 degrees) D. 
Maximum amplitude (MA, 44-64mm).  * p <0.05 LPS vs. LPS + MgSO4 (MG), 
Wilcoxon matched-pairs signed rank test. 
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4.4  Discussion 
 
4.4.1 Key findings 
 
1.  Lipopolysaccharide produces hypercoagulability in both healthy 
volunteers and preoperative surgical patients 
The principal finding is that LPS activates coagulation in whole blood ex vivo, 
as demonstrated by consistent significant changes in all TEG parameters, as 
reported in previous thromboelastographic studies.  We observed significant 
changes in all TEG parameters, demonstrating both enzymatic and platelet 
hypercoagulability in the presence of LPS.  This trend was seen at both 
concentrations of LPS tested, although the TEG maximum amplitude was not 
significantly increased at the lower LPS concentration.  The magnitude of the 
changes seen with LPS were very similar to the hypercoagulable values seen 
postoperatively in our clinical study group (Chapter 3).  Therefore, both our 
hypothesis that LPS induces TEG-hypercoagulability and the subsequent use 
of our ex vivo incubation model to further investigate potential therapeutic 
modulation have been vindicated. 
 
2.  Simvastatin attenuates the prothrombotic effect of LPS, with the 
CXCR2 antagonist SB225022 producing a similar effect 
Pre-treatment with simvastatin attenuated but did not completely reverse LPS-
induced enzymatic hypercoagulability.  However, neither higher 
concentrations nor post-treatment produced the same effect.  The specific 
CXCR2 antagonist SB225022 similarly attenuated LPS-induced enzymatic 
hypercoagulability, mirroring the effect seen with simvastatin.   
 
3.  Dexamethasone attenuated LPS-induced hypercoagulability by both 
enzymatic and platelet hypercoagulability criteria 
No previous studies have demonstrated any effect on coagulation parameters 
in whole blood in this manner. 
 
Perioperative therapies & modulation of coagulation 
 
 139 
4.  N-acetylcysteine exacerbates hypercoagulability in the presence of 
LPS 
Surprisingly we found that NAC pre-treatment consistently promoted both 
enzymatic and platelet hypercoagulability with changes seen in all TEG 
parameters.  This result was unexpected as previous in vitro studies of NAC 
pre-treatment in endotoxaemia have shown reduction of pro-inflammatory 
cytokines under mild oxidative conditions (Parmentier et al., 2000). 
 
5.  Other commonly used perioperative drugs tested had no modifying 
effect on inflammation-induced hypercoagulability  
Pre-treatment with b-blockers, clonidine, magnesium sulphate and lidocaine 
had no significant effect on LPS-induced hypercoagulability. 
 
 
4.4.2 Importance of findings 
 
Our study confirmed that LPS produced a hypercoagulable phenotype, in 
whole blood ex vivo, in both healthy volunteers and preoperative surgical 
patients.  In addition to demonstrating reductions in R-time following LPS 
incubation, as reported by previous thromboelastography studies (Koch et al., 
2009b; Spiel et al., 2006; Zacharowski et al., 2006), we observed consistently 
significant changes in TEG angle and maximum amplitude, reflecting both 
enzymatic and platelet hypercoagulability.  
 
The principal finding from this study was that inflammation-induced 
hypercoagulability was attenuated by pre-treatment with dexamethasone and 
simvastatin.  Our results clearly showed an incomplete reversal of LPS-
induced hypercoagulability with could suggest a potential role in modulating 
the pro-thrombotic perioperative phenotype.  For dexamethasone this 
attenuation was in both enzymatic and platelet components of 
hypercoagulability whereas for simvastatin, changes related to enzymatic 
hypercoagulability only. 
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By demonstrating the modification by simvastatin of the procoagulant 
response to LPS in this ex vivo model,  this supports in vivo data obtained 
from healthy subjects that reported inhibition of LPS-induced elevations of 
plasma high sensitivity C-reactive protein, monocyte chemoattractant protein 
(MCP)-1 and monocyte tissue factor expression by high dose simvastatin 
(Steiner et al., 2005).  Furthermore, it may provide useful insight into the 
potential mechanism by which statin therapy has been shown to reduce 
thrombotic events in certain clinical cohorts (Glynn et al., 2009; Ridker et al., 
2008).   
In investigating a potential mechanism for an anti-inflammatory, anti-
thrombotic action of simvastatin, we demonstrated that the specific CXCR2 
antagonist SB225022 similarly attenuated LPS-induced enzymatic 
hypercoagulability, mirroring the effect seen with simvastatin.  Although we 
cannot confirm a direct effect of simvastatin on the chemokine receptor from 
our results, as previously demonstrated (Zhang et al. 2011), we have 
extended these studies by demonstrating that CXCR2 antagonism is 
associated with partial reversal of a prothrombotic phenotype. 
The results for dexamethasone suggest a more marked effect on LPS-
stimulated hypercoagulability.  However, clinical data have so far failed to 
demonstrate any reduction in major adverse events with perioperative 
steroids that are potentially attributable to hypercoagulability (Dieleman et al., 
2012).  Both in vitro and in vivo studies have produced conflicting results with 
regard to the overall effect on coagulation and the assessment of outcome in 
clinical studies has relied on composite outcome measures rather than 
specific coagulation parameters.  This is the first study to demonstrate 
attenuation of combined pattern hypercoagulability following an ex vivo 
inflammatory stimulus.  This should form the basis of more detailed 
investigation of the effect of steroid treatment on global coagulation indices in 
vivo. 
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In the LPS-TEG model, NAC pre-treatment generated an even more 
hypercoagulable phenotype, mostly in the presence of LPS.  This was a 
surprising but consistent result with clearly demonstrated exacerbation of both 
enzymatic and platelet hypercoagulability.  No previous studies had examined 
the effect of antioxidants on coagulation in this manner so further work is 
undoubtedly required to investigate this finding, both in terms of studying 
alternative antioxidants and examining the specific effect of NAC on 
coagulation parameters, including TEG, in vivo.  However, our data may partly 
explain the failure of the experimental promise of NAC to translate to 
convincing improvements in clinical outcome. 
 
Furthermore, our results did not support a thrombomodulatory role of 
magnesium in the presence of LPS.  Intraoperative MgSO4 infusion has been 
reported to reduce clotting times and maximal clot firmness in separate 
surgical cohorts by the same group, but alterations were inconsistent and 
arguably did not constitute hypercoagulability (Na et al., 2012, 2014) 
  
 
4.4.3 Strengths and limitations 
 
This study has more than 3-fold the subjects compared with previous LPS 
based reports and reflects changes in both healthy subjects and patients 
immediately prior to major surgery. Although previous studies have examined 
modification of LPS-stimulated blood by individual drug classes in vivo 
(Pernerstorfer et al., 1999), this study is unique in examining a comprehensive 
range of perioperative therapies in an ex vivo model.   
 
However, there were several limitations to the study.  This ex vivo model of 
LPS induced activation of coagulation was tested using thromboelastography 
as a surrogate for assessing perioperative thrombotic risk.  Although we 
identified specific drug classes that attenuate inflammation-induced 
hypercoagulability, exploring the precise underlying mechanism involved was 
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beyond the scope of this study.  It must be acknowledged that activation of 
coagulation in vivo is a complex process and our whole blood ex vivo model 
represented a much simpler paradigm which, in particular, did not examine 
the contribution of endothelium to coagulation activation. Although our model 
did not account for the effect of endothelial components such as endogenous 
anticoagulants, thrombomodulin and Protein C, whole blood analysis did allow 
examination of the cellular contribution to coagulation activation, especially 
the role of neutrophils.  To account for any potential effect of haemodilution on 
hypercoagulability by the addition of both selected drugs and LPS, volumes 
added to whole blood samples were minimised in our experimental protocol.   
 
Despite demonstrating LPS induced hypercoagulability at two different LPS 
concentrations, a comprehensive dose response assessment was not 
undertaken.  The choice of dose of LPS was therefore based on both similar 
published experimental protocols (Koch et al. 2009; Zacharowski et al. 2006) 
and by initial experiments demonstrating that 100ng/ml consistently produced 
both enzymatic and platelet hypercoagulability, which was less convincingly 
seen at the lower dose of 10ng/ml. 
 
In comparing the whole blood response to LPS in healthy volunteers and 
preoperative surgical patients, it was necessary to consider these as two 
separate groups. All volunteer blood sampling used venous blood whereas 
arterial blood was used in the patient group.  Previous studies have 
demonstrated different TEG variables in corresponding arterial and venous 
samples taken during cardiac surgery, with a relatively hypercoagulability in 
arterial blood (Manspeizer et al., 2001).  Therefore, any discrepancy between 
groups, in terms of sample collection and subject characteristics, was 
accounted for by excluding surgical patients from the drug pretreatment phase 
of this study.  
 
Thromboelastography was used as our default monitoring tool as it allowed a 
global assessment of whole blood coagulation. This modality has been 
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previously validated, with alterations in TEG parameters corresponding to 
other markers of coagulation activation (Spiel et al., 2006), in particular TEG 
R-time with tissue factor expression (Lakshmanan et al., 2016).  Clinically, 
numerous surgical cohort studies have demonstrated an association between 
TEG-defined hypercoagulability in the perioperative phase and higher risk of 
postoperative thromboembolic complications (Kashuk et al., 2009; McCrath et 
al., 2005), with no indication given by conventional haematological 
parameters such as APTT or INR (Hincker et al. 2014).  A multitude of similar 
studies have demonstrated the presence of hypercoagulability in the 
postoperative cohort, without demonstrating this association with adverse 
outcome, although largely in highly specific surgical subgroups.  Therefore, 
existing evidence suggests that TEG is a superior modality to conventional 
haematological parameters in assessing hypercoagulability in this model, but 
it is accepted that further work is warranted beyond our ex vivo model to fully 
characterise indirect effects of potential thrombomodulatory drugs on whole 
blood. 
 
4.4.4 Conclusion 
 
In assessing the thrombomodulatory potential of perioperative drugs, both 
steroids and statins attenuated while NAC exacerbated hypercoagulability in 
the presence of inflammation.  However, further investigation in the clinical 
context, together with quantification of postoperative thrombotic events, is 
crucial to fully evaluate the significant potential clinical relevance of these 
findings.   
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5.1  Introduction 
 
The postoperative phase following major surgery is characterized by the 
concurrent activation of both inflammatory and coagulation systems.  A 
significant proportion of postoperative morbidity, including major 
cardiovascular events, acute lung injury and gastrointestinal dysfunction, may 
be manifestations of an exaggerated pro-inflammatory pro-thrombotic 
response observed following surgical insult, contributing to end organ 
dysfunction and death. 
 
Whereas the controlled production of pro-inflammatory cytokines, such as 
interleukins (IL)-1b, IL-6, IL-8; tumour necrosis factor (TNF)-α and high 
mobility group box protein B1 (HMGB1) triggers beneficial inflammatory 
responses to promote local coagulation and contain infection and tissue 
damage, excessive or persistent cytokine production and subsequent 
systemic release leads to the systemic inflammatory response syndrome 
(Tracey, 2007).  Increased plasma concentrations of pro-inflammatory 
cytokines have been demonstrated after major surgery and the magnitude of 
cytokine mediated inflammatory response is related to the extent of the 
surgical insult (Desborough, 2000).  Furthermore, raised levels of pro-
inflammatory cytokines have been shown to correlate with negative outcome 
measures including postoperative mortality (Sato et al., 2002; Welborn et al., 
2000). 
 
The inflammatory response is balanced by anti-inflammatory factors including 
cytokines IL-10 and IL-4, IL-1 receptor antagonist and transforming growth 
factor (TGF)b, produced through a normal immune response to inhibit release 
of TNFα and other pro-inflammatory cytokines.  Neutralising the effects of 
excessive pro-inflammatory cytokine production by inhibition of single 
cytokines (such as monoclonal anti-TNFα therapy) has been successful in 
certain inflammatory conditions, such as rheumatoid arthritis.  However, such 
targeted therapies have not been successful in models of SIRS and severe 
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sepsis (Abraham, 1999). 
 
Recent research has highlighted the role of the autonomic nervous system in 
regulating the immune system and adjusting the inflammatory response by 
modulating the production of multiple inflammatory cytokines (Wang et al., 
2003; Wittebole et al., 2006).  In particular the cholinergic nervous system has 
been implicated, forming an ‘inflammatory reflex’ with both 
immunosuppressing and immunosensing roles.  These effects are rapid, 
localised and integrated compared to the slower and more diffuse humoral 
anti-inflammatory mechanisms. 
 
The afferent vagal nerve performs an immunosensing function with sensory 
vagal afferents shown to detect low tissue concentrations of cytokines and 
inform the brain of inflammation in the periphery via ascending fibres (Figure 
5.1).  Central integration of afferent and efferent components of this 
‘cholinergic anti-inflammatory pathway’ occurs in the medullary nucleus 
tractus solitaries (NTS), which is the major site for termination of vagal 
afferents.  NTS neurones then project to the dorsal motor nucleus of the 
vagus (DMN) where most of the efferent vagal preganglionic fibres originate 
(Pavlov et al., 2003).   
 
Evidence for immunomodulation by the vagus nerve is now available for 
models of sepsis, haemorrhagic shock (Guarini et al., 2003), ischaemia-
reperfusion injury (Saeed et al., 2005), localised inflammation (Golparvar et 
al., 2014) and pancreatitis (van Westerloo et al., 2006a).  
 
Acetylcholine (ACh) is the principal neurotransmitter of the parasympathetic 
nervous system.  Macrophages and other cytokine producing cells 
prominently express ACh receptors and, when exposed to ACh, are 
inactivated.  ACh post-transcriptionally suppresses TNF synthesis and 
attenuating the release of pro-inflammatory cytokines, IL-1b, IL-6 and IL-8 in 
experimental sepsis (Tracey et al., 2000).   
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The alpha 7 nicotinic receptor (α7nAChR) has been identified as the specific 
receptor responsible for mediating these immunomodulatory effects (Jonge 
and Ulloa, 2009; Wang et al., 2003).  Selective α7nAChR agonists have 
proven effective in reducing macrophage cytokine production and 
inflammation in animal models (van Westerloo et al., 2006b).  Furthermore, 
nicotine has been shown to suppress LPS-induced inflammatory changes in 
vivo, together with increased circulating IL-10 levels (Wittebole et al., 2006). 
 
nAChRs are traditionally described as ligand-gated ion channels which allow 
calcium ions to enter the cells.  However, the intracellular signalling pathway 
which follows is complex and incompletely defined in non-neuronal cell types.  
In models of neuroprotection, the α7nAChR has been shown to be closely 
associated with the activated phosphatidylinositol 3-kinase (PI3K) cascade, 
with nicotine exerting a neuroprotective effect by activating PI3K, which 
subsequently activates Akt and upregulates the anti-apoptotic protein Bcl-2 
(Kihara et al., 2001).  Studies in macrophages indicate that the anti-
inflammatory potential of α7nAChR is mediated by the inhibition of the 
transcription factor, nuclear factor kappa B (NF-kB).  During infection or 
trauma, bacterial components (LPS) or intracellular mediators (HMGB1) 
trigger pro-inflammatory pathways that converge on the activation of NF-kB.  
Candidate intracellular signalling mechanisms between α7nAChR activation 
and NF-kB inhibition include the PI3K and Jak2-STAT3 pathways.  Studies 
have shown that the PI3K pathway regulates LPS signalling in monocytes 
(Guha and Mackman, 2002), whereas α7nAChR activation by nicotine has 
been linked to activation of transcription factor STAT3 via phosphorylation of 
tyrosine kinase Jak2 in macrophages (de Jonge et al., 2005).  Therefore, in 
examining the anti-inflammatory potential of the α7nAChR, consideration of 
the candidate intracellular pathways is required to fully understand how the 
immunomodulatory effect is mediated at a cellular level. 
 
Despite rapidly emerging evidence for the ‘cholinergic anti-inflammatory 
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pathway’, the effect on coagulation of this previously unknown neural circuit 
requires further elucidation.  Previous work has been confined to animal 
studies, with electrical vagal nerve stimulation shown to attenuate 
lipopolysaccharide (LPS)-induced activation of coagulation, as assessed by 
plasma concentrations of thrombin-antithrombin complexes and D-dimers 
(van Westerloo et al. 2006).  PI3K pathway inhibition has been shown to 
suppress both LPS-induced TNF-a and tissue factor expression in both 
human monocytic cells and an animal model of endotoxaemia (Schabbauer et 
al., 2004).  However, further demonstration of cholinergic modulation of 
coagulation with human or in vivo studies is not available.  Given our previous 
observation that LPS activates coagulation in whole blood, as demonstrated 
by thromboelastography, the effect of nicotine and PI3K inhibition was 
investigated using the same LPS TEG experimental protocol. 
 
 
5.1.1  Hypothesis 
 
Lipopolysaccharide administered to whole blood results in activation of 
coagulation and produces hypercoagulability, as assessed by 
thromboelastography.  Nicotinic ACh receptor activation, with nicotine, 
attenuates the promotion of hypercoagulability by LPS. 
 
 
5.1.2 Aims 
 
The hypothesis was addressed by characterising the coagulation changes in 
whole blood, taken from both healthy volunteers and preoperative surgical 
patients, following the addition of LPS (model for inflammatory stimulus) after 
pre-treatment with either nicotine or a PI3K inhibitor, at clinically relevant 
concentrations. 
 
Primary outcome 
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TEG (citrated native TEG) parameters following pre-treatment with nicotine or 
the selective PI3K inhibitors, LY294002 and ZSTK474, compared to control in 
whole blood incubated with either LPS or endotoxin-free saline. 
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Figure 31 
 
Figure 5.1 Cholinergic anti-inflammatory pathway 
 
Tissue injury results in cytokine release from macrophages.  Cytokines are 
sensed by the afferent vagus nerve and information relayed to nucleus tractus 
solaritus (NTS) and then to the dorsal motor nucleus.  This results in the 
activation of the efferent vagus nerve with subsequent inhibition of cytokine 
production via activation of the a7 nicotinic acetylcholine receptor (a7nAChR) 
located on macrophages and other immune cells.  Afferent vagal signals that 
activate an efferent response to inhibit cytokine production is termed the 
inflammatory reflex 
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5.2 Methods 
 
5.2.1 Study population 
 
Following ethics committee approval and informed consent, venous blood 
samples were taken from healthy, drug-naive volunteers at the Royal Free 
Hospital.  Recruitment and exclusion criteria have been described in detail in 
the Methods section. 
 
5.2.2 Study protocol 
 
Venous blood samples were obtained in a standardised manner from healthy 
volunteers, as previously outlined.  Following collection into Vacutainer tubes 
containing sodium citrate 3.8% (Becton Dickinson, Plymouth, UK), samples 
were gently inverted to ensure mixing of sample and then transferred in 1ml 
aliquots to polypropylene tubes.  Pre-treatment with 10µl of either sterile 
saline (control), or nicotine (100nM) was undertaken after 20 minutes.  
Following a further 20 minutes, each pre-treated whole blood sample had LPS 
(100ng/ml) added, prior to incubation at 37oC for 4 hours. 
 
5.2.3 PI3K sub-study 
 
To further elucidate the proposed mechanism of action by nicotine, additional 
drugs were studied, namely the selective PI3K inhibitors, LY294002 and 
ZSTK474.  These experimental drugs were added in the same manner as the 
nicotine prior to incubation with LPS or saline.  The aim of this sub-study was 
to investigate if any anti-thrombotic effect seen by nicotine on TEG could be 
recapitulated by pharmacological blockade of the PI3K pathway.  Sample 
sizes in the PI3K inhibitor treatment groups were limited by the amount of 
drug solution available, resulting different sized drug pre-treatment groups. 
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5.2.4  Thromboelastography (TEG) 
 
Thromboelastographic assays were performed immediately after the 
incubation period and following recalcification of incubated citrated blood, as 
described in Chapter 2.  Citrated native TEG parameters were measured: R-
time (reference range 2-27 min); K-time (reference range 2-9 min); angle 
(reference range 22-58 degrees); maximum amplitude (MA, reference range 
44-64 mm).  Each TEG parameter and the terminology of hypercoagulability 
have been previously defined in the Methods section. 
 
5.2.5  Statistical analysis 
 
Data are expressed as means (with SD) or medians (with interquartile ranges) 
as appropriate.  The normality of continuous data was assessed using the 
D’Agostino & Pearson normality test.  Differences between treatment groups 
were compared using a 2-tailed paired t-test for parametric data sets of 2 
matched groups or a Kruskall Wallis test (with Dunn’s multiple comparison 
test) or non-parametric data sets of 3 groups with different sample sizes.  
Statistical significance was set at p < 0.05.  GraphPad Prism 8 (San Diego, 
CA, USA) was used for statistical analysis. 
 
Sample size calculations 
We powered the primary outcome (TEG R-time) on the basis that potential 
anti-thrombotic therapies would reverse the LPS-induced decrease in R-time 
by 50%. Previous work described ~60% reduction in clotting time CT (R-time 
equivalent) following LPS incubation (Koch et al. 2009).  Thus, for selected 
drugs to attenuate pre-defined LPS-induced hypercoagulability, at least 6 
subjects per experimental comparison would be required to detect this R-time 
difference at the alpha=0.05 level (80% power).   
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5.3  Results 
 
5.3.1 Effect of nicotine on LPS-induced hypercoagulability 
 
Pre-treatment with nicotine (100nM) attenuated the prothrombotic effect of 
LPS incubation with a relative increase in R-time and reduction in angle, with 
respect to LPS alone (Figure 5.2).  This effect related primarily to enzymatic 
hypercoagulability. 
 
5.3.2 Effect of selective PI3K inhibitors on LPS-induced 
hypercoagulability 
 
Pre-treatment with both selective PI3K inhibitors, LY294002 (20nM) and 
ZSTK474 (1µM), did not attenuate the hypercoagulable effect of LPS, with no 
significant difference seen for any TEG parameter (Figure 5.3). 
 
  
Modulation of autonomic regulation of coagulation 
 
 154 
 
 
Figure 32 
 
Figure 5.2 TEG parameters in whole blood pre-treated with nicotine prior to 
incubation with LPS  
 
Samples were pre-treated with nicotine (n=8) or sterile saline prior to incubation with  
LPS (100ng/ml) for 4 hours to produce 4 experimental groups, control (CTRL),  
nicotine (NICO), LPS and LPS + nicotine (LPS + NICO). Data are mean (SD).  
Citrated native thromboelastography (TEG) parameters are shown: A. R-time. B.  K- 
time C. Angle. D. Maximum amplitude (MA). * p <0.05 LPS vs. LPS + Nicotine (2  
tailed paired t-test) 
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Figure 33 
 
Figure 5.3 TEG parameters in whole blood pre-treated with selected PI3K 
inhibitors prior to incubation with LPS  
 
Samples were pre-treated with PI3K inhibitor, LY294002 (n=5) or ZSTK474 (n=7), or  
sterile saline prior to incubation with LPS (100ng/ml) for 4 hours to produce   
experimental groups.  Data are median (with IQR and range shown).  Citrated native  
thromboelastography (TEG) parameters are shown: A. R-time. B. K-time C. Angle. D. 
Maximum amplitude (MA). * p <0.05 LPS vs. LPS + PI3K inhibitor (Kruskall Wallis  
test).  ns represents p > 0.05 
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5.4 Discussion 
 
5.4.1 Key findings 
 
1.  Nicotine attenuates the prothrombotic effect of LPS 
Pre-treatment with nicotine attenuated but did not completely reverse LPS-
induced enzymatic hypercoagulability.  This result corroborated previous work 
that vagal nerve stimulation inhibits activation of coagulation (van Westerloo 
et al. 2006), but is the first study to report pharmacological manipulation of the 
cholinergic anti-inflammatory pathway in whole human blood. 
 
2.  PI3K inhibitors have no effect on LPS-induced hypercoagulability. 
The anti-thrombotic effect seen with nicotine was not recapitulated with either 
selective PI3K inhibitor tested.  These results suggest that the attenuation of 
the pro-thrombotic effect of LPS by nicotine is not mediated by the PI3K 
intracellular pathway.  
 
 
5.4.2 Importance of findings 
 
This study supports the concept of the ‘cholinergic anti-inflammatory pathway’ 
having a further role in suppressing the activation of coagulation, by 
demonstrating the attenuation of inflammation induced hypercoagulability in 
human whole blood.  
 
Autonomic dysregulation is an early and common feature following major 
surgery (Amar et al., 1998).  Preservation of parasympathetic function confers 
cellular and anti-inflammatory protection across diverse organs (Andersson 
and Tracey, 2012).  Experimental data have identified that vagal nerve activity 
is crucial for cardioprotection during ischaemia (Mastitskaya et al., 2012), an 
increasingly recognised source of perioperative morbidity.  Furthermore, the 
parasympathetic neurotransmitter acetylcholine dampens inflammation by 
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nicotinic receptors in tissue macrophages, thus limiting multi-organ 
dysfunction (Andersson and Tracey, 2012).  Therefore, these results draw 
attention to the additional role of the parasympathetic nervous system in 
regulation of coagulation, such that autonomic dysfunction may yield 
thromboembolic consequences, outside the end-organ sequelae already 
reported.    
 
5.4.3 Strengths and limitations 
 
This is the first study to specifically examine the effect of nicotine on 
inflammation-induced hypercoagulability, and in so doing confirms a role of 
the cholinergic pathway in suppressing the activation of coagulation.  This 
non-specific nicotinic acetylcholine receptor agonist attenuated enzymatic 
hypercoagulability and highlights further potential targets for modulation of the 
pro-thrombotic phenotype.  The LPS TEG experimental model used allowed a 
global assessment of haemostasis in human whole blood and thus supports 
previous work measuring individual components of coagulation activation, 
following vagal nerve stimulation, in animal studies (van Westerloo et al. 
2006). 
 
The strengths and limitations of this ex vivo model of LPS induced activation  
of coagulation have been discussed in Chapter 4.  If resources had not been  
limited, the study would have benefitted from larger sample sizes and  
assessing the effect other nAChR agonists, particularly selective a7nAChR  
agonists, in this same experimental model.  The PI3K sub-study aimed to  
determine whether the effect seen with nicotine could be recapitulated by  
pharmacological blockade of a candidate intracellular signalling pathway.  A  
similar pattern was not seen but that does not conclusively exclude the role of  
the PI3K pathway in autonomic regulation of coagulation.   More  
comprehensive investigation should include determining whether Jak2 STAT3  
pathway inhibition produces attenuation of inflammation-induced  
hypercoagulability in the same LPS model.  However, the experimental  
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paradigm used in this study was not designed to ascertain the precise  
mechanism of nicotinic receptor activation in relation to coagulation activation  
at a cellular level so alternative models would be better placed to examine.   
Previous studies have demonstrated a reciprocal role between procoagulant 
activity and the PI3K signalling pathway but crucially this related to tissue 
factor expression on endothelial cells (Blum et al., 2001), which were absent 
from our experimental model. 
 
 
5.4.4 Conclusion 
 
In summary, this study demonstrated that inflammation-induced 
hypercoagulability is attenuated by non-specific nicotinic acetylcholine 
receptor activation when assessed by thromboelastography.  This identifies a 
role for the parasympathetic nervous system in the modulation of coagulation 
changes following major surgery, such that preservation of parasympathetic 
function may confer favourable postoperative outcomes, with reduction of 
thrombotic risk being a potential component of improving morbidity.  Further 
work is undoubtedly required to study the effect of specific nicotinic receptor 
(α7nAChR) activation on biomarkers of coagulation activation and the effect 
of parasympathomimetics on in vivo models of coagulation with an intact 
endothelial component. 
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Chapter 6 
 
Discussion 
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6.1 Summary of key findings 
 
Data presented in this thesis demonstrate that postoperative 
hypercoagulability is seen in patients undergoing major intra-abdominal 
surgery up to at least postoperative day 5.  This pro-thrombotic phenotype 
was diagnosed by pre-defined thromboelastography criteria to detect both 
enzymatic and platelet hypercoagulability.  The results confirm that 
conventional coagulation tests are incapable of determining the 
hypercoagulable state in this population and are not accurate global 
assessments of haemostasis. Different surgical subtypes produce a broadly 
similar effect on coagulation, with subtle differences in pre-existing 
hypercoagulability relating to the underlying pathology.  The postoperative 
goal directed fluid regimen studied was associated with excessive fluid 
administration but no adverse effect in terms of haemodilution-induced TEG-
defined hypercoagulability was demonstrated.  However, patients receiving 
goal directed therapy and the associated increased colloid fluid volume 
showed evidence of a higher degree of endothelial injury and specifically 
glycocalyx damage.   
 
Ex vivo interrogation of inflammation-induced hypercoagulability using an 
experimental model demonstrated that the procoagulant response to an 
inflammatory insult such as major surgery is potentially modifiable by pre-
existing perioperative therapies through off-target effects.  Statin and steroid 
therapy attenuated hypercoagulability produced in vitro with the anti-oxidant 
N-acetylcysteine exacerbating the prothrombotic state both in the presence of 
inflammation.  The results also support the concept of cholinergic autonomic 
modulation of coagulation with nicotine suppressing the hypercoagulable 
response to inflammation in the same experimental model. 
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6.2  Interpretation of results 
 
The hypothesis that major surgery is associated with postoperative 
hypercoagulability has been robustly tested.  The aim of the clinical TEG 
study was to elucidate the specific pattern of hypercoagulability in surgical 
cohorts and that has been achieved.  This data supports previous work on 
specific surgical cohorts reporting procoagulant profiles postoperatively either 
by viscoelastic parameters or other biomarkers of coagulation activation.  
However, the identification of the hypercoagulable state cannot be regarded 
as confirmation of an increased risk of thromboembolic complications.  Thus, 
it should be acknowledged that this study was not designed to determine the 
true predictive value of thromboelastography on postoperative thrombotic 
events. 
 
Dai et al. published a systematic review of the literature to assess the 
accuracy of thromboelastography in predicting thromboembolic complications 
in different cohorts of surgical patients (Dai et al. 2008).  The majority of 
published studies demonstrate a diagnostic and predictive value for TEG but 
the quality assessment of the data showed wide variation, in terms of 
verification of TEG data with other haematological parameters, blinding and 
insufficient details of TEG sampling and reference testing.  The definition of 
hypercoagulability was inconsistent with different studies using a variety of 
single absolute or derived parameters, most commonly maximum amplitude 
or maximum clot firmness, to define the procoagulant subgroup.  Therefore, 
these studies were assessing the predictive value of platelet 
hypercoagulability rather than both the enzymatic and platelet components of 
clot formation measurements.  The results in this thesis demonstrate a 
combined pattern of hypercoagulability, with subtle differences seen 
depending on the underlying pathology and the nature of the surgery.  It is 
important to examine the precise pattern of hypercoagulability not only in 
establishing potential mechanisms to modulate this response to surgery but 
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also to determine whether enzymatic or platelet hypercoagulability is more 
predictive of unfavourable outcome.   
 
The clinical utility of viscoelastic testing in reliably determining the 
hypercoagulable state in the perioperative period is reiterated in this study.  
Conventional coagulation tests provided no consistent information on the 
global assessment of coagulation with interpretation of routine variables 
suggesting normo- or hypocoagulability despite clear evidence of 
hypercoagulability on TEG.  Therefore, reliance on conventional coagulation 
tests, in current practice, to determine risk of thromboembolic complications or 
guide adequacy of thromboprophylaxis is fundamentally flawed.  Failure to 
identify the prothrombotic phenotype in this manner may be associated with 
patient harm by not recognising the risk of thrombosis or appropriately 
preventing potential clinical sequelae.  In particular, prothrombin time 
(PT/INR) is widely clinically used to determine suitability for administration 
perioperative low molecular weight heparin, with elevated INR deemed 
reflective of an ‘auto-anticoagulated’ state and an increased risk of 
postoperative bleeding, thus precluding the use of thromboprophylaxis.  
However, the correlation between PT and the clot initiation parameters, R-
time (TEG) and CT (ROTEM), is poor (Coakley et al., 2006).  The viscoelastic 
variables better reflect the overall haemostatic balance between pro- and 
anticoagulant factors in clot formation, rather than PT which quantifies specific 
procoagulant proteins traditionally considered to comprise the extrinsic 
system of coagulation.   
 
In assessing the impact of major surgery on the coagulation profile, it is 
important to evaluate the relative contribution of each modifiable surgical and 
patient factor.  This thesis aimed to investigate the effect of postoperative goal 
directed therapy on the coagulation profile postoperatively to determine 
whether different haemodynamic management strategies adversely affected 
the postoperative coagulation status.  In the regimen studied, the main 
difference between treatment groups was the volume of colloid fluid 
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administered in the postoperative period.  Although there was no 
demonstrable alteration of goal directed therapy on overall coagulation status 
as per thromboelastography criteria, there was an association with the degree 
of endothelial injury.  This study did not determine how glycocalyx damage is 
potentiated in this therapy group but shear stress from relative hypervolaemia 
is one plausible mechanism.  However, relative excess of fluid administered 
was not manifested in terms of laboratory evidence of significant 
haemodilution so alternative hypotheses should be considered.  A key finding 
from the parent POM-O trial was a reduction of parasympathetic activity in the 
goal directed therapy, as detected by alterations in heart rate variability 
parameters (Ackland et al. 2015).  Given the results from the ex vivo LPS 
TEG model, with nicotine attenuating inflammation-induced 
hypercoagulability, it is conceivable that the modulation of autonomic 
regulation of coagulation activation may be altered by components of goal 
directed therapy, such that suppression of the cholinergic anti-inflammatory 
reflex may be associated with a propensity to a hypercoagulable state.   
 
Whereas the role of glycocalyx damage in sepsis and trauma is increasingly 
understood, the aetiology of endothelial injury and the resultant effect on the 
coagulation status in the perioperative setting undoubtedly requires further 
elucidation. Sepsis leads to ubiquitous degradation of the glycocalyx and 
altered endothelial permeability, with hypovolemia, hypoalbuminaemia, and 
oedema (Chelazzi et al., 2015).  Inflammatory-mediated injury to glycocalyx 
may be responsible for numerous clinical sequelae of sepsis, including acute 
kidney injury, respiratory failure, and hepatic dysfunction.  Biomarkers of 
glycocalyx degradation, such as circulating levels of syndecan or selectins, 
may be used as to indicate the severity of endothelial dysfunction in sepsis.  
In severely injured trauma patients, glycocalyx shedding is associated with 
reduced plasma colloid oncotic pressure and impaired thrombin generation 
(Rahbar et al., 2015).   
 
However, the net effect of shedding glycocalyx components on the global 
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haemostatic picture following surgical trauma is poorly characterised.  
Elevated syndecan-1 and heparan sulphate levels have been demonstrated 
following major surgery (Rehm et al., 2007).  Given heparan sulphate is a 
major component of the glycocalyx layer, the predicted effect of endothelial 
injury may be one of heparin-like activity with reduction in thrombin generation 
and a less hypercoagulable phenotype.  However, endothelial injury also 
leads to adhesion of platelets, leukocytes and other neutrophil-endothelial cell 
interactions that promote coagulation activation.  Trauma patients who had 
high levels of shed syndecan-1 demonstrated higher levels of pro-
inflammatory cytokine IL-10 with a correlation with changes in endothelial 
permeability (Haywood-Watson et al., 2011). Preservation or restoration of the 
glycocalyx, assessed by both endothelial permeability and syndecan-1 levels, 
have been demonstrated with steroid treatment, antithrombin and fresh frozen 
plasma or whole blood resuscitation in different in vitro models (Chappell et 
al., 2007, 2009).   
 
The results in this thesis suggest that glycocalyx damage is promoted by goal 
directed therapy in the immediate postoperative period but the net effect on 
global haemostasis is neutral.  The lack of demonstrable haemodilution 
following an intervention associated with excessive fluid administration could 
potentially be attributable to increased endothelial permeability secondary to 
the glycocalyx damage seen. No significant endogenous heparin effect was 
demonstrated in the clinical TEG study to suggest an attributable rise in shed 
heparan sulphate. The aetiology of endothelial injury seen in surgical patients 
and the overall effect of coagulation is uncertain.  Furthermore, the effect of 
limiting glycocalyx damage on perioperative coagulation, by potential 
therapeutic strategies to preserve or restore glycocalyx, requires specific 
investigation. 
 
The inflammation-induced coagulation activation model was chosen to test 
the potential modification of the procoagulant effect of a standardised 
inflammatory stimulus by selected widely used perioperative therapies.  This 
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facilitated ex vivo assessment of a wide range of medication with putative 
anti-inflammatory anti-thrombotic properties, via off-target effects.  This model 
had the advantage of not exposing subjects directly to the inflammatory 
stimulus and allowing LPS treated samples to be pre-treated with multiple 
medications simultaneously.  However, although this experimental paradigm 
demonstrated modulation of inflammation-induced hypercoagulability by 
simvastatin, dexamethasone and N-acetylcysteine, the results need to be 
interpreted cautiously due to the limitations of the experimental model.  
Activation of coagulation in vivo is much more complex than that seen in this 
model which, in particular, does not take into account the contribution by the 
endothelium and components such as endogenous anticoagulants, 
thrombomodulin and Protein C.  The disadvantages of ex vivo investigation 
are somewhat offset by the use of whole blood analysis so the cellular 
contribution of particularly leucocyte mediated tissue factor production is 
accounted for.   
 
In comparing the alteration in TEG parameters in the clinical study to the ex 
vivo experimental model, the pattern of predominantly enzymatic 
hypercoagulability and the magnitude of the changes demonstrated were 
similar.  Therefore, although this simplified artificial model has limitations, it 
does provide a sound basis for further investigation of positive results.  The in 
vivo effect of pre-treatment with statins, steroids and antioxidants should now 
be further assessed by testing if modification of TEG parameters is seen 
following systemic administration of LPS in either an animal model or human 
subjects.  This in vivo endotoxaemia model has been widely used in the 
assessment of modulation of LPS-induced pro-inflammatory cytokine 
production and coagulation activation.  Whereas primary outcome has been 
previously measured in this model in terms of individual biomarkers of 
activation of coagulation (Pernerstorfer et al., 1999; Steiner et al., 2005), 
thromboelastography is the ideal modality to evaluate the global effect on 
haemostasis, as a surrogate for thrombotic risk, in the same manner as the ex 
vivo paradigm. 
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The partial reversal of LPS-stimulated hypercoagulability by simvastatin and 
nicotine prompted sub-study analysis to investigate potential mechanisms for 
further anti-thrombotic properties of each therapy.  Proposed actions for 
simvastatin have focussed on the inhibition of platelet-dependent neutrophil 
recruitment, mediated by CD40L, secreted from activated platelets, and CXC 
chemokines respectively (Zhang et al., 2011a).  The aim of investigating the 
effect of a CXCR2 antagonist in the LPS TEG study was to demonstrate if the 
attenuation seen with simvastatin could be recapitulated but it did not provide 
specific clarification of the mechanism of action.  Although the pattern of 
modulation of coagulation activation was similar, detailed mechanistic studies 
are necessary to confirm any proposed anti-thrombotic action.  Flow 
cytometry studies to elucidate whether simvastatin alters CXCR2 expression 
on neutrophils would be beneficial in the same whole blood model, given that 
simvastatin reduces neutrophil recruitment via reduced CXC chemokine 
release in murine models (Zhang et al. 2011).  Providing a biological 
explanation for the effect seen with simvastatin on inflammation-induced 
hypercoagulability would more robustly confirm the effect seen in this TEG 
model but also identify further potential therapeutic targets to modulate 
coagulation activation. 
 
 
6.3 Importance of findings and clinical relevance 
 
Thromboembolic complications are the leading cause of preventable 
postoperative morbidity and mortality.  Of the 312 million surgical procedures 
performed worldwide each year (Weiser et al., 2016), around 8% are 
complicated by an arterial or venous thrombotic event (Donze et al., 2014). 
Postoperative myocardial infarction, ischaemic stroke, deep vein thrombosis 
and pulmonary thromboembolism (PTE) continue to represent a substantial 
healthcare burden, despite routine thromboprophylaxis and significant 
improvements in perioperative care.  The scale of the problem is set to 
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increase with the expanding volume of surgery performed worldwide and the 
rising proportion of surgical patients with risk factors for perioperative 
hypercoagulability, such as advancing age and an underlying cancer 
diagnosis.   
 
Although the data presented in this thesis did not include the rate of 
thromboembolic complications, the results demonstrate the significance of 
the perioperative shift to the prothrombotic phenotype.  Key factors in 
improving postoperative outcomes will be more reliable identification of 
patients at increased risk of thromboembolic complications and appropriate 
risk stratification to enable more effective thromboprophylactic regimens to 
be implemented.  Current strategies rely on generic patient and surgical 
factors to assess overall risk throughout the perioperative period.  More 
dynamic assessment is required to reflect the differential risk throughout the 
perioperative period with easy and accurate identification of underlying 
perioperative hypercoagulability.  Quantification of both preoperative risk, 
based on risk factors such as cancer or age, and postoperative risk, based 
on the response to surgical trauma and haemodynamic therapy, would allow 
more accurate evaluation of both the need for and duration of 
pharmacological thromboprophylaxis. 
 
The impact of goal directed therapy on composite measures of postoperative 
outcome is well documented.  The results from this thesis did not show any 
consistent exaggeration of the procoagulant response to surgery but did 
demonstrate potential harm attributable to endothelial damage.  Despite the 
lack of net effect on global haemostasis, this finding highlights the 
importance of perioperative fluid regimens and the impact on endothelial 
function.  Further exploration is required to elucidate the precise effect of 
goal directed therapy strategies on the glycocalyx, in combination with 
specific outcome measures of postoperative morbidity.   
 
The results from the ex vivo incubation model demonstrate the potential of 
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certain commonly used perioperative therapies in the modulation of 
coagulation activation.  Additional treatment benefit may be attributable to off-
target effects, with anti-inflammatory anti-thrombotic properties, beyond their 
established mechanism of action.  The prospect of utilising existing well-
established medications in the perioperative phase to further reduce a 
component of perioperative risk is attractive and should be further 
investigated.  Pre-treatment with appropriate doses of steroid or statin therapy 
could be evaluated in a corresponding in vivo LPS model to demonstrate if 
similar patterns of amelioration of inflammation-induced hypercoagulability are 
produced.  Further mechanistic studies are needed to investigate the potential 
anti-thrombotic action and to identify additional therapeutic targets for 
modulation of this procoagulant response.  
 
The experimental model employed was designed to reflect the inflammatory 
stimulus of surgical trauma.  Although the results have been interpreted in the 
context of the perioperative coagulation status, the paradigm used is also 
applicable to the investigation of both the prothrombotic and pro-inflammatory 
state seen in sepsis and malignancy.   Statin therapy, for example, has 
postulated benefit in the terms of cancer-related mortality (Nielsen et al. 
2012).  Further examination of the relationship between coagulation status, 
complication rate and mortality in this cohort may elucidate the mechanism by 
which statins confer this overall benefit.  Moreover, the demonstrated 
alteration in coagulation status should be evaluated in parallel with biomarkers 
of inflammation to identify agents with potential to modulate other end-organ 
effects of the inflammatory response to surgery. 
 
 
6.4 Further work 
 
The results presented in this thesis highlight the considerable promise of 
thromboelastography in the reliable identification of perioperative 
hypercoagulability.  Existing literature either demonstrates the presence of 
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hypercoagulability in specific postoperative surgical cohorts or, less 
commonly, the increased incidence of thromboembolic complications in TEG-
defined hypercoagulable patients.  It is vital that more high quality research is 
done to elucidate the efficacy and cost-effectiveness of thromboelastography 
in predicting and/or reducing thromboembolic complications.  Alterations to 
the coagulation status should be examined in large cohorts of surgical 
patients into the extended postoperative phase with investigation of the 
incidence of both manifested and subclinical thrombotic events.  
Consequently, the time taken to return to a normocoagulable state following 
different types of major surgery could be more reliably demonstrated and 
surgery-specific thromboprophylaxis regimens could be tested.  The 
association between the incidence of thromboembolic events and both TEG-
defined composite hypercoagulability and individual TEG parameters requires 
further more detailed investigation.  There remains no consensus on how best 
to define hypercoagulability by TEG criteria and more comprehensive 
investigation of the impact of different aspects or parameters of global 
haemostasis on thrombotic risk is warranted.   
 
Ultimately the predictive value of viscoelastic testing and its clinical utility in 
diagnosing perioperative hypercoagulability and identifying patients at 
increased thrombotic risk would be best assessed by a randomised controlled 
trial to compare rates of postoperative thromboembolic complications in 
subjects prescribed generic thromboprophylaxis regimens or more 
individualised protocols based on viscoelastic test criteria.  The prospect of 
routine use of thromboelastography to assess hypercoagulability in the 
surgical patient would entirely depend on a demonstrable outcome benefit 
rather than detection of the hypercoagulable state. 
 
The use of thromboelastography is well-established in the management of 
haemorrhage and clotting disorders associated with major trauma, liver 
transplantation and cardiac surgery in specialist centres (Hunt et al., 2015; 
Wikkelsø et al., 2016).  Although no improvement in mortality has been 
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demonstrated, coagulation monitoring with TEG/ROTEM can reduce overall 
transfusion requirements as empirical therapy is eliminated and specific 
management of coagulation defects is instituted at an early stage.  Clinical 
provision of viscoelastic testing has hitherto been limited by the moderate 
complexity of performing TEG and ROTEM analysis, such that the personnel 
running the tests need to be adequately trained, equipment required is subject 
to quality control procedures and existing modalities suffer from a unique set 
of pre-analytic and analytic variables that impact test reliability and 
reproducibility.  However, modern adaptations of this technology, such as the 
TEG 6 machine, are significantly more self-automated, with ease of use 
provided by cartridge technology and machine portability and will represent 
true point of care tests.   Therefore, access to viscoelastic tests and 
interpretation of TEG-derived parameters should become more readily 
available enabling more widespread adoption.  Thus, real time dynamic 
characterisation to alterations in coagulation seen in both bleeding scenarios 
and in the context of perioperative hypercoagulability should become more 
routine practice in the future. 
 
The ex vivo interrogation of inflammation-induced hypercoagulability has 
produced some interesting results and formed the basis for future 
investigation to refine the experimental model to more accurately reflect the 
perioperative scenario.  Further studies should concentrate on whole blood 
and defining the in vivo effect of potential thrombomodulatory agents in 
modulating the procoagulant response to inflammation.  Global haemostatic 
assessment with thromboelastography is superior to both conventional 
coagulation testing and individual biomarkers of coagulation activation and 
allows dynamic evaluation of the interaction between platelets, plasma and 
leucocytes.  Crucially, in vivo investigation will demonstrate the contribution of 
the endothelium on the response to both an inflammatory stimulus and pre-
treatment with selected perioperative therapies.  
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6.5 Conclusion 
 
Hypercoagulability and increased risk of thromboembolic complications are 
commonly encountered in the perioperative phase of major surgery. 
Thromboelastography is superior to conventional coagulation testing in 
demonstrating this prothrombotic phenotype and may have a role in guiding 
more adequate individualised thromboprophylaxis regimens.  In mitigating this 
increased perioperative thrombotic risk, it is crucial to evaluate the impact of 
individual components of perioperative management, particularly intravenous 
fluid therapy and co-existing cancer diagnosis, in order to minimise the 
hypercoagulable response to the same surgical insult.  Through further 
exploration of the relationship between inflammation and coagulation seen 
with surgical trauma, it may be possible to discover novel thrombomodulatory 
agents with minimal bleeding risk which can modify the risk of perioperative 
thromboembolic complications and improve postoperative outcome.   
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